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Nucleotide levels play a critical role in genome stability, and proper regulation 
of these pools is crucial for survival. Ribonucleotide reductase (RNR) 
catalyzes the rate- limiting step in de novo dNTP biosynthesis. The enzyme is 
composed of two non-identical homodimeric subunits, a large subunit encoded 
by a single gene Rrm1, and a small subunit encoded by either Rrm2 or a DNA-
damage-inducible gene p53R2. In mammals, RNR activity is thought to be 
controlled by two main mechanisms: limitation of small subunit protein levels 
and allosteric feedback control. Studies in yeast and cultured mammalian cells 
have shown that disabling RNR regulation results in increased mutation rates. 
The objective of the studies described here was to develop mouse models to 
elucidate the physiological consequences of disrupting RNR regulatory 
mechanisms in vivo, either individually or in combination. We first overrode the 
control of RNR protein levels by generating multiple mouse strains that 
featured overexpression of individual RNR subunits. Mice that overexpressed 
either small RNR subunit developed lung cancer at a high frequency, while 
mice that overexpressed both Rrm1 and either small RNR subunit developed 
age-dependent mitochondrial DNA depletion in addition to lung cancer. These 
findings highlight the impact of RNR deregulation on the stability of both the 
nuclear and mitochondrial DNA genomes.  In order to disrupt RNR allosteric 
control, we also generated transgenic mice that overexpress a feedback-
resistant form of Rrm1, Rrm1-D57N, as well as knock-in mice in which the 
D57N mutation was introduced directly into the Rrm1 genomic locus. These 
mouse strains were used individually or in various combinations to assess the 
effects of loss of RNR regulation on genome maintenance, tumorigenesis, and 
survival. Although mice that overexpress Rrm1-D57N were grossly normal, 
mice that overexpress Rrm1-D57N in combination with either small RNR 
subunit were inviable, indicating that simultaneous loss of both main RNR 
regulatory mechanisms is incompatible with survival. Preliminary work 
suggested large dNTP pool alterations in the skeletal muscle of bitransgenic 
neonates, resulting in pathological changes in multiple organ systems and 
premature lethality. It was also found that mice homozygous for the Rrm1-
D57N knock-in mutation are inviable, further indicating that proper allosteric 
feedback control of RNR is critical for survival.  All together, these results 
indicate that RNR plays a central role in genome maintenance, and that 
alterations in RNR activity are detrimental for survival. 
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Chapter 1: Role of ribonucleotide reductase in regulating dNTP 
metabolism and maintenance of genomes 
1.1 Overview of nucleotide metabolism 
1.1A Biological significance of nucleotides 
Proper maintenance and transmission of genetic information is key to 
the survival of all species. In order to preserve genetic information, DNA needs 
to be maintained and replicated exactly throughout the life of the organism. 
DNA is also under constant stress from both exogenous and endogenous 
processes, and so the ability to repair or replace damaged DNA bases is 
necessary for survival. Nucleotides, specifically deoxynucleoside 
triphosphates (dNTPs), are the building blocks of DNA, and it is crucial to 
maintain an adequate supply of dNTPs so that DNA replication and repair can 
occur accurately. Organisms have evolved many mechanisms to ensure the 
proper supply and balance of dNTPs, and regulate both the production and the 
degradation of dNTPs to keep nucleotides at an optimal level.  
1.1B Summary of nucleotide synthesis 
Nucleotides are generated via de novo and salvage pathways. Salvage 
pathways convert bases back into ribonucleosides by conjugating a ribose 
moiety to the base. De novo purine and pyrimidine biosynthetic pathways 
follow separate patterns. Pyrimidine bases are synthesized first and then 
attached to a ribose sugar, while purines are assembled piece by piece onto a 
ribose. Biosynthesis of both purines and pyrimidines utilize 5-phosphoribosyl 
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1-pyrophosphate (PRPP) to link a 5-phosphoribosyl moiety onto the nitrogen 
atom of an aglycone(6). The enzyme responsible for generation of PRPP, 
ribosepyrophosphorylase, was isolated by Kornberg, Lieberman, and Simms 
and demonstrated to couple a pyrophosphate to ribose-1-phosphate on 
carbon 1(7).  
1.1C De novo synthesis of pyrimidine nucleotides 
Pyrimidine biosynthesis (summarized in Figure 1.1) starts from 
bicarbonate, Mg2+ATP, and glutamine(8). Glutamine supplies the ammonia, 
which is combined with bicarbonate in a multi-step reaction catalyzed by 
carbamoyl phosphate synthetase (CPS) to produce carbamoyl phosphate(8). 
Two isoforms of CPS exist; CPS I is localized to the mitochondrion, where it 
participates in arginine biosynthesis and the urea cycle, and CPS II is cytosolic 
and is involved in the de novo production of pyrimidine nucleotides(8). The 
enzyme aspartate transcarbamoylase couples an aspartate to carbamoyl 
phosphate to produce carbamoylaspartate, which is cyclized by dihydroorotate 
synthetase to produce dihydroorotate(9). These first 3 enzymes responsible 
for the initial steps in de novo pyrimidine biosynthesis were demonstrated to 
be a trifunctional enzyme polypeptide, termed CAD, an acronym based on the 
enzyme names(10).  
The product of these enzymes, dihydroorotate, diffuses into the 
mitochondria to be converted into orotate by dihydroorotate dehydrogenase 
(DHOdeHase). 
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Figure 1.1 Overview of de novo pyrimidine biosynthesis. A. Synthesis of 
uridine. B. Interconversion of uridine, cytosine, and thymidine. Enzymes: (1) 
Carbamoyl phosphate synthetase; (2) aspartate transcarbamoylase; (3) 
dihydroorotate synthetase; (4) pyrimidine phosphoribosyltransferase; (5) cytidine 
synthetase; (6) cytidine deaminase; (7) ribonucleotide reductase; (8) thymidine 
synthetase. Modified from Berg et al. Biochemistry 5th ed. 
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  The unique situation of DHOdeHase within the inner mitochondrial 
membrane allows it to participate in both the synthesis of pyrimidines and in 
the respiratory chain(9). DHOdeHase uses an NAD+ to oxidize dihydroorotate 
to orotate, which diffuses back into the cytosol for the final steps. A final 
bifunctional enzyme, UMP synthetase, contains the enzymes orotate 
phosphoribosyltransferase and orotidine 5ʼ-monophosphate decarboxylase. 
Orotate phosphoribosyltransferase couples orotate to an activated ribose from 
PRPP(6, 11). Orotidylate decarboxylase removes the carboxyl from orotidylate 
to produce uridine -5ʼ-monophosphate (UMP)(11). UMP is the precursor for all 
other pyrimidine nucleotides. 
UMP is first phosphorylated by UMP/CMP kinase to produce uridine-5ʼ-
diphosphate (UDP)(9). From here, UDP can be converted into 3 different 
nucleotides or be used in the production of UDP sugars(9). UDP is 
phosphorylated by nucleoside diphosphate kinase to produce uridine-5ʼ-
triphosphate (UTP), which is used in RNA synthesis, or can be aminated to 
produce cytidine-5ʼ-triphosphate (CTP) by CTP synthetase(9). To be used for 
DNA synthesis, CTP must be dephosphorylated into CDP in order to be a 
substrate for ribonucleotide reductase (RNR), which removes the 2ʼ-OH to 
produce dCDP(12). One nucleoside diphosphate kinase acts to phophorylate 
all NDPs and dNDPs to produce NTPs and dNTPs(13). CMP can be converted 
back into UMP by CMP deaminase, an important enzyme for controlling 
nucleotide pool ratios(14). 
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UDP can also be a substrate for RNR to produce dUDP(15). dUDP is 
not itself a substrate for DNA synthesis, but is instead dephosphorylated to 
produce dUMP. dUMP is methylated to form dTMP by thymidylate synthetase 
(Figure 1.3). 5, 10-methylene-5,6,7,8- tetrahydrofolate serves as a cofactor 
and donates a methyl group to dUMP to produce dTMP and 7,8-
dihydrofolate(16). dTMP is phosphorylated into dTTP through the actions of 
dTMP kinase(13).  
1.1D De novo synthesis of purine nucleotides 
Purine biosynthesis begins with PRPP(6) (illustrated in Figure 1.2). The 
1-pyrophosphate within PRPP is displaced by ammonia to form 5-
phosphoribosyl-1-amine (PRA). The enzyme glutamine phosphoribosyl 
amidotransferase catalyzes this reaction, using an ammonia from 
glutamine(17). The reaction proceeds as two half-reactions, channeling an 
unstable ammonia intermediate between separate active sites to catalyze 
each step of the process(18). The first half-reaction is the hydrolysis of 
glutamine to form glutamate and ammonia, and the second is the replacement 
of the pyrophosphate from PRPP with ammonia, forming phosphoribosylamine 
(PRA)(18). From here, 9 enzymatic steps assemble the two-ring structures of 
guanine and adenine. First a glycine is added to the amino group of PRA to 
form glycinamide ribonucleotide, in a reaction catalyzed by glutamine PRPP 
amidotransferase(19). The enzyme glycinamide ribonucleotide transformylase 
uses N10-formyl tetrahydrofolate to transfer a formyl group to the amino group 
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on the glycine residue to form formylglycinamide ribonucleotide. Step 3 
involves phosphorylation of the carboxy oxygen on the glycine residue and 
replacement of the phosphate with ammonia from glutamine, forming 
formylglycinamidine ribonucleotide. Hydrolysis of an ATP stimulates an 
intramolecular coupling reaction to produce 5-aminoimidazole ribonucleotide. 
Bicarbonate is first added to an amino group within the ring to be the first 
exocyclic group and then transfers to the adjacent carbon atom, producing 
carboxyaminoimidazole ribonucleotide. ATP hydrolysis couples an aspartate 
residue to the bicarbonate, forming 5-aminoimidazole-4-(N-
succinylcarboxamide)  ribonucleotide. A fumarate molecule is released, 
forming 5-aminoimidazole-4-carboxamide ribonucleotide. N10-
formyltetrahydrofolate supplies another formyl residue to produce 5-
formylaminoimidazole-4-carboxamide ribonucleotide, which cyclizes, releasing 
a water molecule and forming inosine-5ʼ-monophosphate (IMP)(20).  
IMP is the precursor purine from which AMP and GMP are formed. The 
enzyme adenylosuccinate synthetase uses aspartate to donate an ammonia to 
IMP, eventually releasing fumarate and adenosine-5ʼ-monophosphate(19). To 
produce GMP, additional steps are required. A water is added to IMP by 
inosine-5ʼ-monophosphate dehydrogenase and is then dehydrogenated by 
NAD+ to add a second carbonyl moiety to the molecule, producing xanthine -
5ʼ-monophosphate(20). An ammonia derived from glutamine replaces the 
carbonyl, yielding the final GMP nucleotide. 
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Figure 1.2. De novo synthesis of purines. A. Generation of IMP. B. 
Interconversion of IMP, AMP, and GMP. Enzymes: (1) Glutamine phosphoribosyl 
transferase; (2) adenyl-succinate synthetase; (3) GMP synthetase. Modified from 
Berg et al. Biochemistry 5th ed. 
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 The enzyme which catalyzes this process is GMP synthetase(19). AMP and 
GMP are phosphorylated to ADP and GDP, respectively by their own unique 
kinases. Similar to UDP and CDP, ADP and GDP are also substrates for 
ribonucleotide reductase, forming dADP and dGDP, which are phosphorylated 
to dATP and dGTP by the same nucleotide diphosphate kinase as the 
pyrimidines(20).  
1.1E Overview of nucleotide salvage pathways 
Nucleotide salvage pathways serve to recycle dNTPs from the diet or 
from damaged DNA and prepare them for new DNA synthesis. Nucleosides 
(without phosphates) from the diet are carried into cells through broad-
spectrum nucleoside transporters(13). The liver has been suggested to be a 
major site of dNTP salvage from dietary sources, having high levels of activity 
of PRPP amidotransferase(21). Like de novo nucleotide synthesis, the salvage 
pathways also utilize PRPP(21). The purine salvage enzyme 
hypoxanthine/guanosine ribosyltransferase (HPRT) combines hypoxanthine to 
PRPP to form IMP(21), which can be converted into AMP or GMP as 
discussed previously. 
Cells can utilize salvaged thymidine nucleoside by thymidine kinase 1-
dependent phosphorylation(22). Mitochondrial DNA replication is independent 
of cell cycle stage, but draws from the same nucleotide pool as the nuclear 
genome. Mitochondrial membranes harbor specific nucleotide transporters, 
which traffic dNDPs and dNTPs between the mitochondria and cytosol in both 
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directions(4). Mitochondria contain salvage enzymes distinct from those of the 
rest of the cell. Especially in quiescent tissues lacking RNR activity, 
mitochondria can utilize thymidine kinase 2 (TK2) and deoxyguanosine kinase 
(dGK) to produce dNTPs to replicate their DNA(22). TK2 is specific for 
phosphorylating pyrimidine nucleotides, while dG and dA are phosphorylated 
by dGK(23). The dNMPs are further phosphorylated by mitochondrial 
nucleotide monophosphate kinases, and the dNDPs are phosphorylated by 
mitochondrial nucleotide diphosphate kinases, a multifunctional enzyme(23).  
One mechanism in place for limiting dNTP production to S-phase is 
degradation of TMP kinase and TK1 by the anaphase-promoting complex 
(APC). Both the APCCdc20 and APCCdh1 complexes degrade TMPK(24). 
Knockdown of the APC leads to dramatic dNTP pool imbalances, 
characterized most by a huge increase in dTTP levels(24). Additionally, 
reduction of NDPs into dNDPs by ribonucleotide reductase is largely limited to 
S-phase of the cell cycle(25), and will be discussed in detail later (Chapter 
1.3). 
1.1F Overview of nucleotide catabolism 
In addition to feedback control mechanisms that limit the production of 
dNTPs, cells do harbor mechanisms conferring the ability to degrade 
excessive nucleotides. The major step in nucleotide catabolism is the removal 
of the 5ʼphosphates by 5ʼnucleotidases, yielding nucleosides(26). 
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Figure 1.3. Summary of nucleotide substrate cycles and cross-talk 
between cytosolic and mitochondrial nucleotide pools. A. Regulation of 
thymidine pools between the cytosol and mitochondria (modified from Ferraro et 
al.(2)) B. Regulation of guanine nucleotide pools between the cytosol and 
mitochondria (Modified from Leanza et al.(4)). C. Regulation of cytidine pools. 
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Nucleotidase activity is constant in cells undergoing de novo dNTP synthesis, 
sometimes balancing out the effect of nucleoside kinases, leading to a 
substrate cycle(27). Experiments in cultured cells have shown a tight balance 
between nucleoside phosphorylation and nucleotide dephosphorylation(28, 
29). Inhibition of DNA synthesis in the continued presence of de novo dNTP 
biosynthesis leads to enhanced nucleoside excretion from the cell and no net 
increase in dNTP pools, while inhibition of de novo synthesis with hydroxyurea 
stimulated nucleoside uptake and phosphorylation(28). Mammalian cells 
contain several 5ʼ-nucleotidases, the cytosolic high Km 5ʼ-nucleotidase (hkm-
NT)(26), a cytosolic 5ʼ-deoxynucleotidase (dNT-1)(26) a mitochondrial 5ʼ-
deoxynucleotidase (dNT-2)(26, 30), and a cell membrane-bound 
ectonucleotidease(26). Through substrate-flow experiments, it was shown that 
hkm-NT degrades ribonucleotides GMP and IMP, while dNT-1 degraded 
pyrimidine deoxynucleotides dCMP and dUMP(26), but was later found to also 
degrade purine deoxynucleotides(30). dNT-2 was shown to have specificity 
towards dTTP and deoxyuridine, suggesting a possible mechanism for 
protection of mitochondrial dNTP pools from cytosolic imbalances(30).  
Another important step in nucleotide catabolism is cleavage of the C-N 
glycosidic bond to release the ribose sugar from the free base(31). This 
process is carried out by nucleotide phosphorylases, of which there are two 
main families. Members of the phosphorylase-I family harbor a single domain 
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fold and can work on a range of purine and pyrimidine substrates(31). The 
phosphorylase-II family harbors a dimeric structure and cleaves exclusively 
pyrimidine nucleotides(31). Rather than using hydrolysis to cleave the 
glycosidic bond, it has been shown that the process is carried out through 
phosphorolysis, yielding the nucleotide base as well as ribose-1-
phosphate(31). Loss of function of the purine nucleoside phosphorylase (PNP) 
leads to accumulation of dGTP in lymphoid tissues(27). Loss of function of 
thymidine phosphorylase (TP) leads to accumulation of both dTTP and dGTP 
in the mitochondria(32). Both dC and dA (by adenosine deaminase (ADA)(27)) 
must be deaminated prior to this step, yielding dU and dI, respectively(13). 
Accumulation of adenosine and 2ʼ-deoxyadenosine in ADA-null mice results in 
a wide spectrum of phenotypes, from pulmonary insufficiency to renal 
abnormalities(33, 34). 
Hyperactive nucleotide degradation results in elevated levels of 
xanthine, hypoxanthine, and uric acid in the blood. The cause/effect 
relationship is unclear, however elevated uric acid is associated with 
hypertension in rats(35). Additionally, elevated purine degradation products 
are found in the bloodstream of hypertensive and exercise-intolerant 
patients(36, 37). Elevated uric acid levels are also linked to essential 
hypertension in humans, which can lead to stroke, congestive heart failure, 
renal disease, and myocardial infarction(38). Elevated uric acid in humans can 
also cause gouty arthritis and renal stones(39).  
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1.2  Nucleotides and mutagenesis 
The cellular processes outlined above all participate towards a common 
goal: to keep nucleotide levels balanced and in adequate, but not excessive, 
supply. Accurate replication of DNA and transmission of genetic information 
depends on the fidelity of the replicative DNA polymerases, which are all 
impacted by perturbations in nucleotide pools. This chapter will discuss first 
the fidelity of the individual DNA polymerases as well as evidence for 
enhanced mutagenesis by each in conditions of elevated or unbalanced 
dNTPs. Next we will focus on effects of inadequate nucleotide supplies on 
genome maintenance. 
1.2A Fidelity of replicative DNA polymerases 
It is proposed that the bulk of correct base-base pairing during DNA 
replication occurs at the initial step of incorporating a new base into the strand, 
as polymerases that lack proofreading domains still show low substitution 
rates(40). Such high specificity was proposed to occur through a combination 
of entropy/enthalpy balance in Watson-Crick base pairing of the correct 
bases(41), and through tight arrangement of residues within the active site of 
the polymerase, so that correct base-base pairs fit snugly but incorrect pairs 
encounter steric clashes(41, 42). Indeed, experiments show that mutating key 
residues within the active site which allow the replicative polymerase to detect 
the correct base is mutagenic in yeast and homozygous lethal in 
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mammals(42). Heterozygous mutant animals show a decreased lifespan, 
increased genomic instability and increased cancer formation(42).  
The next step in accurate DNA synthesis is proper function of 3ʼ-5ʼ 
exonuclease domains, which proofreads the polymeraseʼs work. The 
mechanism proposed to be at work here is an inefficiency of extending past a 
mismatched base(42). A loss of speed in elongating from the primer terminus 
allows the mismatch time to detach from its pairing partner and move towards 
the exonuclease domain for cleavage(42). 
Eukaryotic systems utilize three main nuclear DNA polymerases, DNA 
polymerase α (Pol α), polymerase δ (Pol δ), and DNA polymerase ε (Pol ε), 
which catalyze the bulk of DNA replication. Pol α lacks a 3ʼ-5ʼ exonuclease 
domain, making it a low-fidelity enzyme, while δ(43) and ε both harbor a 
proofreading domain. Pol α forms a complex with DNA primase to synthesize 
RNA/DNA primers on both the leading strand and the lagging strand to initiate 
replication. DNA pol α has a low fidelity(40), and recent work suggests it does 
not have a role in primer extension; instead a polymerase-switch occurs on 
each strand(44-46). This switch on the lagging strand allows Pol δ to replace 
any errors made by Pol α(45). It is hypothesized that Pol δ and Pol ε replicate 
the leading and lagging strands, and data suggests that Pol δ replicates the 
bulk of the lagging strand(44, 45) and is responsible for Okazaki fragment 
maturation(44). Further data indicates that Pol ε replicates the leading 
strand(46).  
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Pol δ and Pol ε have base substitution rates around 10-8 to 10-6, due in 
large part to high selectivity for the correct base and an exonuclease domain 
that removes the wrong base. Exonuclease-deficient Pol δ and Pol ε have 
fidelity rates of 10-6 to 10-4 (41). In vitro work with Pol ε and Pol δ purified from 
calf thymus have shown a mutation frequency of around 7 x 10-4 and 19 x 10-4, 
respectively at optimal dNTP concentrations. Both Pol δ and Pol ε were shown 
to have fairly high fidelity for single base changes (transitions and 
transversions) and small frameshift errors(40).  
Mitochondrial DNA is replicated by DNA polymerase γ (Pol γ), a 
nuclear-encoded enzyme localized exclusively to the mitochondria(42). Pol γ 
belongs to the B-family of replicative polymerases, harboring a proofreading 
domain(41, 42, 47). Disabling the proofreading domain of Pol γ in mice 
increased the misincorporation rate to as high as 5-fold that of wild type(48). 
Studies of Pol γ from porcine liver showed a high fidelity both in the presence 
of balanced but excessive dNTPs and in the presence of dGMP, which inhibits 
the proofreading domain(47). Further experiments seeking to explain the high 
prevalence of mtDNA mutations in certain mutational hotspots of the 
mitochondrial genome found again very high fidelity, similar to the previously-
reported most faithful enzyme(49). Extensive work from the Bianchi lab 
indicates that dNTP pools in the cytosol and mitochondria are tightly linked 
and mitochondrial dNTP pools reflect cytosolic dNTP pools(50). Therefore, 
under normal situations, mtDNA synthesis by Pol γ should be quite faithful. 
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Experiments with minorly unbalanced dNTP pools and Pol γ showed extremely 
high fidelity again, even in the presence of high concentrations of dGMP(47).  
1.2B Effects of elevated, unbalanced, or depleted nucleotide pools on 
DNA replication fidelity 
Elevated dNTP pools can be beneficial in many ways. In yeast, 
elevated dNTP pools were able to promote lesion bypass by the replicative 
polymerase, at the expense of a higher mutation rate(51, 52). Damage-
induced dNTP synthesis provides dNTPs for other essential processes, from 
homologous recombination repair of a DNA double-strand break, to 
replacement of excised bases. Consistent with this is the fact that treatment of 
specific mutagens such as UV light, X-rays, ethylmethane sulfonate (EMS), or 
MNNG(53) induces increases in dNTP pools. In mammals, dNTPs are rapidly 
produced following DNA damage, and are used for repair at an equal rate, 
leading to stable dNTP pools(54). 
Elevated or unbalanced dNTP pools are mutagenic. Elevated 
nucleotide pools cause base-base mismatches during DNA replication through 
direct substitution of the correct base by an incorrect base, and can also cause 
increased mismatches through a “next-nucleotide effect”, where an 
overrepresented base at the correct position influences the misincorporation 
rate of the base before it(13). More specifically, the availability of the “next 
nucleotide” a DNA polymerase will incorporate causes reduced proofreading of 
the base it is in the process of incorporating, making a mistake more likely. 
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This is likely to be the mechanism by which excessive but balanced nucleotide 
pools are mutagenic. However, not all mismatches induced by mutagenic 
dNTP pools can be explained this way. Increases in a particular dNTP can 
directly inhibit the proofreading domain of some DNA polymerases, such as 
Pol III from E. coli(53). Moreover, DNA polymerase proofreading domains may 
be less efficient at correcting some mismatches than others, allowing some 
mistakes to persist(53). DNA polymerase susceptibility to these mutagenic 
pools is variable. When dNTP pools were increased as much as 50-fold for Pol 
ε, mutation rates increased 3-fold, while a 5-fold increase in dNTP 
concentration doubled the mutation frequency by Pol δ(40). 
Further unbalanced dNTP pools can cause more dramatic genome 
instability, especially in the mitochondrial genome. A recent study(55) found 
grossly unbalanced dNTP pools in wild type rat mitochondria, and in vitro 
assays of Pol γ fidelity using these pools showed drastically increased 
mutation rates. While the measurements of dNTP pools in this study were 
flawed, and a later study indicated balanced nucleotide pools within the 
mitochondria(56), the Song et al. study again underscores the effect 
unbalanced nucleotide pools can have on DNA replication fidelity. Studies 
culturing HeLa cells in artificially unbalanced dNTP pools stimulated long 
deletions in mitochondrial DNA(32). Mutation(57) or loss of TK2 both cause 
dNTP pool imbalances(58, 59) which lead to mitochondrial DNA depletion and 
disease phenotypes. Individuals harboring dGK mutations show liver failure 
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and neurological abnormalities resulting from depletion of mtDNA(60), from 
dNTP pool imbalances caused by reduction of dGTP and dATP within the 
mitochondria(61). Cultured myotubes from patients with dGK deficiency 
showed the same mitochondrial DNA depletion, which could be partially 
rescued by supplementation with exogenous dGMP and dAMP(62). Loss of 
thymidine phosphorylase in the TTP substrate cycle also leads to dNTP pool 
imbalances and causes destabilization of the mitochondrial genome(63). 
Eukaryotic systems also utilize polymerases that can bypass damaged 
DNA bases. These translesion synthesis (TLS) polymerases show a very low 
fidelity, sometimes misincorporating an incorrect base with higher efficiency 
than the correct base(41). 
1.3 Ribonucleotide reductase (RNR) 
1.3A Introduction to RNR 
 De novo dNTP biosynthesis takes place in the cytosol(64) and is 
catalyzed by the conserved enzyme ribonucleotide reductase. RNR is a 
cytosolic enzyme(65, 66), and dNTPs are shuttled into the nucleus or the 
mitochondria in order to take part in DNA synthesis and repair. All organisms 
found have an RNR that belongs to one of 3 classes(67). The differences 
between the 3 classes is found in which metal cofactor is used for catalysis; 
Class I has two subclasses, differing in homology of polypeptide sequences 
and allosteric control patterns. Class I reductases utilize an iron cofactor and 
are oxygen-dependent(68). E. coli, S. cerevisiae, and mammals have Class Ia 
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enzymes(67). Class II enzymes utilize a cobaltous cofactor, while Class III 
enzymes utilize an iron-sulfur cluster(67).  
 
 
1.3B RNR structure 
The enzyme is composed of two subunits, each proposed to comprise a 
dimer (Figure 1.4). In yeast, the large or R1 subunit is a homodimer of Rnr1p, 
while the small (R2) subunit is a heterodimer of Rnr2p and Rnr4p(69, 70). In 
mammals, RNR is traditionally described as being composed of two 
homodimers. The large subunit (Figure 1.5) is encoded by a single gene, 
Rrm1, while the small subunit is encoded by either the Rrm2 or Rrm2b (a.k.a. 
p53R2) gene(71) (Figure 1.6). Recent reports have challenged the notion that 
the bulk of active RNR is an a2b2 tetramer, instead suggesting that it is an α6β6 
dodecamer(72) or an α6β2 octamer(73). Yeast, but not mammals, also 
contains a fourth RNR gene, a DNA damage-inducible large subunit 
Rnr3p(74), which can form a heterodimer with Rnr1p. A homodimer of Rnr3p 
has low catalytic activity(74).  
The large subunit of RNR harbors the catalytic site as well as binding 
sites for allosteric effectors(67). The small subunit (Figure 1.6) generates a 
tyrosyl radical which is transferred to the large subunit for catalysis(15, 67, 69, 
70, 75). The radical is generated when dioxygen is split to generate 2 water 
molecules(67). The protons necessary for this come from each iron within the 
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diiron center and another comes from the tyrosine (Y177 in mammals), 
generating the radical. The fourth hydrogen is currently of unknown origin, but 
is speculated to come from an external source(67). Due to the extremely 
reactive nature of radicals, the radical is generated in a location that is buried 
about 10 Å inside the protein and is not transferred to the large subunit until 
substrate is bound(76). However buried the radical may be, it is located at the 
edge of a channel through the small subunit that is large enough for 
hydroxyurea to fit in and strip away the radical, thus inhibiting RNR 
activity(77). Mutation of residues within this channel to bulkier residues blocks 
access by HU and protects the radical(77). The radical transfer takes place 
through a proton-coupled electron transfer mechanism and covers a long 
range and involves many residues(78). Mutation of residues within the path, 
such as Y370 or Arg 265, decrease or abolish RNR activity by preventing the 
radical from reaching the catalytic site(78). 
The large subunit (Figure 1.5) is composed of three large domains. The 
largest domain forms an a/b barrel in 2 antiparallel halves. The other 2 
domains are a smaller N-terminal domain and excursions of the α/β barrel(79). 
Protected within the barrel domain is a β-hairpin structure, containing at its tip 
one of the most important conserved residues, Cys 439(79). Two other 
conserved redox-active cysteines within the catalytic site serve to abstract the 
2ʼ-OH from the substrate(67). The three cysteines are located far apart in the 
primary structure but are brought into close proximity in the barrel domain, 
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however not so close that they can form interfering disulfide bonds. They are 
positioned so as to be able to interact with the 2ʼ- and 3ʼ-OH, while the third 
cysteine is able to remove the 3ʼ-H during the reaction(79). 
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(12)
Figure 1.4. Schematic depicting RNR structure. Key enzyme sites are 
highlighted. General structure is simplified from Eriksson et al.(3), Smith et al.(1), 
and Uppsten, et al.(5). 
	   26	  
 
Figure 1.5. Crystal structure of  R1 dimer from E. coli. Critical sites are 
highlighted. Yellow, redox-reactive cysteines; magenta, allosteric activity site; 
blue, specificity site Loop 1; green, specificity site Loop 2. Loop 3 is not visible 
in this structure. A third R1 monomer is visible in the background but does not 
interact with either monomer within the dimer, Structure solved by Eriksson et 
al.(3) 
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Figure 1.6. Crystal structure of human p53R2 protein. Critical residues are 
highlighted. Red, iron cofactor; yellow, iron-coordinating residues; blue, radical 
transfer pathway. Structure was solved by Smith et al.(1). 
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1.3C Regulation of RNR in yeast	  
Yeast RNR is a tetramer encoded by four separate genes. RNR1 
encodes the large subunit and is expressed in a cell-cycle dependent 
manner(80). rnr1D is lethal to yeast. RNR2 and RNR4 together encode the 
small subunits(81), which in the active complex form a heterodimer(70). Rnr2p 
generates a tyrosine radical that is necessary for catalysis, while Rnr4p does 
not contain an iron center and cannot generate a radical(70, 81). The fourth 
RNR gene is encoded by RNR3, which is a DNA damage-inducible large 
subunit(74).  
In yeast, RNR activity is controlled by four known mechanisms with 
possibly more yet to be discovered. Three of the four mechanisms seem to be 
of equal importance, as disabling each of these independently shows the 
same phenotype. Primarily, RNR activity is limited to S-phase in the cell cycle 
by limiting the availability of the large subunit protein(80), and overall activity is 
limited by allosteric feedback control through an activity site within the large 
subunit(82). Substrate choice is controlled by a second allosteric regulatory 
site, the specificity site(80). An equally important mechanism is direct inhibition 
by the small protein SML1 in S. cerevisiae(83). A similar protein in the fission 
yeast Schizosaccharomyces pombe, Spd1, performs the same function(84). 
To date, no similar small protein has been found in mammals. The fourth RNR 
regulatory mechanism in yeast is differential subcellular localization, in which 
in the absence of DNA damage, Wtm1 anchors both Rnr2p and Rnr4p in the 
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nucleus while Rnr1p is cytoplasmic(85, 86). Following DNA damage, Rnr2p 
and Rnr4p translocate to the cytoplasm to form a complex with Rnr1p to 
produce dNTPs. During S-phase, Rnr2p and Rnr4p are found in both the 
nucleus and the cytoplasm, while Rnr1p remains cytoplasmic(85). 
Mutation of SML1 was originally noted to be able to suppress the 
lethality caused by loss of the essential checkpoint kinase MEC1(87). During 
DNA replication, encounters with DNA damage causes activation of a stress 
response and a signaling cascade, which ultimately results in the repair of 
DNA damage. In the absence of MEC1, the cells cannot recover from the 
replication stress and accumulate ssDNA which is prone to breakage, 
ultimately killing the cell(88). sml1D functions to increase the dNTP pool. This 
allows for increased survival by promoting lesion bypass(51) so that during 
replication, DNA damage is not a complete block to synthesis, and ssDNA 
does not accumulate, allowing cells to survive(87). 
1.3D Allosteric regulation of RNR in mammals 
Two sites within the large subunit bind allosteric effectors to influence 
RNR activity (Figure 1.5). Binding of allosteric effectors not only influences 
which substrate is bound for reduction, but also stimulates dimerization of the 
subunits, a step that is necessary for activity. In the specificity site, dATP (or 
ATP), dGTP, and dTTP bind in order to determine substrate choice, promoting 
reduction of CDP/UDP, ADP, or GDP, respectively(67). A somewhat-
disordered loop (Loop 2) within R1 forms part of this specificity site; mutation 
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of residues within loop 2 inhibits proper specificity site function and leads to 
imbalances and mutagenic dNTP pools(89). There is a cross-talk between the 
specificity and catalytic sites between two large subunit monomers; binding of 
an effector in the specificity site of one monomer will affect the conformation of 
Loop 2 and its interaction with the catalytic site of the other monomer, 
influencing substrate choice (refer back to Figure 1.4) (89, 90). In crystal 
structures with an effector bound at the specificity site, Loop 2 takes on a 
conformation that participates in shaping the active site uniquely to fit the 
proper substrate(91). Further crystal structures of Rrm1 show that this site, 
formed from the 100 N-terminal amino acids, is close to where the R2 subunit 
is proposed to bind and could affect subunit interactions(3). Studies show that 
in the absence of allosteric effectors, R1 exists as monomers while R2 exists 
in a dimeric form already. Binding of effectors to the large subunit stimulates 
formation of the R1 homodimer, which then forms strong associations with the 
R2 dimer, leading to the active tetramer(92).  
 A second allosteric site binds ATP and dATP and determines whether 
RNR activity will continue or not. This is a simple feedback system, such that 
binding of ATP stimulates activity, while binding dATP signals to the protein 
that there are enough dNTPs and activity stops(93). It is proposed that the 
mechanism of dATP inhibition of RNR activity is not through dATP-promoted 
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Figure 1.7. Summary of RNR specificity 
site effects. Binding of dATP within the 
specificity site promotes reduction of CDP 
and UDP. dTTP binding promotes reduction 
of  GDP, and dGTP binding promotes 
reduction of ADP. 
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 subunit dissociation, but through interference of the radical transfer pathway, 
blocking access by the radical to the catalytic site(92). Interestingly, dATP 
binding can have both a stimulatory and an inhibitory effect. The affinity for 
dATP is higher at the specificity site, so the inhibitory effect is only seen at 
high dNTP concentrations(67). This site will be discussed in detail further. 
A third allosteric site was proposed recently, in which ATP binding 
stimulates hexamerization of the subunits (to an α6β6 structure)(72). The 
presence of a third allosteric regulatory site would provide a model for the 
enzyme transitioning from an inactive state to a highly active state in S-phase, 
to a state (in the tetrameric situation) of lower activity to provide low amounts 
of dNTPs outside S-phase.  
1.3E Regulation of RNR activity in mammals through small subunit 
availability 
In addition to allosteric regulation, RNR activity is controlled by other 
mechanisms. Mammals limit Rrm2 protein levels outside of S-phase so that an 
Rrm1-Rrm2 complex cannot be formed, and dNTPs are not produced(67, 94). 
During S-phase, Rrm2 is transcribed to a maximal level that is unchanged 
even when DNA damaging agents are introduced, and Rrm2 protein is 
stabilized such that levels are constant throughout S-phase, even if damaging 
agents artificially prolong S-phase(95). It is proposed that in S-phase, the R2 
protein is induced to such a high extent that it becomes the excessive subunit 
and the R1 subunit is therefore limiting(96). Rrm1 also shows S-phase-specific 
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transcription(97), but due to a long protein half-life, Rrm1 protein levels are 
relatively constant throughout the cell cycle(98). When no longer needed to 
produce dNTPs for DNA synthesis, Rrm2 is specifically degraded in M-
phase(95), by the APCCdh1 complex(94). Cells that overproduce Rrm2 by 
roughly 14-fold were shown to also elevate enzymatic activity 6-fold, further 
confirming that RNR activity is partially limited by controlling availability of the 
R2 subunit(99). 
p53R2 follows a distinct pattern of regulation from Rrm2. Expressed at 
only low levels throughout the cell cycle(54), p53R2 is induced by p53 
following DNA damage(71, 100). Rrm2, but not p53R2, contains a KEN box, 
targeting Rrm2 for proteolytic degradation by the  APCCdh1 complex at M-
phase. p53R2 harbors a dinuclear iron radical-producing center similar to 
Rrm2, and can form an active complex with Rrm1(101), although in vitro 
studies on recombinant proteins have indicated lower activity in an Rrm1-
p53R2 complex than in an Rrm1-Rrm2 complex(102). In quiescent cells, Rrm2 
protein is undetectable, yet dNTP production persists and can be inhibited by 
treatment with hydroxyurea, indicating that a complex of Rrm1 and p53R2 is 
active(103). A study showed that while purified Rrm2 was able to oxidize a 
reporter molecule H2-DCFDA, purified p53R2 did not, and in fact was able to 
scavenge radicals in vitro(104).  
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1.4 RNR plays a role in maintaining genome stability  
1.4A Protective functions of RNR 
RNR is part of a regulatory pathway in yeast that begins with the Mec1 
kinase, the yeast homologue of Atm/Atr. The role of Atr and Mec1 is to survey 
the genome during S-phase and respond to replication stress, signaling 
downstream effectors that include RNR(105). Loss of Mec1 is lethal except in 
the presence of an unlinked suppressor known as sml1-1(87). It was found 
that sml1-1 is able to suppress mec1Δ lethality by allowing for increased 
activity of RNR, increasing dNTP pools and enabling cells to survive DNA 
damage(87). Following DNA damage in wild type cells, Sml1p is rapidly 
degraded, allowing for greater activity and elevating dNTP pools(106). 
1.4B RNR and the DNA-damage response 
 p53R2 is transcriptionally regulated by p53, and contains a p53-binding 
motif in the first intron(71, 107). Following several types of DNA-damaging 
events, p53R2 is induced, producing dNTPs which are then incorporated into 
DNA as the damage is repaired(107). In human oropharyngeal cancer (KB) 
cells, UV irradiation induced expression not only of p53R2 but also of Rrm2, 
while in a p53-null cancer cell line, UV irradiation only induced expression of 
Rrm2(108). A separate study reports that Rrm1 is also induced following UV 
irradiation, forming the holoenzyme with p53R2 in order to generate dNTPs for 
repair(101). This same study failed to detect Rrm2 induction following UV 
treatment, in opposition to the previous study(101). Furthermore, ectopic 
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expression of high-risk human papilloma virus oncoproteins suppressed 
p53R2 induction following oxidative stress, and cells derived from HPV-
positive cervical carcinoma cells were completely unable to elevate p53R2 
following H2O2 treatment, suggesting that carcinogenesis is inhibited by p53R2 
expression(109). 
In yeast, DNA damage induces expression of each RNR gene(74, 81, 
82). RNR is also released from its regulatory constraints; Sml1p is 
degraded(83) and Wtm1p allows Rnr2p and Rnr4p to translocate to the 
cytosol(86), permitting ribonucleotide reduction and elevating dNTP pools for 
DNA repair(82). Following DNA damage in mammals, p53R2 is induced, 
presumably in order to provide dNTPs for DNA repair(71). However, unlike in 
yeast, an increase in dNTP pools was not observed after DNA damage in 
mammalian cells (54). It was found that while p53R2 was induced and 
complexed with Rrm1, the dNTPs produced were used directly for DNA repair. 
Treatment of cells following DNA damage with hydroxyurea caused a 
decrease in dNTP pools, indicating that p53R2 was actively producing 
dNTPs(54). 
1.4C Mutagenic effects of RNR deregulation 
Overexpression of Rnr1p or expression of a feedback-resistant mutant 
of Rnr1p, rnr1-D57N, in yeast results in increased dNTPs levels(52, 82, 110, 
111) and an increased mutation rate, as would be expected from previous 
discussions of the fidelity of each replicative DNA polymerase. Somewhat 
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paradoxically, these increases are associated with improved survival following 
DNA damage. This is hypothesized to be due to an ability of cells to bypass 
DNA lesions or promote restart of stalled replication forks when enough (i.e. 
excessive) dNTPs are available, resulting in increased point mutations but 
decreased chromosomal rearrangements, such as sister-chromatid 
exchanges(52, 82).  
The previous manipulations had the effect of generating elevated dNTP 
pools within yeast. However, unbalanced dNTP pools can also be extremely 
mutagenic. Unbalanced dNTP pools were generated in yeast by mutating 
various residues within Loop 2, thereby disrupting the specificity site function. 
These mutations all generated a mutator phenotype(89). Furthermore, 
mutations which generated pools in which at least one dNTP was depleted 
activated the intra-S-phase checkpoint(89). 
1.4D RNR and carcinogenesis 
RNR also has several links to cancer. In a colorectal adenocarcinoma-
derived cell line (HCT116), p53R2 contains a point mutation which decreases 
enzyme activity by the Rrm1-p53R2 complex(107). Overexpression of Rrm2 in 
KB cells also led to hydroxyurea resistance and increased invasive 
potential(99).  
In mice, overexpression of either Rrm2 or p53R2 elevated lung cancer 
incidence in FVB mice, a background strain that is particularly susceptible to 
lung tumorigenesis(112). Overexpression of Rrm1 did not lead to lung 
	   37	  
tumorigenesis, and another study reports that Rrm1 overexpression is 
protective in an induced lung cancer model(113), and suppresses metastasis 
and invasion in cancer cells through PTEN induction(114). Both Rrm2 and 
p53R2 overexpression were able to synergize with deletion of Msh6 in mice to 
reduce lifespan, while again, Rrm1 overexpression was not(112), indicating 
that Rrm2 and p53R2 overexpression is mutagenic. The lack of mutagenesis 
in Rrm1-overexpressing mice can have several possible explanations. Firstly, 
the Rrm1 transgene showed limited overexpression in mouse tissues, while 
both Rrm2 and p53R2 were highly overexpressed in a broad range of tissues, 
most notably the lungs. Cell-cycle regulation of RNR is also a factor, as the 
Rrm1 protein is expressed at relatively constant levels throughout the cell 
cycle and is normally in excess, so that additional overexpression has limited 
effects. Meanwhile, Rrm2 and p53R2 are either tightly limited to S-phase or 
expressed at low levels, so that constantly high-level overexpression 
represents a complete loss of a regulatory mechanism. Lastly, both Rrm2 and 
p53R2 participate to form a free radical for catalysis, so elevated oxidative 
stress within the lungs (already a high-oxygen environment) overwhelms the 
DNA damage-repair machinery and leads to transformation and 
tumorigenesis. These possibilities are not mutually exclusive, however, and 
further work is underway to dissect the molecular mechanisms of RNR-
induced lung tumorigenesis. 
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1.4E RNR and mitochondrial genome maintenance 
Consistent with a role for p53R2 in maintaining genomic stability, it was 
found that p53R2-knockout mice are inviable(115). These mice die at around 3 
months of age from severe renal failure, and have depletion of mitochondrial 
DNA. The link between p53R2 and mitochondrial DNA maintenance is further 
supported by the discovery of p53R2 truncating mutations(116) and a 
homozygous missense mutation (G229V)(117) in humans with severe mtDNA 
depletion. Two other missense mutations were also reported that are 
proposed to interfere with the Rrm1/p53R2 docking interface and reduce 
enzyme activity, again causing mitochondrial DNA depletion and mitochondrial 
neurogastrointestinal encephalopathy (MNGIE)(118).  
In yeast, overexpression of the large (limiting) subunit of RNR, RNR1p, 
causes an expansion of mtDNA and can rescue mtDNA depletion. Similarly, 
mtDNA levels are elevated when a hyperactive mutant of RNR1p is expressed 
at physiological levels(82). Both treatments have previously been shown to 
elevate dNTP pools, indicating that nucleotide levels are an important 
determinant of mtDNA copy number. Interestingly, it was found that dNTPs are 
not limiting for mtDNA synthesis, as these changes lengthen the cell cycle, 
allowing more time for mtDNA synthesis at a normal rate. Deletion of RAD53 
also lengthens the cell cycle, and allows for mtDNA accumulation 
independently of dNTP levels(119). 
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1.5 Rrm1D57N, a feedback-resistant large RNR subunit 
The existence of separate regulatory sites within the enzyme was 
demonstrated by studies in murine lymphoma cell lines(93, 111, 120). Two 
separate cell lines exhibiting altered nucleotide pools were selected, and each 
had a mutator phenotype(93). Cells were selected to survive in an excess of 
dGTP, which normally stimulates the production of dATP, and inhibits CDP 
reduction(93). These cells were still sensitive to dATP inhibition, indicating that 
there are 2 sites that bind allosteric effectors, and only one was mutated(93, 
120). Cells were also selected that were resistant to dATP inhibition. RNR 
from these cells was stimulated by dATP binding when it should be 
inhibited(93). The mutation responsible for the dATP insensitivity was mapped 
to the third exon of Rrm1, and is a G-to-A transition at codon 57 (D57N)(111). 
The question was posed as to whether the activity site of RNR is unresponsive 
to dATP due to a lowered affinity of binding dATP, or if affinity is unchanged 
but the ability to distinguish ATP from dATP is lost. Studies on the 
corresponding residue (His 59) in the E. coli R1 homologue (NrdA) show that 
mutant proteins are 1) able to bind dATP with the same affinity as wild type; 
and 2) dATP binding in both the wild type and mutant proteins increases the 
association between the R1 and R2 subunits(121). These studies support the 
model proposed by Ingemarson and Uhlin(92), that dATP inhibition does not 
involve dissociation of the subunits, and further indicates that dATP 
insensitivity is through the inability to distinguish ATP from dATP in the activity 
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site. In transfected mammalian cells, the Rrm1D57N mutation caused elevated 
and dATP-resistant RNR activity, which conferred a mutator phenotype(111).  
In yeast, mutation of Rnr1p to rnr1-D57N results in 2-fold elevated (but 
balanced) dNTP pools, which lead to a 3-fold increase in mutation rate, as 
measured by canavanine resistance(82). The mutator phenotype was 
confirmed in a second study that found a synergistic increase in canavanine 
resistance when rnr1-D57N was combined with deletion of MutSa components 
Msh2 or Msh6(112). Also in yeast, constitutive overexpression of rnr1-D57N 
had a more dramatic phenotype, increasing pools of dNTPs while also 
decreasing pools of NTPs(110). This had the effect of slowing the cell cycle 
and preventing entry into S-phase, but did not trigger activation of the S-phase 
checkpoint(110). The DNA-damage checkpoint was actually inhibited in these 
cells, possibly because dNTP pools were already elevated. 
1.6 Summary and remaining questions 
This chapter discussed how nucleotides are generated and maintained, 
how they affect DNA replication and impact genome stability, and how RNR 
specifically is regulated and how it controls nucleotide pools and genome 
stability. The details of RNR regulation in mammals are still something of an 
unknown, however. Previous work has revealed that the basic regulatory 
mechanisms discovered in other organisms such as allosteric feedback control 
and transcriptional control, are present in mammals(25, 95, 120). It is still 
unknown how these mechanisms interact, and what is the impact of disabling 
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regulatory control of RNR. In yeast, RNR can be manipulated through 
overexpression or by loss of allosteric site function to elevate RNR activity, but 
whether these same manipulations alter RNR activity in mammals is untested. 
The main questions we want to answer are: how do the two main RNR 
regulatory mechanisms interact in mammals? What physiological function 
does RNR play in genome maintenance? Can RNR activity by manipulated 
through overexpression or hyperactivity, and can this have a therapeutic value 
for treatment of MDS? 
We have demonstrated the consequences of overexpressing either 
small subunit of RNR in mice. However, aside from generating lung tumors in 
mice, the full effects of Rrm2 and p53R2 overexpression are still unknown, in 
terms of RNR activity and dNTP pool effects. Moreover, we expect that lung 
tumorigenesis is caused by nuclear genome instability, but the impact on 
mitochondrial genome stability cannot be ascertained from those experiments. 
Previous work in mice and yeast has shown that dysfunction of RNR causes 
mitochondrial genome instability and that unbalanced nucleotide pools can 
cause mtDNA depletion. In yeast, overexpression of Rnr1p causes elevated 
mtDNA levels. It still remains to be seen whether similar RNR manipulation in 
mammals can cause increases in mtDNA content.  
RNR can be further deregulated in mammals. For example, 
simultaneous overexpression of Rrm1 and Rrm2 or p53R2 might be expected 
to further deregulate the enzyme and create a more hyperactive RNR. 
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Alternative methods to deregulate RNR in mammals may also be employed. 
The effect of the feedback-insensitive mutant Rrm1D57N is known in cultured 
mammalian cells and yeast, but the effect of expressing that mutant in a 
multicellular organism is unknown. Lastly, overexpressing the feedback-
insensitive mutant Rrm1D57N simultaneously disabled both main regulatory 
mechanisms in yeast. In mice, this could be accomplished by overexpressing 
either small RNR subunit in the presence of the Rrm1D57N mutant. If 
simultaneous disruption of both RNR regulatory mechanisms has the same 
effect in mammals as it has in yeast, we would expect that the slow cell 
proliferation would cause lethality during embryonic time points. Together, 
these experiments will allow us to more fully understand the importance of 
RNR regulation in mammals. 
In Chapter 2, I generated mice that overexpress multiple RNR subunits. 
With collaborators, I found that Rrm1Tg + Rrm2Tg and Rrm1Tg + p53R2Tg 
bitransgenic mice displayed altered RNR activity, which generated unbalanced 
dNTP pools and caused late-onset mitochondrial DNA depletion. In Chapter 3, 
we deregulated RNR by disabling the other main regulatory mechanism, 
allosteric feedback control. I found that mice with one regulatory mechanism of 
RNR disabled were grossly normal, but mice in which both main regulatory 
mechanisms were disabled are not viable. In Chapter 4, I generated mice in 
which the Rrm1-D57N allele was knocked in to the endogenous locus. I found 
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that mice homozygous for the mutant allele are not viable, and die during 
embryonic time points.  
	   44	  
 
References 
 
1. Smith P, Zhou B, Ho N, Yuan YC, Su L, Tsai SC, et al. 2.6 A X-ray 
crystal structure of human p53R2, a p53-inducible ribonucleotide reductase. 
Biochemistry. 2009;48(46):11134-41. PMCID: 2844085. 
2. Ferraro P, Pontarin G, Crocco L, Fabris S, Reichard P, Bianchi V. 
Mitochondrial deoxynucleotide pools in quiescent fibroblasts: a possible model 
for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). J Biol 
Chem. 2005;280(26):24472-80. 
3. Eriksson M, Uhlin U, Ramaswamy S, Ekberg M, Regnstrˆm K, Sjˆberg 
B, et al. Binding of allosteric effectors to ribonucleotide reductase protein R1: 
reduction of active-site cysteines promotes substrate binding. Structure. 
1997;5(8):1077-92. 
4. Leanza L, Ferraro P, Reichard P, Bianchi V. Metabolic interrelations 
within guanine deoxynucleotide pools for mitochondrial and nuclear DNA 
maintenance. Journal of Biological Chemistry. 2008;283(24):16437. 
5. Uppsten M, Farnegardh M, Domkin V, Uhlin U. The first holocomplex 
structure of ribonucleotide reductase gives new insight into its mechanism of 
action. Journal of molecular biology. 2006;359(2):365-77. 
6. Carter CE. Metabolism of purines and pyrimidines. Annu Rev Biochem. 
1956;25:123-46. 
7. Kornberg A, Lieberman I, Simms ES. Enzymatic synthesis and 
properties of 5-phosphoribosylpyrophosphate. J Biol Chem. 1955;215(1):389-
402. 
8. Holden H, Thoden J, Raushel F. Carbamoyl phosphate synthetase: an 
amazing biochemical odyssey from substrate to product. Cellular and 
Molecular Life Sciences. 1999;56(5):507-22. 
	   45	  
9. Huang M, Graves L. De novo synthesis of pyrimidine nucleotides; 
emerging interfaces with signal transduction pathways. Cellular and Molecular 
Life Sciences. 2003;60(2):321-36. 
10. Jones M. Pyrimidine nucleotide biosynthesis in animals: genes, 
enzymes, and regulation of UMP biosynthesis. Annual review of biochemistry. 
1980;49(1):253-79. 
11. Lieberman I, Kornberg A. Enzymatic synthesis and breakdown of a 
pyrimidine, orotic acid. I. Dihydroortic acid, ureidosuccinic acid, and 5-
carboxymethylhydantoin. J Biol Chem. 1954;207(2):911-24. 
12. Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev 
Biochem. 2006;75:681-706. 
13. Reichard P. Interactions between deoxyribonucleotide and DNA 
synthesis. Annual review of biochemistry. 1988;57(1):349-74. 
14. Bianchi V, Pontis E, Reichard P. Interrelations between substrate 
cycles and de novo synthesis of pyrimidine deoxyribonucleoside triphosphates 
in 3T6 cells. Proceedings of the National Academy of Sciences of the United 
States of America. 1986;83(4):986. 
15. Nordlund P, Reichard P. Ribonucleotide reductases. 2006. 
16. Carreras C, Santi D. The catalytic mechanism and structure of 
thymidylate synthase. Annual review of biochemistry. 1995;64(1):721-62. 
17. Hartman S. Phosphoribosyl pyrophosphate amidotransferase. Journal 
of Biological Chemistry. 1963;238(9):3024. 
18. Smith J. Glutamine PRPP amidotransferase: snapshots of an enzyme 
in action. Current opinion in structural biology. 1998;8(6):686-94. 
19. Smith J. Enzymes of nucleotide synthesis. Current opinion in structural 
biology. 1995;5(6):752-7. 
	   46	  
20. Hartman S, Buchanan J. Nucleic acids, purines, pyrimidines (nucleotide 
synthesis). Annual review of biochemistry. 1959;28(1):365-410. 
21. Murray A. The biological significance of purine salvage. Annual review 
of biochemistry. 1971;40(1):811-26. 
22. Frangini M, Rampazzo C, Franzolin E, Lara MC, Vila MR, Marti R, et al. 
Unchanged thymidine triphosphate pools and thymidine metabolism in two 
lines of thymidine kinase 2-mutated fibroblasts. FEBS J. 2009;276(4):1104-13. 
23. Saada A. Deoxyribonucleotides and disorders of mitochondrial DNA 
integrity. DNA Cell Biol. 2004;23(12):797-806. 
24. Ke PY, Kuo YY, Hu CM, Chang ZF. Control of dTTP pool size by 
anaphase promoting complex/cyclosome is essential for the maintenance of 
genetic stability. Genes Dev. 2005;19(16):1920-33. PMCID: 1186191. 
25. Chabes AL, Bjorklund S, Thelander L. S Phase-specific transcription of 
the mouse ribonucleotide reductase R2 gene requires both a proximal 
repressive E2F-binding site and an upstream promoter activating region. J Biol 
Chem. 2004;279(11):10796-807. 
26. Gazziola C, Ferraro P, Moras M, Reichard P, Bianchi V. Cytosolic high 
K M 5 -nucleotidase and 5 (3 )-deoxyribonucleotidase in substrate cycles 
involved in nucleotide metabolism. Journal of Biological Chemistry. 
2001;276(9):6185. 
27. Hˆglund L, Reichard P. Cytoplasmic 5'(3')-nucleotidase from human 
placenta. Journal of Biological Chemistry. 1990;265(12):6589. 
28. Bianchi V. Regulation of deoxynucleotide pools by substrate cycles. 
Adv Exp Med Biol. 1998;431:501-6. 
29. Hˆglund L, Pontis E, Reichard P. Effects of deoxycytidine and thymidine 
kinase deficiency on substrate cycles between deoxyribonucleosides and their 
5 -phosphates. Cancer research. 1988;48(13):3681. 
	   47	  
30. Gallinaro L, Crovatto K, Rampazzo C, Pontarin G, Ferraro P, Milanesi 
E, et al. Human Mitochondrial 5 -Deoxyribonucleotidase. Journal of Biological 
Chemistry. 2002;277(38):35080. 
31. Pugmire M, Ealick S. Structural analyses reveal two distinct families of 
nucleoside phosphorylases. Biochemical Journal. 2002;361(Pt 1):1. 
32. Song S, Wheeler LJ, Mathews CK. Deoxyribonucleotide pool imbalance 
stimulates deletions in HeLa cell mitochondrial DNA. J Biol Chem. 
2003;278(45):43893-6. 
33. Blackburn MR, Aldrich M, Volmer JB, Chen W, Zhong H, Kelly S, et al. 
The use of enzyme therapy to regulate the metabolic and phenotypic 
consequences of adenosine deaminase deficiency in mice. Differential impact 
on pulmonary and immunologic abnormalities. J Biol Chem. 
2000;275(41):32114-21. 
34. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: 
metabolic basis of immune deficiency and pulmonary inflammation. Adv 
Immunol. 2005;86:1-41. 
35. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et 
al. Elevated uric acid increases blood pressure in the rat by a novel crystal-
independent mechanism. Hypertension. 2001;38(5):1101-6. 
36. Guyenet P. The sympathetic control of blood pressure. Nature Reviews 
Neuroscience. 2006;7(5):335-46. 
37. Zandi-Nejad K, Luyckx V, Brenner B. Adult hypertension and kidney 
disease: the role of fetal programming. Hypertension. 2006;47(3):502. 
38. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Finch J, et 
al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential 
hypertension. Kidney Int. 2004;66(1):281-7. 
	   48	  
39. Wu X, Wakamiya M, Vaishnav S, Geske R, Montgomery C, Jr., Jones 
P, et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. 
Proc Natl Acad Sci U S A. 1994;91(2):742-6. PMCID: 43025. 
40. Thomas D, Roberts J, Sabatino R, Myers T, Tan C, Downey K, et al. 
Fidelity of mammalian DNA replication and replicative DNA polymerases. 
Biochemistry. 1991;30(51):11751-9. 
41. Kunkel T. DNA replication fidelity. Journal of Biological Chemistry. 
2004;279(17):16895. 
42. McCulloch S, Kunkel T. The fidelity of DNA synthesis by eukaryotic 
replicative and translesion synthesis polymerases. Cell research. 
2008;18(1):148-61. 
43. Byrnes JJ, Downey KM, Black VL, So AG. A new mammalian DNA 
polymerase with 3' to 5' exonuclease activity: DNA polymerase delta. 
Biochemistry. 1976;15(13):2817-23. 
44. Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. 
Division of labor at the eukaryotic replication fork. Mol Cell. 2008;30(2):137-44. 
PMCID: 2654179. 
45. Pavlov Y, Frahm C, McElhinny S, Niimi A, Suzuki M, Kunkel T. 
Evidence that Errors Made by DNA Polymerase [alpha] are Corrected by DNA 
Polymerase [delta]. Current Biology. 2006;16(2):202-7. 
46. Pursell ZF, Isoz I, Lundstrom EB, Johansson E, Kunkel TA. Yeast DNA 
polymerase epsilon participates in leading-strand DNA replication. Science. 
2007;317(5834):127-30. PMCID: 2233713. 
47. Kunkel T, Mosbaugh D. Exonucleolytic proofreading by a mammalian 
DNA polymerase. gamma. Biochemistry. 1989;28(3):988-95. 
48. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink J, Rovio A, 
Bruder C, et al. Premature ageing in mice expressing defective mitochondrial 
DNA polymerase. Nature. 2004;429(6990):417-23. 
	   49	  
49. Zheng W, Khrapko K, Coller H, Thilly W, Copeland W. Origins of human 
mitochondrial point mutations as DNA polymerase [gamma]-mediated errors. 
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 
2006;599(1-2):11-20. 
50. Rampazzo C, Ferraro P, Pontarin G, Fabris S, Reichard P, Bianchi V. 
Mitochondrial deoxyribonucleotides, pool sizes, synthesis, and regulation. J 
Biol Chem. 2004;279(17):17019-26. 
51. Sabouri N, Viberg J, Goyal DK, Johansson E, Chabes A. Evidence for 
lesion bypass by yeast replicative DNA polymerases during DNA damage. 
Nucleic Acids Res. 2008;36(17):5660-7. PMCID: 2553575. 
52. Fasullo M, Tsaponina O, Sun M, Chabes A. Elevated dNTP levels 
suppress hyper-recombination in Saccharomyces cerevisiae S-phase 
checkpoint mutants. Nucleic Acids Res. 2010;38(4):1195-203. PMCID: 
2831302. 
53. Kunz B, Kohalmi S. Modulation of mutagenesis by deoxyribonucleotide 
levels. Annual review of genetics. 1991;25(1):339-59. 
54. Hakansson P, Hofer A, Thelander L. Regulation of mammalian 
ribonucleotide reduction and dNTP pools after DNA damage and in resting 
cells. J Biol Chem. 2006;281(12):7834-41. 
55. Song S, Pursell Z, Copeland W, Longley M, Kunkel T, Mathews C. DNA 
precursor asymmetries in mammalian tissue mitochondria and possible 
contribution to mutagenesis through reduced replication fidelity. Proceedings 
of the National Academy of Sciences of the United States of America. 
2005;102(14):4990. 
56. Ferraro P, Nicolosi L, Bernardi P, Reichard P, Bianchi V. Mitochondrial 
deoxynucleotide pool sizes in mouse liver and evidence for a transport 
mechanism for thymidine monophosphate. Proc Natl Acad Sci U S A. 
2006;103(49):18586-91. PMCID: 1693706. 
57. Akman HO, Dorado B, Lopez LC, Garcia-Cazorla A, Vila MR, Tanabe 
LM, et al. Thymidine kinase 2 (H126N) knockin mice show the essential role of 
	   50	  
balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol 
Genet. 2008;17(16):2433-40. 
58. Zhou X, Solaroli N, Bjerke M, Stewart JB, Rozell B, Johansson M, et al. 
Progressive loss of mitochondrial DNA in thymidine kinase 2-deficient mice. 
Hum Mol Genet. 2008;17(15):2329-35. 
59. Ashley N, Adams S, Slama A, Zeviani M, Suomalainen A, Andreu AL, et 
al. Defects in maintenance of mitochondrial DNA are associated with 
intramitochondrial nucleotide imbalances. Hum Mol Genet. 2007;16(12):1400-
11. 
60. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, et al. 
The deoxyguanosine kinase gene is mutated in individuals with depleted 
hepatocerebral mitochondrial DNA. Nat Genet. 2001;29(3):337-41. 
61. Saada A. Mitochondrial deoxyribonucleotide pools in deoxyguanosine 
kinase deficiency. Mol Genet Metab. 2008;95(3):169-73. 
62. Bulst S, Abicht A, Holinski-Feder E, Muller-Ziermann S, Koehler U, 
Thirion C, et al. In vitro supplementation with dAMP/dGMP leads to partial 
restoration of mtDNA levels in mitochondrial depletion syndromes. Hum Mol 
Genet. 2009;18(9):1590-9. 
63. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene 
mutations in MNGIE, a human mitochondrial disorder. Science. 
1999;283(5402):689-92. 
64. Pontarin G, Fijolek A, Pizzo P, Ferraro P, Rampazzo C, Pozzan T, et al. 
Ribonucleotide reduction is a cytosolic process in mammalian cells 
independently of DNA damage. Proc Natl Acad Sci U S A. 
2008;105(46):17801-6. PMCID: 2584719. 
65. Engstrom Y, Rozell B, Hansson HA, Stemme S, Thelander L. 
Localization of ribonucleotide reductase in mammalian cells. EMBO J. 
1984;3(4):863-7. PMCID: 557439. 
	   51	  
66. Engstrom Y, Rozell B. Immunocytochemical evidence for the 
cytoplasmic localization and differential expression during the cell cycle of the 
M1 and M2 subunits of mammalian ribonucleotide reductase. EMBO J. 
1988;7(6):1615-20. PMCID: 457144. 
67. Kolberg M, Strand KR, Graff P, Andersson KK. Structure, function, and 
mechanism of ribonucleotide reductases. Biochim Biophys Acta. 2004;1699(1-
2):1-34. 
68. Gon S, Beckwith J. Ribonucleotide reductases: influence of 
environment on synthesis and activity. Antioxid Redox Signal. 2006;8(5-
6):773-80. 
69. Ortigosa AD, Hristova D, Perlstein DL, Zhang Z, Huang M, Stubbe J. 
Determination of the in vivo stoichiometry of tyrosyl radical per betabeta' in 
Saccharomyces cerevisiae ribonucleotide reductase. Biochemistry. 
2006;45(40):12282-94. 
70. Chabes A, Domkin V, Larsson G, Liu A, Graslund A, Wijmenga S, et al. 
Yeast ribonucleotide reductase has a heterodimeric iron-radical-containing 
subunit. Proc Natl Acad Sci U S A. 2000;97(6):2474-9. PMCID: 15953. 
71. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, 
et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle 
checkpoint for DNA damage. Nature. 2000;404(6773):42-9. 
72. Kashlan O, Scott C, Lear J, Cooperman B. A Comprehensive Model for 
the Allosteric Regulation of Mammalian Ribonucleotide Reductase. Functional 
Consequences of ATP-and dATP-Induced Oligomerization of the Large 
SubunitÜ. Biochemistry. 2002;41(2):462-74. 
73. Rofougaran R, Vodnala M, Hofer A. Enzymatically active mammalian 
ribonucleotide reductase exists primarily as an 6 2 octamer. Journal of 
Biological Chemistry. 2006;281(38):27705. 
74. Domkin V, Thelander L, Chabes A. Yeast DNA damage-inducible Rnr3 
has a very low catalytic activity strongly stimulated after the formation of a 
cross-talking Rnr1/Rnr3 complex. J Biol Chem. 2002;277(21):18574-8. 
	   52	  
75. Tong W, Burdi D, Riggs-Gelasco P, Chen S, Edmondson D, Huynh BH, 
et al. Characterization of Y122F R2 of Escherichia coli ribonucleotide 
reductase by time-resolved physical biochemical methods and X-ray 
crystallography. Biochemistry. 1998;37(17):5840-8. 
76. Uhlin U, Eklund H. Structure of ribonucleotide reductase protein R1. 
Nature. 1994;370(6490):533-9. 
77. Sneeden JL, Loeb LA. Mutations in the R2 subunit of ribonucleotide 
reductase that confer resistance to hydroxyurea. J Biol Chem. 
2004;279(39):40723-8. 
78. Narvaez AJ, Voevodskaya N, Thelander L, Graslund A. The 
involvement of Arg265 of mouse ribonucleotide reductase R2 protein in proton 
transfer and catalysis. J Biol Chem. 2006;281(36):26022-8. 
79. Uhlin U, Eklund H. The Ten-stranded [beta]/[alpha] Barrel in 
Ribonucleotide Reductase Protein R1. Journal of molecular biology. 
1996;262(3):358-69. 
80. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, 
regulation, regulation. Trends Biochem Sci. 1992;17(3):119-23. 
81. Wang PJ, Chabes A, Casagrande R, Tian XC, Thelander L, Huffaker 
TC. Rnr4p, a novel ribonucleotide reductase small-subunit protein. Mol Cell 
Biol. 1997;17(10):6114-21. PMCID: 232461. 
82. Chabes A, Georgieva B, Domkin V, Zhao X, Rothstein R, Thelander L. 
Survival of DNA damage in yeast directly depends on increased dNTP levels 
allowed by relaxed feedback inhibition of ribonucleotide reductase. Cell. 
2003;112(3):391-401. 
83. Chabes A, Domkin V, Thelander L. Yeast Sml1, a protein inhibitor of 
ribonucleotide reductase. Journal of Biological Chemistry. 
1999;274(51):36679. 
	   53	  
84. Hakansson P, Dahl L, Chilkova O, Domkin V, Thelander L. The 
Schizosaccharomyces pombe replication inhibitor Spd1 regulates 
ribonucleotide reductase activity and dNTPs by binding to the large Cdc22 
subunit. J Biol Chem. 2006;281(3):1778-83. 
85. Yao R, Zhang Z, An X, Bucci B, Perlstein D, Stubbe J, et al. Subcellular 
localization of yeast ribonucleotide reductase regulated by the DNA replication 
and damage checkpoint pathways. Proceedings of the National Academy of 
Sciences. 2003;100(11):6628. 
86. Lee YD, Elledge SJ. Control of ribonucleotide reductase localization 
through an anchoring mechanism involving Wtm1. Genes Dev. 
2006;20(3):334-44. PMCID: 1361704. 
87. Zhao X, Muller EG, Rothstein R. A suppressor of two essential 
checkpoint genes identifies a novel protein that negatively affects dNTP pools. 
Mol Cell. 1998;2(3):329-40. 
88. Feng W, Collingwood D, Boeck M, Fox L, Alvino G, Fangman W, et al. 
Genomic mapping of single-stranded DNA in hydroxyurea-challenged yeasts 
identifies origins of replication. Nature cell biology. 2006;8(2):148-55. 
89. Kumar D, Viberg J, Nilsson AK, Chabes A. Highly mutagenic and 
severely imbalanced dNTP pools can escape detection by the S-phase 
checkpoint. Nucleic Acids Res. 2010. 
90. Reichard P, Eliasson R, Ingemarson R, Thelander L. Cross-talk 
between the allosteric effector-binding sites in mouse ribonucleotide 
reductase. J Biol Chem. 2000;275(42):33021-6. 
91. Larsson KM, Jordan A, Eliasson R, Reichard P, Logan DT, Nordlund P. 
Structural mechanism of allosteric substrate specificity regulation in a 
ribonucleotide reductase. Nat Struct Mol Biol. 2004;11(11):1142-9. 
92. Ingemarson R, Thelander L. A Kinetic Study on the Influence of 
Nucleoside Triphosphate Effectors on Subunit Interaction in Mouse 
Ribonucleotide ReductaseÜ. Biochemistry. 1996;35(26):8603-9. 
	   54	  
93. Eriksson S, Gudas LJ, Clift SM, Caras IW, Ullman B, Martin DW, Jr. 
Evidence for genetically independent allosteric regulatory domains of the 
protein M1 subunit of mouse ribonucleotide reductase. J Biol Chem. 
1981;256(19):10193-7. 
94. Chabes AL, Pfleger CM, Kirschner MW, Thelander L. Mouse 
ribonucleotide reductase R2 protein: a new target for anaphase-promoting 
complex-Cdh1-mediated proteolysis. Proc Natl Acad Sci U S A. 
2003;100(7):3925-9. PMCID: 153024. 
95. Chabes A, Thelander L. Controlled protein degradation regulates 
ribonucleotide reductase activity in proliferating mammalian cells during the 
normal cell cycle and in response to DNA damage and replication blocks. J 
Biol Chem. 2000;275(23):17747-53. 
96. Lin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, et 
al. Excess ribonucleotide reductase R2 subunits coordinate the S phase 
checkpoint to facilitate DNA damage repair and recovery from replication 
stress. Biochem Pharmacol. 2007;73(6):760-72. 
97. Bjorklund S, Skog S, Tribukait B, Thelander L. S-phase-specific 
expression of mammalian ribonucleotide reductase R1 and R2 subunit 
mRNAs. Biochemistry. 1990;29(23):5452-8. 
98. Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. 
Cell cycle-dependent expression of mammalian ribonucleotide reductase. 
Differential regulation of the two subunits. J Biol Chem. 1985;260(16):9114-6. 
99. Zhou B, Tsai P, Ker R, Tsai J, Ho R, Yu J, et al. Overexpression of 
transfected human ribonucleotide reductase M2 subunit in human cancer cells 
enhances their invasive potential. Clinical and Experimental Metastasis. 
1998;16(1):43-9. 
100. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura 
Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell 
cycle checkpoint. Cancer Res. 2001;61(22):8256-62. 
	   55	  
101. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa 
H, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in 
vitro with the R1 protein, which is expressed both in resting cells in response 
to DNA damage and in proliferating cells. J Biol Chem. 2001;276(44):40647-
51. 
102. Yen Y, Chu B, Yen C, Shih J, Zhou B. Enzymatic property analysis of 
p53R2 subunit of human ribonucleotide reductase. Adv Enzyme Regul. 
2006;46:235-47. 
103. Pontarin G, Ferraro P, Hakansson P, Thelander L, Reichard P, Bianchi 
V. p53R2-dependent ribonucleotide reduction provides deoxyribonucleotides 
in quiescent human fibroblasts in the absence of induced DNA damage. J Biol 
Chem. 2007;282(23):16820-8. 
104. Xue L, Zhou B, Liu X, Wang T, Shih J, Qi C, et al. Structurally 
dependent redox property of ribonucleotide reductase subunit p53R2. Cancer 
research. 2006;66(4):1900. 
105. Elledge SJ, Davis RW. Two genes differentially regulated in the cell 
cycle and by DNA-damaging agents encode alternative regulatory subunits of 
ribonucleotide reductase. Genes Dev. 1990;4(5):740-51. 
106. Zhao X, Chabes A, Domkin V, Thelander L, Rothstein R. The 
ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 
kinase cascade during growth and in response to DNA damage. EMBO J. 
2001;20(13):3544-53. PMCID: 125510. 
107. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino M, Nakamura Y, 
et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell 
cycle checkpoint. Cancer research. 2001;61(22):8256. 
108. Zhou B, Liu X, Mo X, Xue L, Darwish D, Qiu W, et al. The human 
ribonucleotide reductase subunit hRRM2 complements p53R2 in response to 
UV-induced DNA repair in cells with mutant p53. Cancer research. 
2003;63(20):6583. 
	   56	  
109. Lembo D, Donalisio M, Cornaglia M, Azzimonti B, Demurtas A, Landolfo 
S. Effect of high-risk human papillomavirus oncoproteins on p53R2 gene 
expression after DNA damage. Virus Res. 2006;122(1-2):189-93. 
110. Chabes A, Stillman B. Constitutively high dNTP concentration inhibits 
cell cycle progression and the DNA damage checkpoint in yeast 
Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 2007;104(4):1183-8. 
PMCID: 1783093. 
111. Caras IW, Martin DW, Jr. Molecular cloning of the cDNA for a mutant 
mouse ribonucleotide reductase M1 that produces a dominant mutator 
phenotype in mammalian cells. Mol Cell Biol. 1988;8(7):2698-704. PMCID: 
363480. 
112. Xu X, Page JL, Surtees JA, Liu H, Lagedrost S, Lu Y, et al. Broad 
overexpression of ribonucleotide reductase genes in mice specifically induces 
lung neoplasms. Cancer Res. 2008;68(8):2652-60. PMCID: 2459241. 
113. Gautam A, Bepler G. Suppression of lung tumor formation by the 
regulatory subunit of ribonucleotide reductase. Cancer Res. 2006;66(13):6497-
502. 
114. Gautam A, Li Z, Bepler G. RRM1-induced metastasis suppression 
through PTEN-regulated pathways. Oncogene. 2003;22(14):2135-42. 
115. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. 
Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure 
through attenuation of dNTP pools. Nat Genet. 2003;34(4):440-5. 
116. Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, et al. Mutation 
of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes 
severe mitochondrial DNA depletion. Nat Genet. 2007;39(6):776-80. 
117. Kollberg G, Darin N, Benan K, Moslemi AR, Lindal S, Tulinius M, et al. 
A novel homozygous RRM2B missense mutation in association with severe 
mtDNA depletion. Neuromuscul Disord. 2009;19(2):147-50. 
	   57	  
118. Shaibani A, Shchelochkov OA, Zhang S, Katsonis P, Lichtarge O, 
Wong LJ, et al. Mitochondrial neurogastrointestinal encephalopathy due to 
mutations in RRM2B. Arch Neurol. 2009;66(8):1028-32. PMCID: 2747647. 
119. Lebedeva MA, Shadel GS. Cell cycle- and ribonucleotide reductase-
driven changes in mtDNA copy number influence mtDNA Inheritance without 
compromising mitochondrial gene expression. Cell Cycle. 2007;6(16):2048-57. 
PMCID: 2606055. 
120. Weinberg G, Ullman B, Martin DW, Jr. Mutator phenotypes in 
mammalian cell mutants with distinct biochemical defects and abnormal 
deoxyribonucleoside triphosphate pools. Proc Natl Acad Sci U S A. 
1981;78(4):2447-51. PMCID: 319363. 
121. Birgander P, Kasrayan A, Sjˆberg B. Mutant R1 proteins from 
Escherichia coli class Ia ribonucleotide reductase with altered responses to 
dATP inhibition. Journal of Biological Chemistry. 2004;279(15):14496. 
 	  
 57 
Chapter 2: Ribonucleotide reductase is not limiting for mitochondrial 
DNA copy number in mice1 
 
ABSTRACT 
Ribonucleotide reductase (RNR) is the rate-limiting enzyme in 
deoxyribonucleoside triphosphate (dNTP) biosynthesis, with important roles in 
nuclear genome maintenance. RNR is also essential for maintenance of 
mitochondrial DNA (mtDNA) in mammals. The mechanisms regulating mtDNA 
copy number in mammals are only being discovered. In budding yeast, RNR 
overexpression resulted in increased mtDNA levels, and rescued the disease 
phenotypes caused by a mutant mtDNA polymerase. This raised the question 
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of whether mtDNA copy number increase by RNR induction could be a 
strategy for treating diseases with mtDNA mutations. We show here that high-
level overexpression of RNR subunits (Rrm1, Rrm2 and p53R2; separately or 
in different combinations) in mice does not result in mtDNA copy number 
elevation. Instead, simultaneous expression of two RNR subunits leads to 
imbalanced dNTP pools and progressive mtDNA depletion in the skeletal 
muscle, without mtDNA mutagenesis. We also show that endogenous RNR 
transcripts are downregulated in response to large increases of mtDNA in 
mice, which is indicative of nuclear-mitochondrial crosstalk with regard to 
mtDNA copy number. Our results establish that RNR is not limiting for mtDNA 
copy number in mice, and provide new evidence for the importance of 
balanced dNTP pools in mtDNA maintenance in postmitotic tissues. 
 
 
INTRODUCTION 
Ribonucleotide reductase (RNR) catalyzes the rate-limiting step in de 
novo synthesis of deoxyribonucleoside triphosphates (dNTPs) [reviewed in 
(1)]. The enzyme is known to contribute to malignant transformation (2, 3). 
During S-phase, RNR is abundant as a tetramer composed of homodimers of 
the large Rrm1 and small Rrm2 subunits. In non-cycling cells, Rrm2 is 
replaced by the alternative small subunit p53R2 (4). The latter is induced by 
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the tumour suppressor p53 and was initially considered to contribute to 
nuclear DNA damage responses (5, 6).   
Mutation of p53R2 has recently been found to be an important cause of 
human inherited diseases. Inactivating mutations of RRM2B, the gene 
encoding p53R2, were not associated with neoplasms, but caused early-onset 
fatal depletion of mitochondrial DNA (mtDNA) (MIM #612075) (7). Similarly, 
knock-out mice lacking p53R2 exhibited near-total loss of mtDNA and died 
shortly after weaning (7, 8). We recently reported that a dominant RRM2B 
mutation led to truncated p53R2 and caused adult-onset progressive external 
ophthalmoplegia (PEO) with multiple mtDNA deletions (9). Certain compound 
heterozygote RRM2B mutations have also been shown to result in 
mitochondrial neurogastrointestinal encephalopathy (MNGIE; MIM #603041) 
(10). Defects in p53R2 can therefore cause diseases of differing severity, 
ranging from fatal multisystem disorders with mtDNA depletion in children, to 
an adult-onset muscle disorder with multiple mtDNA deletions. These results 
highlight the essential role of RNR in mtDNA maintenance in postmitotic cells. 
Increasing mtDNA copy number has emerged as an attractive target of 
intervention for mtDNA diseases. Even a minimal amount of wild-type mtDNA 
can compensate a functionally recessive mutant (11). In the budding yeast 
Saccharomyces cerevisiae, RNR overexpression led to elevation of mtDNA 
copy number (12) and to the rescue of the petite phenotype of mtDNA 
polymerase mutants that carried mutations equivalent to those in autosomal 
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dominant PEO (13). This suggested that RNR levels, by affecting dNTP pools, 
might be rate-limiting for mtDNA synthesis, and that increasing the availability 
of the enzyme might be a tool for increasing mtDNA abundance. Whether 
RNR induction could increase mtDNA in mammals, as it does in yeast, has so 
far not been investigated. 
In mice, considerable increase of mtDNA copy number has only been 
achieved in two mouse models, overexpressing the mitochondrial transcription 
factor A (TFAM) or the mitochondrial DNA helicase Twinkle (14, 15). TFAM is 
required for mtDNA transcription, but it also binds DNA with low specificity and 
packages mtDNA in a histone-like manner (16-18). Its levels closely follow 
mtDNA levels. Twinkle helicase is known to increase mtDNA copy number by 
affecting the replication initiation rate (19). In this study, we set out to 
determine whether overexpression of RNR subunits, alone or in combination 
with each other, influence mtDNA copy number in mammalian tissues. 
 
MATERIALS AND METHODS 
Generation of transgenic mice  
The Rrm1Tg, Rrm2Tg, and p53R2Tg mice have been previously described (3). 
Briefly, the mice were maintained on a pure FVB/N strain background and 
expressed their transgene under the control of chicken beta-actin promoter 
and cytomegalovirus enhancer regulatory sequences. The transgenic mice 
seemed grossly normal and were fertile. The presence of the transgene was 
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verified by PCR analysis as described previously (3). Rrm1Tg mice showed 
restricted overexpression of Rrm1 protein primarily in the skeletal muscle by 
immunoblotting whereas Rrm2Tg and p53R2Tg mice had widespread, high-level 
overexpression of the transgene in all tested tissues. For this study, we 
created mice overexpressing Rrm1 together with either Rrm2 or p53R2 by 
cross-breeding mice that were hemizygous for each transgene. Because the 
PCR assay used to detect Rrm1Tg and p53R2Tg is not transgene-specific (3), 
the presence of Rrm1Tg or p53R2Tg in offspring from these crosses was 
determined by Southern blotting. Briefly, tail DNA obtained from offspring was 
digested overnight with BamHI (Rrm1Tg) or EcoRV (p53R2Tg). After DNA was 
immobilized on a nylon membrane (GeneScreen Plus, Perkin Elmer), 
transgene bands were detected by hybridization with radiolabeled probes 
derived from previously described pCaggs RNR expression constructs (3). 
Pathological examination of lung neoplasms was performed as before (3).  
The TwinkleTg (15) and TFAMTg mice (20) used here were also previously 
described. Both were in C57BL/6 background, and expressed the transgene 
under a ubiquitous beta-actin promoter. The Twinkle-mice were backcrossed 
to C57BL/6 from FVB/N for more than twelve generations, and the congeneity 
was confirmed with the Mouse Medium Density SNP Panel (Illumina). 
 
Quantification of RNR transgene overexpression 
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Western blotting for RNR subunits was performed as previously described (3). 
Chemiluminescent signal was detected on a VersaDoc Imaging system and 
quantified using Quantity One software (Bio-Rad Laboratories). Band intensity 
was determined for each dilution series sample and plotted following 
subtraction of background signal. The measured intensity for each undiluted 
wild-type band was fitted to the generated line for the corresponding RNRTg 
dilution series. Fold overexpression values were corrected for loading by 
standardization based on α-tubulin signal. 
 
Southern blotting for mtDNA copy number determination 
Total DNA was isolated from tissues by proteinase K digestion and standard 
phenol-chloroform extraction. Southern blotting was performed essentially as 
described (21). Briefly, three micrograms total DNA was digested with SacI 
overnight at 37◦C, samples were then separated by electrophoresis in an 
agarose gel and blotted by alkaline transfer onto a Hybond N+ membrane 
(Amersham Biosciences). The membrane was hybridized overnight at 68◦C in 
a roller hybridizer using 5 μCi/ml 32P-dCTP labeled (PCR-generated) mouse 
mtDNA probe, and 18S rDNA probe in pBR322 plasmid. Phosphoimager 
analysis was done with Typhoon 9400 (Amersham Biosciences) and mtDNA 
was quantified against the 18S rDNA signal using ImageQuant v5.0 software 
(Amersham Biosciences). 
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Real time PCR 
For mtDNA quantification, the quantitative real-time (Q)PCR reactions were 
done with 25 ng total DNA used as template and normalizing the mt-Cytb gene 
amplification level (primer sequences: 5'-
GCTTTCCACTTCATCTTACCATTTA-3' and 5'-
TGTTGGGTTGTTTGATCCTG-3') against the nuclear beta actin gene (primer 
sequences: 5'-GGAAAAGAGCCTCAGGGCAT-3' and 5'-
GAAGAGCTATGAGCTGCCTGA-3'). Samples were run on an Abi Prism SDS 
7000 machine (Applied Biosystem). Amplification conditions were: 95◦C for 7 
minutes followed by 35 cycles of 95◦C for 10 seconds and 60◦C for 30 
seconds. Dissociation curves were checked to ensure the existence of a single 
PCR product. Each sample was run in duplicate, and samples with significant 
variation between duplicates were excluded. QPCR data were analyzed using 
7000 System Sequence Detection Software version 1.2.3 (Applied 
Biosystems).  
 
For gene expression analysis, 1000 ng total RNA was DNase digested using 
the Amplification Grade DNase I kit (Invitrogen) according to the 
manufacturerʼs instructions. Reverse transcription was done using M-MLV 
reverse transcriptase (Promega). Taqman gene expression assay for Rrm2b 
(assay ID Mm01165706_m1) and the Gapdh endogenous control were 
purchased from Applied Biosystems. The PCR reactions for Rrm2b and 
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Gapdh were done using TaqMan Universal PCR Master Mix (Applied 
Biosystems), and run on an Abi Prism SDS 7000 machine (Applied Biosystem) 
according to the manufacturerʼs protocol. The PCR for Rrm1 was done using 
the DyNAmo™ Flash SYBR® Green QPCR Kit (Finnzymes) as above (primer 
sequences 5ʼ-TGGACTCAACATGGACTTTG-3ʼ and 5ʼ-
GGCCTTGGATTACTTTCATG-3ʼ). QPCR data were analyzed using 7000 
System Sequence Detection Software version 1.2.3 (Applied Biosystems). The 
amplification level of Rrm2b or Rrm1 was normalized by dividing by the Gapdh 
amplification level. 
 
MtDNA point mutation analysis 
For mtDNA point mutation analysis we used primers that specifically amplified 
the mt-Cytb gene (nucleotide pair 14,073–14,906) and non-coding control 
region (15,357–138) of mouse mtDNA. In the PCR, we utilized the high fidelity 
Phusion polymerase (Finnzymes) according to the manufacturerʼs instructions, 
with 25 ng total DNA from quadriceps femoris muscle as template. The PCR 
program was 98◦C for 30 seconds followed by 30 cycles of 98◦C for 10 
seconds, 61◦C for 10 seconds and 72◦C for 30 seconds. PCR products were 
cloned into pCR®2.1 plasmid using the TA cloning kit (Invitrogen) according to 
the manufacturerʼs instructions. Multiple PCR clones were sequenced to 
generate approximately 30,000 bp of sequence for each region. 
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Long PCR 
Long PCR to amplify the entire mitochondrial genome or selectively deleted 
mtDNA molecules was done using the Expand Long Template PCR System 
(Roche). 50 ng total DNA was used as template. Cycling conditions were: 92◦C 
for 2 minutes followed by 30 cycles of 92◦C for 10 seconds and 68◦C for 12 
minutes. PCR products were separated by electrophoresis on 1% agarose 
gels and visualized with a Typhoon 9400 scanner (Amersham Biosciences). 
Primers hybridized to the control region of mtDNA located at nucleotide 
positions 1953-1924 and 2473-2505. 
 
Measurement of nucleotide pools in skeletal muscle 
Nucleotides were extracted from skeletal muscle of aged mice using 
previously described methods with modifications (22, 23). Briefly, skeletal 
muscle was excised following euthanasia by CO2 asphyxiation and snap-
frozen in liquid nitrogen. When sufficient tissue was available, samples were 
divided into two equal portions, processed separately, and compared to 
assess measurement consistency. Tissues were weighed and immersed in 
approximately 5µL/mg 10% trichloroacetic acid, 10mM MgCl2. Tissues were 
homogenized in a Qiagen Tissue Lyser by six cycles of 30 seconds at 30 Hz 
followed by 30 seconds on ice. Tissue homogenates were incubated on ice for 
20 minutes, then spun at 13,000g for 1 minute. The supernatant was taken to 
a fresh tube and re-spun. An approximately equal volume of 0.5N trioctylamine 
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in fluorotrichloromethane was added to the supernatant. The samples were 
vortexed briefly and spun for 2 minutes at 16,000g. The volume of the upper 
phase was estimated by pipetting and aliquots were snap-frozen in liquid 
nitrogen and stored at -80C until nucleotide measurements were performed. 
dNTPs were measured using an indirect enzymatic assay as reported by 
Ferraro et al. (24). Standard curves were prepared from concentrated stocks 
of pure individual dNTPs (Fermentas). Reactions in 50 µL total volume were 
incubated for 1 hour and then 30mL was spotted to Whatman DE81paper 
discs and dried. Discs were washed three times in 5%Na2HPO4, and once 
each in dH2O and 95% EtOH. Discs were dried and counted on a Beckman 
Coulter LS6500 scintillation counter. Measurement of ribonucleosides was 
performed as in N. Kochanowski et al. (25) with modifications. Analyses were 
carried out on a Shimadzu UHPLC system. Samples were separated on a 
Supelco LC-18T column in 30mM KH2PO4 and 10mM tetrabutylammonium 
hydrogen sulfate, pH 6.5 : methanol (A=91.7:8.3, B=71.6:28.4) over a 40-
minute time period. The program ran 0%-100%B from 0-24 minutes, 1 minute 
at 100% B, and 100%-0% B from 25-30 minutes at a flow rate of 1 mL/minute. 
Identities of analytes were confirmed both by comparison of elution time to 
known standards and by wavelength of maximum absorbance (λmax). Sample 
extracts in which ATP comprised less than 65% of the total adenine 
nucleotides were excluded from further analysis. 
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 RESULTS 
Generation of RNR transgenic mice 
Transgenic mice that express recombinant Rrm1, Rrm2, or p53R2 
(referred to as “Rrm1Tg”, “Rrm2Tg”, and “p53R2Tg” mice hereafter) were 
generated previously and showed broad, high-level RNR overexpression (3). 
Since active RNR requires the presence of the large and the small subunit, 
simultaneous overexpression of both subunits could cause a greater increase 
in RNR activity. We therefore interbred Rrm1Tg mice with Rrm2Tg or p53R2Tg 
mice to generate bitransgenic mice. The Rrm1Tg+Rrm2Tg and 
Rrm1Tg+p53R2Tg mice were born at expected frequencies and showed no 
gross abnormalities (Table 2.1). The endogenous RNR subunits were barely 
or not at all detectable by Western blotting of 25 µg protein for each muscle 
tissue extract, whereas significant overexpression was observed in RNRTg 
samples. We therefore made serial dilutions from each RNRTg sample, and 
plotted the band intensities against the dilution level. Fitting the corresponding 
wild-type samples onto this plot allowed us to estimate the fold overexpression 
for each transgene-encoded protein (Figure 2.1). The calculated threshold 
dilutions for bitransgenic mice are shown in Table 2.2. The level of transgene 
overexpression was comparable between single RNR transgenic and 
bitransgenic mice (Figure 2.2). 
 Rrm2Tg and p53R2Tg mice were previously found to have increased 
lung tumour prevalence at ~17 months of age (3), Rrm2 being a more potent 
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tumour inducer than p53R2. In bitransgenic mice, the lung tumour formation 
occurred with similar frequency as in mice overexpressing either of the small 
RNR subunits alone (Table 2.3). The bitransgenic mice were followed up to 
~17 months age and, excluding lung tumour formation, they appeared grossly 
normal during this time. 
RNR overexpression does not elevate mtDNA copy number in mouse 
tissues 
We used Southern blotting to investigate the effect of RNR expression 
on mtDNA copy number in the skeletal muscle (Figure 2.3A), heart (Figure 
2.3B), liver and kidney (Figure 2.4) of the various RNRTg mice. No significant 
increases in mtDNA copy number were observed in any of the tissues from 9-
12 weeks old mice. In the skeletal muscle of the bitransgenic mice, there was 
actually a modest reduction in mtDNA abundance: Rrm1Tg+Rrm2Tg mice had 
on average 71% (p=0.026) and Rrm1Tg+p53R2Tg mice 62% (p=0.0075) 
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Table 2.1. Genotypes of offspring from crosses between Rrm1Tg mice 
and Rrm2Tg or p53R2Tg mice. 
 
 
 
 
 
 
 
 
 
 
 
Note: Rrm1Tg mice were bred to mice carrying either the Rrm2 or 
p53R2 transgene. Progeny were genotyped at weaning by Southern 
blot. (J.P.) 
cross genotype 
#observed 
(#expected) 
Rrm1Tg x Rrm2Tg Wild-type 57 (48.75) 
 Rrm1Tg 54 (48.75) 
 Rrm2Tg 38 (48.75) 
 Rrm1Tg + Rrm2Tg 46 (48.75) 
   
Rrm1Tg x p53R2Tg Wild-type 29 (37.25) 
 Rrm1Tg 52 (37.25) 
 p53R2Tg 35 (37.25) 
 Rrm1Tg + p53R2Tg 33 (37.25) 
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Figure 2.1. RNR overexpression in skeletal muscle and cardiac muscle 
from Rrm1Tg + Rrm2Tg and Rrm1Tg + p53R2Tg bitransgenic mice. Western-
blot analysis of RNR protein expression was performed on total protein extracts 
prepared from skeletal muscle (A and C) or cardiac muscle (B and D) from wild-
type (WT) as well as Rrm1Tg + Rrm2Tg or Rrm1Tg + p53R2Tg bitransgenic mice. 
Extracts were left undiluted (1×) or diluted as indicated and then subjected to 
immunoblotting with antibodies specific to Rrm1, Rrm2 or p53R2. The asterisk 
indicates a non-specific band in the anti-Rrm2 immunoblot. α-Tubulin signal in 
undiluted skeletal (C) and cardiac (D) muscle samples was used to normalize for 
protein loading. The analysis was performed on three mice of each genotype, 
and representative bands are shown for clarity of comparison. The calculated 
fold overexpression values are shown in Table 1. (J.P.) 
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Figure 2.2. RNR overexpression in skeletal muscle from Rrm1Tg, Rrm2Tg, 
and  p53R2Tg transgenic mice. A. Western-blot analysis of RNR protein 
expression was performed on total protein extracts prepared from skeletal 
muscle from wild-type (WT) as well as Rrm1Tg, Rrm2Tg, or p53R2Tg transgenic 
mice. Extracts were left undiluted (1×) or diluted as indicated and then 
subjected to immunoblotting with antibodies specific to Rrm1, Rrm2 or p53R2. 
The asterisk indicates a non-specific band in the anti-Rrm2 immunoblot. α-
Tubulin signal in undiluted skeletal muscle samples (B) was used to normalize 
for protein loading. (J.P.) 
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Table 2.2 Transgene-encoded protein levels. 
Genotype Protein Skeletal muscle Cardiac muscle 
Rrm1Tg + Rrm2Tg Rrm1 3.3 (± 2.1) 33.7 (± 7.6) 
 Rrm2 >35.7 (± 11.1) >23.7 (± 3.4) 
Rrm1Tg + p53R2Tg Rrm1 11.7 (± 6.7) 34.7 (± 24.5) 
 p53R2 355.3 (± 25) 975.3 (± 726.3) 
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Table 2.3. Lung neoplasm characteristics in RNR bitransgenic mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE: Mice were aged until moribund for up to approximately 500 days, 
euthanized by asphyxiation using carbon dioxide, and subjected to 
pathological examination as described in Materials and Methods. (X.X.) 
 
†WT FVB refers to transgene-negative control mice. 
 
*Statistically significant difference (p<0.05) relative to WT FVB mice. 
Incidences were compared by Chi-square analysis. Neoplasm sizes were 
compared by t-test analysis. 
 
§ Other neoplasms included lymphoma, ovary tumor, urinary bladder tumor.  
Mouse 
 genotype 
# of 
animals 
Age 
(days) 
% of mice  
with lung 
neoplasms 
Average  
lung neoplasm 
size (mm)±SD 
% of mice  
with multiple 
lung 
neoplasms 
% of  mice  
with lung 
adenocarcinoma 
% of  mice  
with other 
neoplasms§ 
WT FVB† 9 508 22% 8.0 ± 8.5 0% 11% 11% 
Rrm1Tg 13 466 8% 6.00 ± 0 0% 8% 0% 
Rrm2Tg 4 489 100%* 5.3 ± 3.3 100%* 50%* 25% 
p53R2Tg 6 516 67%* 1.6 ± 1.1 50%* 0% 0% 
Rrm1Tg Rrm2Tg 14 427 93%* 6.4 ± 2.9 100%* 57%* 21% 
Rrm1Tg p53R2Tg 9 461 56%* 4.7 ± 2.9 40%* 30% 33% 
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residual mtDNA amounts compared to their wild-type littermates (Figure 2.3A). 
The mtDNA depletion in skeletal muscle was progressive; at 11-15 months of 
age, the residual mtDNA copy number was 42% in Rrm1Tg+Rrm2Tg mice 
(p=0.030) and 34% in Rrm1Tg+p53R2Tg mice (p=0.0011) (Figure 2.3B). The 
mtDNA levels in the other examined tissues remained unchanged  also at the 
older age. Therefore, overexpression of RNR did not elevate mtDNA copy 
number in differentiated mouse tissues and was associated with progressive 
mtDNA depletion in bitransgenic animals.  
RNR overexpression does not affect mtDNA integrity or mutagenesis 
Overexpression of RNR causes nuclear genome mutagenesis and 
promotes cancer (3). We therefore asked whether RNR overexpression leads 
to mtDNA instability as well. We examined the presence of mtDNA point 
mutations in the skeletal muscle of a 16- month-old Rrm1Tg+Rrm2Tg mouse by 
amplifying and cloning mtDNA regions from the control region (1080 bp) and 
mt-Cytb gene (833 bp), which encodes cytochrome b, followed by sequencing 
of ~30 kb of DNA from each region. We previously reported the point mutation 
rate in wild-type FVB/N mice to be ~0.5 mutations per 10 kb in the control 
region and ~0.25 mutations per 10 kb in the mt-Cytb gene (15). The 16-month-
old Rrm1Tg+Rrm2Tg showed similar or lower point mutation loads compared to 
a wild-type control (Table 2.4).  
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Figure 2.3 mtDNA quantification in young (9–12 weeks) and aged (11–15 
months) mice. Southern blots of digested total DNA from skeletal (A) and 
cardiac and (B) muscle were probed for full-length mtDNA and the nuclear 
18S rDNA gene to control for loading. (A) mtDNA to nuclear DNA ratios were 
determined by densitometric quantification of Southern blots and by qPCR, 
both methods yielding similar results. mtDNA depletion was found in young 
and aged bitransgenic mice. (B) No change in mtDNA copy number was 
observed in the cardiac muscle of RNRTg mice. Error bars indicate SEM. 
*P < 0.05, **P < 0.01, Studentʼs t-test compared to wild-type where N ≥ 3 
individual animals. (E. Y.) 
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Figure 2.4. mtDNA copy number determination. Southern 
blots of digested total DNA extracted from liver and kidney of 
9-12 week-old mice of the indicated gentoypes were probed 
for full-length mtDNA and nuclear 18S rDNA. No significant 
change in mtDNA abundance was observed in the RNRTg 
mice. (E. Y.) 
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Table 2.4 Effect of RNR overexpression upon mtDNA point mutagenesis. 
(E.Y.) 
 mt-Cytb gene Control Region 
Mouse 
 genotype 
Sequenced 
basepairs 
Mutation rate 
per 10 kb 
Sequenced 
basepairs 
Mutation rate 
per 10 kb 
Wild-type 30,844 0.648 27,332 0.366 
Rrm1Tg + Rrm2Tg 39,438 0.000 28,034 0.356 
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In a long-range PCR assay, full length mtDNA was readily amplified in the 
skeletal muscle of aged bitransgenic mice, with no additional small amplifying 
products. This ruled out the presence of large mtDNA deletions (Figure 2.5). 
These analyses showed that bitransgenic RNR overexpression did not 
increase deletion formation or point mutagenesis of mtDNA, but only caused 
mtDNA depletion. 
RNR overexpression leads to dNTP pool imbalance in skeletal muscle 
In many human diseases and mouse models, mtDNA depletion and instability 
have been suggested to occur as the result of perturbed dNTP pools (26-28). 
To understand the mechanism of mtDNA depletion in RNR overexpressors, 
we measured the relative levels of dNTP pools in muscle extracts. Nucleotides 
are known to easily undergo quick dephosphorylation during the extraction 
procedure (29-31). Under conditions when dNTPs are dephosphorylated 
during sample preparation, ATP is similarly degraded to ADP and AMP. 
Therefore, the level of ATP in the extract closely mirrors that of the dNTPs, 
and can be used as an internal marker of unwanted dNTP destruction (30). 
We measured dNTP levels in skeletal muscle extracts from 12- month-old 
mice by a primer extension assay, using 2-3 mice of each genotype. The 
levels of ATP, ADP and AMP were measured from the same extracts by 
HPLC. 
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Figure 2.5. Analysis of mtDNA integrity in RNRTg mice by mtDNA deletion assay. To 
look for mtDNA deletions, a long-PCR assay was used to amplify the entire mtDNA 
genome from the skeletal muscle of 12-month old wild-type, Rrm1Tg + Rrm2Tg and 
Rrm1Tg + p53R2Tg mice. The full-length mtDNA (16 kb) was readily amplified from all 
samples. A Deletor mouse sample was included as a positive control; this sample 
shows multiple mtDNA fragments of smaller size. The DNA ladder λ Hind was used as a 
size marker. (E. Y.) 
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The average ATP levels were similar across the genotypes, the levels of ADP 
were >10-fold lower than that of ATP, and AMP mounted to <1% of the total 
adenine nucleotide pools (Figure 2.6). These ATP/ADP ratios corresponded 
well with previously reported numbers from mouse liver (30), and suggested 
that general dNTP dephosphorylation did not have a major effect on the dNTP 
level determination. The only exceptions were the Rrm1Tg+Rrm2Tg mice, which 
did exhibit a somewhat lower average ATP/ADP ratio than the other genotypes 
(Figure 2.6), suggesting that dNTP measurements may have been 
underestimated in those mice. To ensure that the high level of RNR 
overexpression did not lead to substrate depletion, we also measured the 
levels of CDP, UDP and GDP, and found no significant differences in their 
levels between the genotypes (Figure 2.7).  
The amounts of the individual dNTPs are shown in Figure 2.8. Data are 
presented according to the respective crosses, with the Rrm1Tg X p53R2Tg 
crosses in panels A-D and the Rrm1Tg X Rrm2Tg crosses in panels E-H. We 
observed increases in the levels of dATP and dCTP in all of the transgenic 
lines, as compared to wild-type control samples. The mice expressing either 
small subunit showed greater relative increases in dATP and dCTP than the 
Rrm1Tg mice. 
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Figure 2.6. Measurement of AMP, ADP, and ATP levels in skeletal muscle extracts 
from RNRTg mice. The pools of ATP, ADP and AMP were measured from skeletal 
muscle extracts by an HPLC assay and quantified relative to standard curves. 
Results are presented as the means of results from two (for wild-type) or three (for 
all other genotypes) mice. The average levels of the adenine nucleotides were 
plotted on linear (A) and logarithmic (B) scales, and found to be similar across 
genotypes, which suggested comparable extraction efficiencies. The only exception 
was with the Rrm1Tg + Rrm2Tg mice, which had lower average ATP levels and 
ATP/ADP ratios compared to the other genotypes. This may cause dNTP pool levels 
in these mice to be underestimated. Error bars indicate SEM. (J.P) 
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Figure 2.8. Overexpression of RNR does not lead to substrate 
depletion. HPLC was used to measure the levels of CDP, UDP and GDP, 
which are substrates of RNR, in skeletal muscle from 12-month-old mice 
of the indicated genotypes. There were no significant differences between 
the genotypes. Data are averages from 2 or 3 mice of each genotype. 
Error bars indicate SEM. (J.P.) 
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 There was also a clear tendency towards higher dATP and dCTP values in 
the bitransgenic Rrm1Tg+p53R2Tg and Rrm1Tg+Rrm2Tg mice as compared to 
the p53R2Tg (Figure 2.8 A and D) and Rrm2Tg(Figure 2.8 E and H) single 
transgenic mice, respectively. In contrast to the elevated levels of dATP and 
dCTP, the levels of dGTP were unchanged in all of the transgenic mice (Figure 
2.8 B and F), and the levels of dTTP were actually decreased significantly in 
the p53R2Tg and Rrm1Tg+p53R2Tg mice (Figure 2.8C), and, to a lesser degree, 
in the Rrm1Tg, Rrm2Tg, and Rrm1Tg+Rrm2Tg mice (Figure 2.8G). Taken 
together, these data suggested that RNR overexpression led to significant 
changes in dNTP pools and considerable imbalances between the different 
dNTPs, with the most pronounced changes in bitransgenic RNRTg mice. 
Similar changes in dNTP pools were observed in young bitransgenic mice. 
(Figure 2.9).  
Increased mtDNA copy number is associated with decreased RNR 
expression 
RNR is involved in a signalling pathway that regulates mtDNA copy number in 
yeast (12), and regulation of RNR expression could be part of a homeostatic 
mechanism to control mtDNA copy number in mammals. We therefore utilized 
mouse models that express recombinant wild-type mouse Twinkle (15) or 
human TFAM (20), with ~2-fold and ~3-fold respective increases of mtDNA 
copy numbers in their skeletal muscle at the age of ten weeks
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Figure 2.8. RNR overexpression alters dNTP pools in skeletal muscle. The levels 
of the four dNTPs were measured by polymerase assay and expressed per unit 
weight of skeletal muscle. Pool sizes for the indicated dNTPs were compared 
between wild-type control mice and mice from Rrm1Tg × p53R2Tg (A–D) or 
Rrm1Tg × Rrm2Tg (E–H) breedings. Results are presented as the means of 
results from two (for wild-type) or three (for all other genotypes) mice. Results for 
the same wild-type and Rrm1Tg mice are presented in (A–D) and (E–H) for 
comparative purposes. The levels of dATP (A and E) were significantly increased 
in p53R2Tg and Rrm1Tg + p53R2Tg mice as well as in Rrm2Tg and Rrm1Tg + Rrm2Tg 
mice. The dGTP levels (B and F) were unchanged in all mice. dTTP (C and G) 
was decreased in p53R2Tg and Rrm1Tg + p53R2Tg mice and to a lesser degree 
also in Rrm1Tg, Rrm2Tg, and Rrm1Tg + Rrm2Tg mice. dCTP (D and H) showed a 
similar pattern as dATP, with increases in p53R2Tg and Rrm1Tg + p53R2Tg mice 
as well as in Rrm2Tg and Rrm1Tg + Rrm2Tg mice. In each case, the Rrm1Tg mice 
showed similar but less pronounced dNTP changes as the mice overexpressing 
the small subunits. Error bars indicate SEM, *P < 0.05, Studentʼs t-test as 
compared to wild-type. (J.P.) 
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Figure 2.9. Nucleotide pool levels in young RNRTg mice. Nucleotide levels 
were measured in skeletal muscle from 9-12 week-old mice of the indicated 
genotypes, using 1 or 2 mice for each genotype. First, to control for nucleotide 
extraction efficiency, the levels of ATP and ADP in each extract were measured 
by HPLC, and results are presented both on linear (A) and logarithmic (B) scales. 
The dNTP levels in the same extracts were then measured by polymerase assay 
using the assay originally described (Anal. Biochem 1989 Aug 1;180 (2):222-6) 
and are presented separately for the Rrm1Tg X p53R2Tg (C-F) and Rrm1Tg X 
Rrm2Tg crosses (G-J). Data are averages. The same wild type and Rrm1Tg 
values are shown with each cross. Error bars indicate standard deviations. (J.P.) 
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. We measured the expression levels of Rrm1 and Rrm2b, the genes encoding 
Rrm1 and p53R2 respectively, in skeletal muscle of TwinkleTg and TFAMTg 
mice. Rrm1 mRNA was decreased to 76% (p=0.011) and 70% (p=0.010) in 
the TwinkleTg and TFAMTg mice, respectively (Figure 2.10A). Rrm2b mRNA 
was similarly decreased to 78% (p=0.045) and 77% (p=0.0093) of normal in 
the TwinkleTg and TFAMTg mice, respectively (Figure 2.10B). Thus the 
expression of RNR genes was found to correlate inversely with mtDNA copy 
number in two mouse models. 
DISCUSSION 
RNR is essential for both nuclear and mitochondrial DNA replication. The 
enzyme is limiting for mtDNA copy number in yeast, but whether the same is 
true in mammals has not been studied previously. dNTP pool regulation has 
emerged as a potential tool to increase mtDNA levels, and thereby to slow 
down progression of mtDNA disease. In vitro supplementation with two 
deoxyribonucleoside monophosphates (dNMPs) rescued mtDNA depletion in 
cultured patient myotubes with mutations in the mitochondrial 
deoxyribonucleoside salvage pathway enzyme deoxyguanosine kinase (dGK) 
(32). However, mtDNA depletion due to patient mutations in the mtDNA 
polymerase gamma (Pol γ) was not restored through nucleotide 
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Figure 2.10. RNR expression levels in mice with high mtDNA copy number. A 
QPCR assay was used to measure the expression levels of Rrm1 and Rrm2b, the 
genes encoding Rrm1 and p53R2, respectively, in the skeletal muscle of mice 
overexpressing Twinkle or TFAM. These mice have increased mtDNA copy number. 
(A) Rrm1 expression was downregulated in the Twinkle-mice and TFAM-mice 
compared to controls. (B) Rrm2b was similarly downregulated. Error bars indicate 
SEM, *P < 0.05, **P < 0.01, Studentʼs t-test compared to wild-type where N ≥ 3 
individual animals. (E.Y.) 
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 supplementation in the same study. Likewise, nucleotide supplementation to 
healthy myotubes did not increase mtDNA levels significantly above normal 
(32). These results suggested that although dNTP pool expansion may be 
beneficial in cases of dNTP deficiency, other factors than the size of the 
mitochondrial dNTP pool are limiting for mtDNA copy number in normal cells 
or in mtDNA replication defects.  
 
RNR overexpression in yeast resulted in elevated mtDNA levels (12), and 
complementation of the respiratory chain deficient phenotype of Pol γ disease 
mutations (13). The results presented here suggest that RNR overexpression 
has partially opposite effects in mammals, which illustrates the marked 
differences in dNTP pool maintenance between organisms. However, we 
cannot exclude the possibility that increased RNR activity or dNTP availability 
in vivo could be beneficial in cases with increased mtDNA turnover or 
mutagenesis. The increased carcinogenesis in RNRTg mice (3) illustrates the 
hazards of altering dNTP pool maintenance and further reduces the potential 
of RNR as a therapeutic tool. 
The mechanisms governing mtDNA copy number in tissues are starting to 
come into focus. In mice, overexpression of the histone-like packaging protein 
TFAM or of the mtDNA helicase Twinkle increase mtDNA copy number two to 
three-fold (14, 15). The mRNA level of Twinkle and the protein level of TFAM 
correlate linearly with mtDNA content, suggesting that these may be limiting 
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factors in determining the amount of mtDNA. Defects in mitochondrial dNTP 
pool maintenance proteins cause loss of mtDNA, indicating that these factors 
are essential for mtDNA maintenance (7, 33-36). However, their contribution to 
the physiological control of mtDNA copy number is not well characterized. 
Heart-specific overexpression of the salvage pathway enzyme thymidine 
kinase 2 (TK2) in mice resulted in a 300-fold increase in enzyme activity and 
produced a ~30% increase in mtDNA copy number (37). Therefore, a very 
large increase in TK2 activity modestly influences mtDNA levels, potentially 
through increases in deoxycytidine and thymidine nucleotide pools. Our results 
show that although RNR is involved in the synthesis of all four dNTPs, very 
high levels of the enzyme do not increase mtDNA copy number and instead 
perturb mtDNA homeostasis. This finding is in line with Twinkle and TFAM 
being the main regulators of mtDNA level under normal circumstances. 
 
A possible mechanism for nuclear control over mtDNA copy number would be 
to alter the transcription of mtDNA maintenance genes. In yeast, the first 
established signalling pathway that regulated mtDNA copy number is activated 
by the Mec1p/Rad53p kinases and leads to induction of RNR expression (12). 
The related ATM (ataxia-telangiectasia mutated) kinase in humans was also 
found to influence RNR expression and mtDNA homeostasis (38). We found 
the transcription of Rrm1 and Rrm2b to be downregulated in two independent 
mouse models with increased mtDNA copy number, suggesting an intimate 
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feedback mechanism between transcriptional regulation of RNR subunits and 
mtDNA levels. RNR could thus contribute to a regulatory mechanism for 
nuclear control of mtDNA copy number in vivo. Such a signalling pathway 
could involve p53, a tumour suppressor and ATM target, which influences the 
expression level of p53R2 and is known to localize in small amounts to 
mitochondria (39). 
 
RNR is rate-limiting for de novo dNTP synthesis, so any alteration to RNR 
activity is expected to induce changes in dNTP pools. These changes are 
transmitted into mitochondria, since the mitochondrial and cytosolic dNTP 
pools are in rapid communication (40). Direct measurement of dNTP pools 
from animal tissues is complicated by dNTP dephosphorylation caused by the 
anaerobiosis that immediately follows the death of the animal (30). Our 
extraction method was optimized to minimize nucleotide degradation during 
extraction, and the ATP, ADP and AMP levels were used as internal controls 
to ensure comparability across samples. We documented clear and 
reproducible differences in total dNTP pools between RNR overexpressors 
and wild-type mice.  
Firstly, there were significant increases in the levels of dATP and dCTP both in 
the Rrm2Tg and p53R2Tg mice. Rrm2 induced higher dNTP increases than 
p53R2, which is consistent with Rrm2 being more active than p53R2 in vitro 
(41). Rrm1 overexpression alone was able to induce a detectable, albeit not 
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statistically significant, increase in dATP and dCTP levels, and overexpression 
of Rrm1 together with either small subunit led to a clear trend towards higher 
levels of dATP and dCTP. This apparent synergy suggested that co-
overexpression of both subunits led to an increase in the abundance of the 
tetramer, with subsequent effects on nucleotide pools. 
 
The allosteric regulation of RNR promotes a balanced production of all four 
dNTPs and therefore manipulation of RNR expression might be expected to 
influence the levels of all four dNTPs equally (1). However, we found 
remarkable dNTP pool imbalances in the RNRTg mice. The dGTP pools were 
unchanged whereas dTTP pools were actually decreased in p53R2Tg as well 
as Rrm1Tg+p53R2Tg mice. This finding illustrates the need for tight control of 
the relative activities of the large number of anabolic and catabolic enzymes 
that determine the final dNTP composition in vivo (42). For instance, the 
synthesis of thymidine phosphates requires – as an additional step – reductive 
methylation of RNR-generated deoxyuridine monophosphate, which is 
catalyzed by thymidylate synthase. Hence, induction of RNR could cause a 
substrate overload for the endogenous thymidylate synthase, which in turn 
could explain why increased RNR does not increase the dTTP level. 
Furthermore, the specificity of RNR for GDP reduction is induced by the 
binding of dTTP to the specificity site of Rrm1 (1). Thus, a relative lack of 
dTTP could explain why the dGTP pools did not increase in our mice. The 
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dNTP imbalance was not due to depletion of any of the substrates of RNR, 
since the levels of ADP, CDP, UDP and GDP were similar in all genotypes. 
 
Unbalanced dNTP pools are known to cause mutagenesis in both nuclear (43) 
and mitochondrial (28) genomes. Given the presence of altered dNTP pools in 
RNRTg mice, the likely mechanism of progressive mtDNA depletion in 
bitransgenic mice is inefficient mtDNA replication caused by perturbed dNTP 
balance. Initiation of nuclear DNA replication is influenced by the dNTP pool 
(44, 45), and an imbalanced pool could lead to reduced frequency of mtDNA 
replication initiation. mtDNA depletion was specifically restricted to 
bitransgenic mice, which was consistent with them displaying the largest dNTP 
alterations. The fact that Rrm2Tg and p53R2Tg mice also had altered dNTP 
pools but no mtDNA depletion, suggests a threshold effect for the relative 
dNTP levels above which mtDNA replication becomes inefficient. 
Nevertheless, we cannot exclude that co-overexpression of Rrm1 and the 
small subunit gave rise to additional, unidentified effects, which did not occur 
upon overexpression of one subunit.  Moreover, mtDNA depletion was 
observed only in the skeletal muscle, although the transgenes were 
overexpressed in both the skeletal and cardiac muscles, suggesting tissue 
specific mechanisms in the regulation of nucleotide pools and/or mtDNA 
maintenance. 
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Altered dNTP pool balance is a hallmark of MNGIE disease, where deficiency 
of the catabolic enzyme thymidine phosphorylase (TP) leads to elevated dTTP 
pools, which cause mtDNA depletion, deletions and point mutations in humans 
(28). Contrary to MNGIE, however, we found no increase in mtDNA point 
mutations or deletions in the RNRTg mice. There are at least two possible 
explanations for the absence of mtDNA instability, other than depletion, in our 
mice. Firstly, the dNTP changes were almost opposite to those in MNGIE, i.e. 
the relative dTTP level decreased instead of increasing. Further studies are 
needed to elucidate the exact effect of changes in the relative levels of each of 
the four dNTPs on mtDNA replication frequency and fidelity. Secondly, the life-
span of a mouse may be too short to develop significant amounts of mtDNA 
deletions or point mutations in the setting of dNTP imbalance. In support of 
this, the MNGIE mouse model lacking TP and the related uridine 
phosphorylase (UP) displayed increased dTTP in brain, and, similar to RNRTg 
mice, developed progressive mtDNA depletion, but no deletions or point 
mutations (27). The authors argued that this was at least partly due to the 
short life-span of mice, emphasizing the differences in dNTP maintenance and 
disorders between species. 
 
In conclusion, we have established that expression of recombinant RNR in 
mice leads to dNTP pool imbalance and progressive depletion of mtDNA. This 
is in contrast to previous findings in yeast, in which RNR is a positive regulator 
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of mtDNA abundance. Furthermore, endogenous RNR expression is 
responsive to increased mtDNA copy number and a potential modifier of 
mtDNA homeostasis. The dNTP pool imbalance and mtDNA decrease caused 
by excess RNR suggests that balanced amounts of RNR are essential for 
mtDNA maintenance in vivo, and that RNR is unlikely to be an optimal target 
for therapeutic engineering of mtDNA levels in mammals. 
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Chapter 3: Lethal Deregulation of Ribonucleotide Reductase 
in Transgenic Mice1 
ABSTRACT 
Mammalian genome stability is dependent in part on the availability of 
nucleotides for nuclear and mitochondrial DNA replication and repair. Elevated 
dNTP levels promote survival following DNA damage but also decrease 
replication fidelity and are mutagenic, necessitating tight control of nucleotide 
metabolism. The cytosolic enzyme ribonucleotide reductase (RNR) catalyzes 
the rate-limiting step in de novo dNTP biosynthesis. The enzyme consists of 
two nonidentical homodimeric subunits, a large R1 subunit (encoded by the 
Rrm1 gene) and a small R2 subunit (encoded by Rrm2 or p53R2). Regulation 
of RNR is accomplished through multiple mechanisms including control of R2 
subunit protein levels and negative feedback regulation through the activity 
site within the R1 subunit. In order to study the effect of loss of allosteric 
feedback control, we created a mouse model featuring a hyperactive mutant 
form of the enzyme. The D57N mutation within the activity site disables 
feedback inhibition and results in a mutator phenotype in cultured cells. Two 
independent transgenic lines that broadly overexpressed the Rrm1D57N mutant 
to different extents displayed no overt phenotypes.  I therefore tested the 
                                                 
1 Jennifer L. Page, Emil Ylikallio, Xia Xu, Joshua Levy, Joshua Darfler, Rachel 
Peters, Teresa Southard, Henna Tynnismaa, Anu Suomalainen, and Robert S. 
Weiss. Manuscript in preparation. 
Author contributions are indicated within figure legends by authorʼs initials. 
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hypothesis that more severe phenotypes would arise upon 
simultaneous overexpression of Rrm1D57N and either small subunit. For this 
purpose, I crossed mice from each Rrm1-D57NTg strain to Rrm2- or p53R2-
overexpressing mice. Interestingly, combining overexpression of Rrm1D57N and 
either small subunit caused synthetic lethality. By contrast, bitransgenic mice 
overexpressing wild type Rrm1 and either small RNR subunit were born at 
expected frequencies and appeared grossly normal. The extent of Rrm1D57N 
overexpression affected the timing of lethality in bitransgenic animals; higher 
levels of Rrm1D57N overexpression were associated with embryonic lethality 
while more modest Rrm1D57N overexpression caused postnatal death. Rare 
surviving adult Rrm1D57N + Rrm2 bitransgenic mice exhibited severe muscle 
degeneration and characteristics of premature aging. I hypothesize that 
simultaneously overriding two primary RNR regulatory mechanisms results in 
greatly elevated RNR activity, producing abnormal dNTP pools that interfere 
with genome maintenance and function. These and further experiments will 
provide insights into how the control of nucleotide levels through regulation of 
RNR catalytic activity impacts genomic stability and mammalian development. 
INTRODUCTION 
Mammalian cells contain two separate and functional genomes, the 
proper maintenance of which is critical for survival. In addition to the nuclear 
genome, comprised of approximately 3.4 gigabases of DNA and encoding 
roughly 28,000 genes in mice (Ensembl assembly m37), eukaryotic cells 
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maintain a mitochondrial genome, which is multicopy, comprised of 
approximately 16 kilobases of DNA and only encodes 39 genes. One of the 
key determinants in genome maintenance is the availability of dNTPs for DNA 
synthesis. Efficient and faithful replication by the 3 main replicative 
polymerases, DNA Pol δ, Pol ε, and the mitochondrial DNA Pol γ, relies on 
adequate and balanced nucleotide pools. All three polymerases contain 
exonucleolytic proofreading domains that function to prevent DNA mismatches 
in the presence of balanced nucleotide pools, but all three are also subject to 
increases in replication errors when the nucleotide pools are perturbed(2-5). 
Elevated nucleotide pools increase the error rate of all three polymerases and 
result in increased mutation rates(6). Conversely, elevated nucleotide pools 
have also been shown to improve cell survival following DNA damage, by 
promoting lesion bypass(7). This has the added effect of suppressing 
potentially deleterious repair mechanisms such as sister chromatid exchange 
and hyperrecombination, thus stabilizing the genome(8). 
Unbalanced nucleotide pools are highly mutagenic(9, 10). During DNA 
synthesis, excessive amounts of an incorrect nucleotide at the site of 
elongation can dramatically increase mismatches(2), and also can promote 
frameshift errors by yeast Pol α and in HeLa cell extracts(11). The stimulation 
of the mismatch-repair system by these replication errors and subsequent 
repair creates transient DNA damage that can also stimulate S-phase 
checkpoint activation(12). At the most extreme, severely unbalanced dNTP 
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pools, particularly those that deplete one or more specific nucleotides, can 
trigger activation of the S-phase checkpoint(10) or stimulate deletions within 
the mitochondrial DNA(13).  
Another significant effect of unbalanced nucleotide pools is depletion of 
mitochondrial DNA(14). Mitochondrial DNA depletion syndromes are a set of 
heterologous disorders characterized by a mitochondrial DNA copy number 
that is typically less than 30% of the wild type level. The mtDNA depletion can 
cause phenotypes in a range of tissues that have high energy needs, such as 
brain(15), liver(16), and skeletal muscle . Mutations causing mtDNA depletion 
are found mostly in genes responsible for nucleotide metabolism, such as de 
novo synthesis (by the small ribonucleotide reductase subunit)(17-19), 
nucleotide salvage pathways (by thymidine kinase and deoxyguanosine 
kinase)(16, 20-22), and nucleotide degradation (by thymidine phosphorylase 
and uridine phosphorylase)(15, 23, 24). 
Control over nucleotide abundance and pool balance is accomplished in 
part through the cytosolic enzyme ribonucleotide reductase (RNR)(25). RNR 
catalyzes the rate-limiting step in de novo dNTP biosynthesis(26), the removal 
of the 2ʼ-hydroxyl from the nucleoside diphosphate to produce the 
deoxynucleoside diphosphate.  The mammalian enzyme is composed of two 
subunits, a large R1 subunit encoded by a single gene, Rrm1, and a small R2 
subunit, encoded by either Rrm2 or Rrm2b (a.k.a. p53R2)(27). All three RNR 
proteins are localized to the cytoplasm for activity(28), even after DNA 
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damage(25). dNTPs are produced in the cytosol and move into either the 
nucleus or the mitochondria in order to take part in DNA replication or DNA 
repair(25). 
Control of RNR activity in mammals is primarily accomplished through 
two main partially redundant mechanisms. The first mechanism limits the 
availability of the R2 subunit to specific stages of the cell cycle. The S-phase 
R2 gene, Rrm2, is not expressed in mammalian cells during quiescent stages 
of the cell cycle(29), but is strongly induced in S-phase to complex with Rrm1 
and synthesize dNTPs for DNA synthesis(30). The Rrm2 protein is targeted for 
proteolytic degradation at the G2/M transition by the APCCdh1 complex(31), 
limiting the bulk of RNR activity to S-phase. The p53R2 protein is expressed at 
low levels throughout the cell cycle and a complex of Rrm1 and p53R2 is 
continually active(29).  
We have previously reported that transgenic mice that overexpress 
either small RNR subunit, Rrm2 or p53R2, develop spontaneous lung tumors 
at a high frequency(1). We found that this lung tumorigenesis proceeds 
through a mutagenic mechanism. While we found that reactive oxygen species 
were increased in cells overexpressing either small subunit, potentially 
providing a mechanism for the increased mutation rate, we were unable to 
exclude elevated RNR activity and increased nucleotide pools as a cause of 
mutagenesis. In that study we were unable to detect changes in dNTP pools in 
the lungs when individual RNR subunits were overexpressed(1), but we were 
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later able to observe dNTP pool alterations in the skeletal muscle (Chapter 2), 
suggesting increased RNR activity due to loss of one regulatory mechanism. 
We have also generated mice that feature simultaneous overexpression of 
Rrm1 and either small RNR subunit. In these mice the overexpressed small 
subunits were able to form more active complexes with overexpressed Rrm1, 
elevating RNR activity. This had the effect of altering nucleotide pools and 
causing age-dependent mtDNA depletion(32). 
A second regulatory mechanism governing RNR activity is allosteric 
feedback control. The R1 subunit contains two allosteric regulatory sites. A 
specificity site monitors the ratio of the four dNTPs in order to keep the ratios 
balanced. Mutation of residues within this site in yeast lead to severely 
unbalanced and mutagenic dNTP pools(10). The activity site controls enzyme 
activity by monitoring the ratio of ATP to dATP, functioning as the second main 
RNR regulatory mechanism (26). The specificity site binds dATP with much 
higher affinity than does the activity site, so that the level of dATP must be 
relatively high before further activity is inhibited(33). The proposed mechanism 
by which dATP binding can inhibit enzyme activity is by blocking the radical 
transfer pathway, preventing the radical from reaching the catalytic site and 
being used to reduce the substrate(33). Binding of the stimulant ATP allows 
for an additional hydrogen bond that moves key residues out of the transfer 
path; when dATP is bound, the residues block the radical transfer 
pathway(34). Mutation of residues within this site abolish dATP recognition by 
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the enzyme and allow for further enzyme activity(33). In yeast and mammals, 
the critical residue in dATP recognition is Asp 57(7, 35). When mutated to an 
asparagine (D57N), the enzyme becomes constitutively active and elevates 
dNTP pools(7). The Rrm1D57N mutation was shown in both yeast and in 
mammalian cell culture models to be mutagenic(7, 35). Further experiments in 
yeast involved overexpression of the rnr1-D57N mutant(36). In yeast, the large 
subunit is limiting for activity while the small subunits are in excess; therefore 
by overexpressing the feedback-resistant form, the authors were able to 
simultaneously disrupt both main regulatory mechanisms controlling RNR 
activity. This more thorough deregulation resulted in constitutively elevated 
dNTP pools that were able to inhibit origin firing in S-phase and cause a slow-
growth phenotype. To date, no studies have been performed to test the 
physiological effect of the Rrm1D57N mutation in an in vivo animal model. We 
therefore generated transgenic mice that broadly overexpress the Rrm1D57N 
mutant to a high degree. 
Here we report on the first mouse model of loss of allosteric feedback 
control of RNR in mice, as well as the effect of simultaneous disruption of 
multiple regulatory modes of RNR. I found that mice that overexpress Rrm1-
D57N alone are grossly normal. However, when I combined overexpression of 
Rrm1-D57N with overexpression of either small subunit, I found that the 
combination causes synthetic lethality in mice. The timing of the lethality 
depends on which small subunit is overexpressed, as well as the 
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overexpression level of the large subunit. These manipulations will allow us to 
study the effects of various degrees of RNR deregulation in mice, and more 
completely understand the complex regulation of this critical enzyme. 
MATERIALS AND METHODS 
Plasmids. An expression plasmid encoding mouse Rrm1 was constructed in 
the pCaggs expression vector as described previously(1). In order to improve 
expression in mice, UTR sequences were removed. The Rrm1 ORF was 
amplified from pCaggs-Rrm1 with primers F: 5ʼ-
CTCGTCGACATGCATGTGATCAAGCGAGATGGC-3ʼ and R: 5ʼ-
TCAGGATCCACACATCAGGCACTC-3ʼ. The PCR product was cloned into 
pCR2.1 with the Topo-TA cloning kit (Strategene). Following sequencing 
analysis of the insertion fragment ends to confirm no PCR-induced mutations, 
the PCR-amplified Rrm1 cDNA was digested out with StuI and replaced by the 
non-amplified StuI fragment from pCaggs-Rrm1. Fragment orientation was 
confirmed by SphI and EcoRI digestion. The Rrm1 ORF was then excised 
from pCR2.1 with SalI/XhoI digest and ligated into XhoI-linearized pCaggs.  
Fragment orientation was confirmed by BamHI and SalI/XhoI digests. The 
Rrm1-D57N mutation was inserted by site-directed mutagenesis. Briefly, 
primers D57N (5ʼ-CCACAGTGGAACTGAACACCCTGGCTGCT-3ʼ) and D57N-
AS (5ʼ-AGCAGCCAGGGTCAGTTCCACTGTGG-3ʼ) were used to amplify the 
entire pCaggs-Rrm1-ORF-new plasmid. Following DpnI digestion, products 
were transformed into DH5α and cultured on NZY+ medium. The presence of 
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the mutation was confirmed by XcmI digest, as the D57N mutation destroys an 
XcmI site. The pCaggs-Rrm1-D57N clone was confirmed to be free of other 
mutations by sequencing. 
Transgenic mice. Transgenic mice were generated by microinjection of linear 
plasmid DNA into the male pronucleus of FVB/N zygotes. The pCaggs-Rrm1-
D57N plasmid was linearized by SalI digestion. Transgenic founder mice were 
identified by Southern blot analysis. Transgenic mice were maintained as 
hemizygotes on the FVB/N inbred background strain. Genotyping of mice 
expected to carry a single RNR transgene was performed as previously 
described(1). In crosses between Rrm1Tg or Rrm1-D57NTg and Rrm2Tg or 
p53R2Tg, mice were genotyped by Southern blot as described below. 
Big Blue mutation rate assay 
Rrm1-D57NTg or Rrm1-D57NTg Msh6+/- (37) mice were crossed to Big BlueTg 
mice(38-40) or Big BlueTg Msh6+/- mice, respectively. All mice were aged to 90 
days in order to allow mutations to accumulate. Tissues were harvested and 
snap-frozen in liquid nitrogen immediately following euthanasia by CO2 
asphyxiation. 
 Frozen tissue was homogenized in a Dounce homogenizer (Wheaton) using 
the loose pestle by 15 strokes in the presence of: 3.3 g/L Na2HPO4·7H2O, 8 
g/L NaCl, 0.2 g/L KCl, 0.2 g/L KH2PO4, and 0.05M EDTA, pH 8.0, 
supplemented with RNaseA at 200 µg/mL. Following homogenization, the 
samples were transferred to a 50-mL conical tube containing 3 mL of the 
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digestion solution (34 mg Proteinase K, 6.8 mL dH2O, 3.4 mL 10% SDS, 6.8 
mL 0.25M EDTA, pH 7.5). Samples were allowed to digest at 50ºC for 4 hours 
(lung), 2 hours (spleen), or 3 hours (thymus) with gentle inversion of the tubes 
every 60 minutes. DNA was then isolated via sequential phenol-chloroform 
extractions and precipitated with the stepwise addition of 100% ethanol. The 
DNA was allowed to dry only briefly at RT before 1mL sterile H2O was added. 
DNA was allowed to dissolve for up to 4 days at 4ºC.  Approximately 8µL of 
DNA was added to 1 red tube of Transpack λ phage recovery packaging 
extract (Stratagene) and incubated at 30ºC for 90 minutes. 12µL Transpack 
packaging extract from the blue tube was added to each λ recovery sample 
and mixed by pipetting. The samples were further incubated at 30ºC for 90 
minutes. Following packaging, the phage were used to infect G1250 E. coli for 
15 minutes and then were plated on TB1 agar plates. Total plaque-forming 
units (PFU) were estimated by averaging the total number of plaques on 
triplicate plates incubated at 37ºC for 24 hours. Total mutant plaques were 
estimated by counting the total number of plaques on 10 replicate plates 
incubated at 24ºC for 48 hours. All potential mutant plaques were picked and 
dissolved in SM buffer overnight. Confirmation of potential plaques was 
performed by infecting fresh G1250 cells at 24ºC for 48 hours. DNA from 
confirmed mutant plaques was amplified by PCR with primers “cII-For2” (5ʼ-
CCGCTCTTACACATTCCAGC-3ʼ) and “cII-Rev1” (5ʼ-
CCTCTGCCGAAGTTGAGTAT-3ʼ) and sequenced with primer “cII-For1” (5ʼ-
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CCACACCTATGGTGTATG-3ʼ) to obtain the specific mutation. Final mutation 
rate and spectra were determined by the total number of unique mutations 
compared to the total PFU. 
Southern blot analysis. DNA extracted from tails of adult mice or yolk sacs of 
embryos was subjected overnight to transgene-specific restriction digest and 
separated on 0.8% agarose gel. The Rrm1 and Rrm1-D57N transgenes were 
detected by digestion with BamHI (Fermentas) and the p53R2 transgene was 
detected by digestion with EcoRV (Fermentas). Following alkaline transfer to a 
nylon membrane (GeneScreen Plus, Perkin Elmer), the presence of transgene 
DNA was detected with a transgene-specific radiolabeled probe.  
Northern blot analysis. Total RNA was extracted from mouse cells with 
RNAStat-60 (TelTech, Inc) and separated on agarose/formaldehyde gel. RNA 
is transferred to a nylon membrane (GeneScreen, Perkin Elmer) and detected 
with Rrm1-specific radiolabeled probe. 
Immunoblot analysis. Tissue extracts were prepared by lysis in RIPA buffer 
(150mM NaCl, 50 mM NaF, 1% NP-40, 0.8% DOC, 0.1% SDS, 50 mM Tris pH 
8.0, and 5 mM EDTA) supplemented with protease inhibitors (apropinin, 
2µg/mL; leupeptin, 2µg/mL; and PMSF, 20µg/mL) and sodium orthovanadate 
(400 µM) as a phosphatase inhibitor. Extracts were separated on 10% 
polyacrylamide gel and transferred to PVDF membrane (Perkin Elmer). R1 
protein was detected by AD203, mouse monoclonal anti-R1 (InRo Biomedtek), 
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and loading was assessed by detecton of α-tubulin with mouse monoclonal 
anti-α-tubulin (Sigma).  
Histology. Adult mice were euthanized by overdose with carbon dioxide. 
Neonates (mice ages P10 and younger) were euthanized by decapitation. 
Tissues for histological analysis were excised and fixed overnight at room 
temperature in 10% buffered formalin. Tissues were sectioned at 5mm 
thickness prior to staining with hematoxylin and eosin (H&E) or Massonʼs 
trichrome, or Periodic Acid Schiffʼs stain. Sample dehydration, embedding, 
sectioning, and staining were conducted by the Core Histology Lab in the 
College of Veterinary Medicine at Cornell University. 
Southern blotting for mtDNA copy number determination. 
Total DNA was isolated from tissues by proteinase K digestion and standard 
phenol-chloroform extraction. Southern blotting was performed essentially as 
described (41). Briefly, three micrograms total DNA was digested with SacI 
overnight at 37◦C, samples were then separated by electrophoresis in an 
agarose gel and blotted by alkaline transfer onto a Hybond N+ membrane 
(Amersham Biosciences). The membrane was hybridized overnight at 68◦C in 
a roller hybridizer using 5 μCi/ml 32P-dCTP labeled (PCR-generated) mouse 
mtDNA probe, and 18S rDNA probe in pBR322 plasmid. Phosphoimager 
analysis was done with Typhoon 9400 (Amersham Biosciences) and mtDNA 
was quantified against the 18S rDNA signal using ImageQuant v5.0 software 
(Amersham Biosciences). 
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Real time PCR. 
For mtDNA quantification, the quantitative real-time (Q)PCR reactions were 
done with 25 ng total DNA used as template and normalizing the mt-Cytb gene 
amplification level (primer sequences: 5'-
GCTTTCCACTTCATCTTACCATTTA-3' and 5'-
TGTTGGGTTGTTTGATCCTG-3') against the nuclear beta actin gene (primer 
sequences: 5'-GGAAAAGAGCCTCAGGGCAT-3' and 5'-
GAAGAGCTATGAGCTGCCTGA-3'). Samples were run on an Abi Prism SDS 
7000 machine (Applied Biosystem). Amplification conditions were: 95◦C for 7 
minutes followed by 35 cycles of 95◦C for 10 seconds and 60◦C for 30 
seconds. Dissociation curves were checked to ensure the existence of a single 
PCR product. Each sample was run in duplicate, and samples with significant 
variation between duplicates were excluded. QPCR data were analyzed using 
7000 System Sequence Detection Software version 1.2.3 (Applied 
Biosystems).  
Long PCR. 
Long PCR to amplify the entire mitochondrial genome or selectively deleted 
mtDNA molecules was done using the Expand Long Template PCR System 
(Roche) with primers 5'- GAG GTG ATG TTT TTG GTA AAC AGG CGG GGT 
-3' and 5'- GGT TCG TTT GTT CAA CGA TTA AAG TCC TAC GTG -3'. 50 ng 
total DNA was used as template. Cycling conditions were: 92◦C for 2 minutes 
followed by 30 cycles of 92◦C for 10 seconds and 68◦C for 12 minutes. PCR 
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products were separated by electrophoresis on 1% agarose gels and 
visualized with a Typhoon 9400 scanner (Amersham Biosciences). Primers 
hybridized to the control region of mtDNA located at nucleotide positions 1953-
1924 and 2473-2505. 
RESULTS 
Generation of Rrm1-D57N transgenic mice and expression analyses 
To generate transgenic mice overexpressing Rrm1D57N, the G to A 
transition within codon 57 was introduced by site-directed mutagenic PCR. 
Two independent transgenic founder animals were obtained (Figure 3.1A, 
lanes 6 and 12). The founder animal in lane 12 shows a more intense band 
than the founder in lane 6; leading us to hypothesize that the founder in lane 
12 would show more robust overexpression than the founder in lane 6. 
Therefore, the resulting strains are referred to hereafter as Rrm1-D57N(low)Tg 
(lane 6) and Rrm1-D57N(high)Tg (lane 12). The strains were maintained on a 
pure FVB/N background.  
Endogenous and transgenic expression was assessed in a variety of 
tissues in Rrm1-D57N(high)Tg and wild-type FVB mice by Northern blot 
analysis (Figure 3.1B). In wild type FVB mice, Rrm1 was detected most 
strongly in the most proliferative tissues, the testis and thymus (Figure 3.1B, 
left). Northern blot analysis of Rrm1-D57N(high)Tg mice revealed two bands 
corresponding to Rrm1 transcript; the upper band is from the endogenous 
locus while the lower band, corresponding to the transcript from the transgene, 
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runs at a lower molecular weight due to the removal of 5ʼ-UTR sequence. The 
upper band is the predominant band in the spleen and thymus, while the lower 
band from the transgene predominates in lung, liver, kidney, and skeletal 
muscle.  
The expression results obtained by Northern blot analysis were 
confirmed by immunoblot (Figure 3.1C). I assessed total R1 protein levels in 
tissues obtained from wild type FVB mice (wt), Rrm1-D57N(low)Tg mice (L), 
and Rrm1-D57N(high)Tg (H) mice. In agreement with the Southern blot in Fig 
3.1A, Rrm1-D57N(high)Tg mice showed higher R1 protein levels than Rrm1-
D57N(low)Tg mice, which were intermediate between wild type and Rrm1-
D57N(high)Tg levels. To obtain a more precise value for Rrm1-D57N 
overexpression in tissues from transgenic mice, I utilized the serial dilution 
method described in Chapter 2. Because pCaggs drives the greatest 
expression in skeletal and cardiac muscle, I assessed the level of D57N 
overexpression in these two tissues (Figure 3.2). I found that the D57N(low)Tg 
is expressed roughly 94-fold (93.99x) in the skeletal muscle while the 
D57N(high)Tg is expressed over 600-fold (608.41x).  
Limited phenotypes in Rrm1-D57NTg mice  
I generated a cohort of mice expressing Rrm1-D57N(low)Tg or Rrm1-
D57N(high)Tg with control littermates. Mice were maintained to a maximum of 
18 months of age and monitored. Because mice overexpressing Rrm2Tg or 
p53R2Tg displayed an increase in spontaneous lung tumorigenesis, I primarily 
 126  
monitored mice for the development of lung cancer. Of 44 total wild type mice, 
12 had developed lung adenomas or adenocarcinomas by 18 months of age, 
roughly 26% of the total (Table 3.1). This number is consistent with the 
reported background lung tumor incidence in wild type FVB/N mice of 
approximately 31%(42). Mice expressing the Rrm1-D57N(low) transgene 
showed a 36.73% incidence of cancer, and mice with the Rrm1-D57N(high) 
transgene showed a 34.62% incidence, for a combined 36% of Rrm1-D57N 
mice with lung tumors. By chi-squared analysis, this increase in lung 
tumorigenesis is significant (p=0.013). While the total lung tumor incidence is 
increased, the mean size of tumors in Rrm1-D57NTg mice was not increased 
with respect to the mean tumor size of wild type mice. Tumor-bearing wild type 
mice had an average lung tumor diameter of 2.72 ± 4.4 mm while tumor-
bearing Rrm1-D57NTg mice had an average lung tumor diameter of 2.51 ± 
3.2mm. Pathological grade was not affected by Rrm1-D57N overexpression, 
as 2 of 44 transgene-negative control mice developed adenocarcinomas 
(4.5%) while 3 of 67 Rrm1-D57N transgenic mice developed adenocarcinomas 
(4.4%). Overall, overexpression of Rrm1-D57N was able to increase the 
incidence of lung tumors in FVB mice, but did not drive lung tumorigenesis, in 
contrast to overexpression of Rrm2 or p53R2.  
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Overexpression of Rrm1-D57N did not increase mutation rate as 
measured by the Big Blue mutation detection system 
Multiple studies have reported that the Rrm1-D57N mutation is 
mutagenic(7, 35). In order to determine if Rrm1-D57N transgenic mice 
suffered a higher mutation rate than transgene-negative control mice, I 
crossed each D57N transgenic mouse strain independently to Big Blue mice. 
Big Blue mice carry multiple copies of the λ phage genome as a transgene. 
From the phage genome, the cII gene functions to control expression of the 
temperature-sensitive cI gene. The cI gene product represses the transcription 
of genes that control lysis, committing the phage for lysogeny. When 
incubated at 24°C, only phage with a mutant cII gene will be able to form 
plaques, while all phage can form plaques at 37°C, allowing for 
standardization of packaging efficiency. Therefore, the cII gene serves as a 
mutational reporter(43).  
Due to the presence of lung tumors in small-subunit-overexpressing mice, I 
analyzed the mutation rate in lung tissues from Rrm1-D57N(low)Tg and Rrm1-
D57N(high)Tg mice with transgene-negative FVB mice serving as a control 
(Figure 3.3). I found no changes in mutant frequency between the three 
genotypes, and there was high variability between the samples, as was also 
found in other studies using Big Blue mice(44). The wild type mice had a mean 
mutant frequency of 3.61 x 10-6, Rrm1-D57N(low)Tg mice had 3.59 x 10-6 
mutants, and Rrm1-D57N(high)Tg mice displayed a mutant frequency of 4.09 x 
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10-6. I next wanted to ask if the mutational spectrum was changed upon Rrm1-
D57N overexpression. To answer this, we sequenced the cII genes isolated 
from individual plaques (Table 3.2). I found that transitions were more likely 
than transversions or deletions in all genotypes, and overexpression of either 
D57N transgene increased the proportion of mutations that were transitions. In 
other studies, base substitutions comprised about 85% of all detected 
mutations at the cII locus(43). Our results were fairly   
consistent with that number, having roughly 60-70% base substitutions. 
Roughly one-third of all mutations found in wild type mice are transitions 
(~38%), another one-third are transversions (~34), and the rest are 
insertions/deletions and non-cII mutations (~21% and 7%, respectively). In 
Rrm1-D57N(low)Tg mice, 50% of all mutations are transitions, while 28% were 
transversions, 17% were insertions/deletions, and non-cII mutations made up 
the last 5%. The overall mutation spectrum was not significantly different from 
that of wild type mice (p=0.102, χ2). In Rrm1-D57N(high)Tg mice, two-thirds 
(67%) of the mutations are transitions, while less than one-third (21%) are 
transversions, and insertions/deletions and non-cII mutations, comprise 7% 
and 5%, respectively. This was significantly different from the mutation 
spectrum of wild type mice (p = 6.07 x 10-8, χ2).  
 
 
 
 129  
Overexpression of Rrm1-D57N on a mismatch-repair-deficient 
background does not affect lymphomagenesis. 
The apparent contradiction between our data, which suggested that 
overexpression of Rrm1-D57N is not mutagenic, and the several published 
reports that indicate that it increases mutation frequency in multiple models 
could be explained by multiple hypotheses. Several factors could contribute to 
an apparent lack of mutagenesis: 1) functional mismatch-repair pathways may 
correct most, if not all, errors induced by elevated dNTP levels; 2) disabling a 
single mechanism controlling RNR activity may have limited effects on dNTP 
levels and mutation frequency; or 3) the Big Blue assay is not sensitive 
enough to detect modest changes in mutation rate. Even in wild-type mice, 
presence of a phage genome in mammalian cells may lead to increased 
efforts for transcriptional silencing. Methylation of cytidines at CpG sites is an 
epigenetic marker associated with transcriptional silencing. The methylated 
cytosine is subject to deamination into uridine(45) which will base-pair with 
adenine during the next round of DNA replication, leading to a G-C to A-T 
transition at CpG sites. This occurrence has been documented in the literature, 
with as many as 78% of the observed mutations at the LacI locus of the Big 
Blue transgene being transitions at CpG sites(38). Consistent with this is our 
.finding that most mutations observed in Big Blue mice, both with and without 
the Rrm1-D57N transgenes, are transitions at CpG sites, suggesting that the 
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Figure 3.1. Generation of Rrm1-D57N overexpressing mice. A. Southern blot 
analysis of DNA from potential Rrm1-D57NTg founder animals. Tail DNA from potential 
founder animals subjected to hybridization with Rrm1-specific radiolabeled probe. 
Arrows indicate bands corresponding to endogenous Rrm1 gene and Rrm1-D57N 
transgene. Asterisks denote founder DNA showing presence of Rrm1-D57N 
transgene. Note that the founder in lane 12 [referred to as Rrm1-D57N(high)] shows 
greater signal intensity and an additional transgene band, indicating integration of a 
greater amount of the transgene DNA than the founder in lane 6 [Rrm1-D57N(low)]. 
(X.X.) B. Northern blot analysis of Rrm1 expression in wild type and Rrm1-D57N(high) 
mice. Total RNA was extracted from the indicated tissues of wild type FVB (left 
panel(1)) and Rrm1-D57N(high) transgenic mice (right panel) and subjected to 
Northern blot analysis with a radiolabeled Rrm1-specific probe. Positions of 
endogenous- and Rrm1-D57N-derived transcripts are indicated. Total ethidium 
bromide-stained RNA is shown as a loading control. Note that skeletal muscle lane in 
right panel was intentionally underloaded. (X.X. and J.P.) C. Immunoblot analysis of 
Rrm1 protein expression in the indicated tissues of wild type (wt), Rrm1-D57N(low)Tg 
(L), and Rrm1-D57N(high)Tg (H) transgenic mice. Total protein from the indicated 
tissues was detected with R1-specific antibody. The same membrane was probed with 
antibody specific to α-tubulin as a loading control. (X.X.) 
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Figure 3.2. Quantification of transgenic overexpression 
by western blot. A. Serial dilutions quantifying Rrm1 
expression in the skeletal muscle of Rrm1-D57N(low) and 
Rrm1-D57N(high) transgenic mice. Lysates from transgenic 
mice were serially diluted in RIPA buffer, and were 
compared to undiluted wild type sample. B. α-tubulin serves 
as a loading control. (J.P.) 
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Table 3.1. Analysis of lung neoplasms in Rrm1-D57N transgenic mice.a 
Genotype 
# 
animals 
# with adenoma 
or 
adenocarcinoma 
lung 
tumor 
% 
% of animals 
with multiple 
tumors 
average 
tumor 
diameter ± 
std (mm) 
wild type FVB 44 12 27.27% 4.55% 2.72 ± 4.4 
Rrm1-D57N(low)Tg 49 18 36.73% 10.20% 2.65 ± 3.2 
Rrm1-D57N(high)Tg 26 9 34.62% 8.00% 2.16 ± 3.16 
aMice of the indicated genotypes were monitored until moribund or to a 
maximum age of 18 months, at which time they were necropsied and the 
overall phenotype recorded. The predominant phenotype was lung 
tumorigenesis, due in large part to the fact that the FVB inbred strain is prone 
to lung tumor development(42). Other criteria for tumorigenicity was not met in 
these mice, indicating that overexpression of Rrm1-D57N does not drive lung 
tumorigenesis. (J.P.) 
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mutations are due to methylation of cytidines to suppress expression of the 
viral genes and not the overexpressed RNR subunits. Because of the reduced 
sensitivity in detecting mutations because of CpG methylation, I sought to 
assess the mutagenicity of Rrm1-D57N overexpression by determining how 
overexpression interacts with a mismatch repair deficiency. 
The mammalian mismatch repair system has two main mismatch-sensing 
complexes: MutSα, consisting of Msh2 and Msh6, and MutSβ, consisting of 
Msh2 and Msh3. MutSα recognizes mispairs and small insertions/deletions 
while MutSβ recognizes larger insertions and deletions. In mice, knockout of 
Msh6 results in an increased incidence of lymphomas and other tumors to a 
smaller extent(37). I hypothesized that overexpression of Rrm1-D57N on an 
already sensitized background would synergize with Msh6 deficiency to 
increase tumor incidence and shorten the tumor latency. To test this, I first 
crossed mice harboring a heterozygous mutation of Msh6 to mice carrying 
either the Rrm1-D57N(low) or Rrm1-D57N(high) transgene. Mice 
heterozygous for Msh6 and carrying the Rrm1-D57N transgene were interbred 
to littermates that were heterozygous for Msh6 alone, generating mice carrying 
6 possible genotypes. I first generated a cohort of these mice and monitored 
them for tumor formation. Mice were euthanized when moribund or when they 
reached 500 days of age. The median age of death for Msh6-/- mice was 
around 439 days, while the median age for Rrm1-D57NTg Msh6-/- mice was 
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shortened to 292; however this difference was not significant by log rank test 
(Figure 3.4). Only 2 Msh6+/- mice died before the 500-day cutoff compared to 7 
Rrm1-D57NTg Msh6+/- mice, this difference is also not significant. Mice were 
analyzed for the formation of lung tumors, lymphoma, and other tumors (Table 
3.3). .None of the 13 Msh6-/- mice developed lung tumors compared to 14% (3 
of 21) of Rrm1-D57NTg Msh6-/- mice; however due to small sample size this is 
not significant. The incidence of lymphomas was not changed in Msh6-/- mice 
when Rrm1-D57NTg was overexpressed. 84% of Msh6-/- mice developed 
lymphoma, while only 71% of Rrm1-D57NTg Msh6-/- mice developed 
lymphoma. Other tumors, such as skin papillomas, were observed at a higher 
frequency in Rrm1-D57NTg Msh6-/- mice than in Msh6-/- mice, but again, due to 
small sample size this is not significant. In the Msh6+/- mice, lung 
tumorigenesis was increased roughly 3-fold and lymphomagenesis was 
increased roughly 5-fold when Rrm1-D57N was overexpressed (p=4.48 x 10-7 
and p=4.44 x 10-20, respectively, χ2). 
To further confirm that overexpression of Rrm1-D57N does not 
synergize with mismatch repair deficiency, I assayed the mutation rate using 
the Big Blue system. Loss of Msh6 in mice was able to significantly elevate the 
mutant frequency compared to mice wild type or heterozygous for Msh6; 
however addition of either Rrm1-D57N transgene failed to further elevate 
mutant frequency (Figure 3.5). 
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Figure 3.3. Mutant frequency in lung tissue from Rrm1-D57N transgenic 
mice as measured by the Big Blue assay. Data are represented as mean 
for each genotype. Wild type (n=3), Rrm1-D57N(low)Tg (n=3) and Rrm1-
D57N(high)Tg (n=4) all displayed low mutant frequencies. Error bars, standard 
deviation. (J.P.) 
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The mutation spectra were quite variable (Table 3.4). In mice harboring wild 
type Msh6, the mutation spectra observed in the mice with the Rrm1-D57N 
transgene were significantly different from the spectra in the transgene-
negative mice (p = 2.39 x 10-5, χ2). Also in the Msh6+/- mice, the mutation 
spectra observed in the mice with the Rrm1-D57N transgene were significantly 
different from the spectra in the transgene-negative mice (p = 3.58 x 10-8, χ2). 
Only in the Msh6-/- mice was there no difference in mutation spectra with or 
without the transgene (p = 0.268, χ2).  
Mismatch-repair deficiency primarily causes gastrointestinal tumors as 
addition to B-and T-cell lymphomas(37, 46), suggesting that analysis of 
proliferative tissues such as thymus and spleen may reveal increases in  
mutant frequency that analysis of lung tissue, being quiescent, cannot 
uncover. I therefore performed the analysis in spleen and thymus from one 
Rrm1-D57NTg Msh6-/- mouse and one Msh6-/- control. I again found no 
difference in mutant frequency between Rrm1-D57NTg Msh6-/- and transgene-
negative Msh6-/- mice; the mutant frequencies in the thymus were 3.25 x 10-4 
in the transgenic and 3.92 x 10-4 in the control and in the spleen, 3.73 x 10-4 in 
the transgenic and 3.63 x 10-4 in the control.  
Overall, these data suggest that overexpression of Rrm1-D57N alone is 
not mutagenic. Furthermore, D57N overexpression was unable to synergize 
with dysfunction of the mismatch repair system to enhance mutagenesis, 
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further suggesting that loss of a single regulatory mechanism of RNR is not 
mutagenic. 
Simultaneous overexpression of Rrm1-D57N and either small RNR 
subunit causes synthetic lethality 
We previously reported that mice overexpressing Rrm2 or p53R2 develop lung 
tumors but are otherwise grossly normal. However, those mice only exhibited  
disruption of one RNR regulatory mechanism, control of RNR activity 
through limitation of small subunit protein levels. As previously stated, mice 
overexpressing Rrm1-D57N alone were also obtained at expected frequencies 
and were grossly normal. In order to assess the effect of simultaneous 
disruption of multiple RNR regulatory modes, I crossed mice overexpressing 
either small RNR subunit with mice overexpressing Rrm1-D57N. I used each 
Rrm1-D57N strain individually in these crosses, resulting in four possible 
overexpression combinations. Remarkably, I found that mice with either level 
of Rrm1-D57N overexpression and either small RNR subunit were inviable 
(Table 3.5). Specifically, of an expected 30 Rrm1-D57N(high)Tg + p53R2Tg 
bitransgenic mice, 0 were obtained. Likewise, 51.25 Rrm1-D57N(low)Tg + 
p53R2Tg bitransgenic mice were expected and 0 were observed, and 26.5 
Rrm1-D57N(high)Tg + Rrm2Tg bitransgenic mice were expected and 0 were 
obtained. Of 69.75 expected Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice 
expected, 5 were obtained that survived to adulthood. Of the five surviving 
bitransgenic adults, two survived only 21 days.
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Figure 3.4. Survival of mice carrying the Rrm1-D57N transgene, mutation 
of Msh6, or both. Mice of the indicated genotypes were housed with 
littermates and monitored every three days to a maximum age of 500 days or 
until moribund. Survival in days was compared between genotypes. Analysis 
was performed with SPSS software.(J.P.) 
 144  
 One survived 25 days, and the last two mice were littermates, one female 
surviving 90 days and one male surviving 102 days. These results suggest 
that simultaneous disruption of multiple regulatory mechanisms of RNR is 
incompatible with survival.  
 Lethality manifests at different stages depending on cross 
While rare surviving adult Rrm1-D57N(low)Tg + Rrm2Tg mice could be 
observed, no other cross exhibited any survivors. To determine the exact 
stage of lethality, I dissected embryos from Rrm1-D57N(high)Tg x p53R2Tg 
mice (Figure 3.6). Through embryonic day 11.5 (e11.5), bitransgenic embryos 
were observed at the expected frequencies, and most were grossly normal. At 
e12.5 and later, only dead Rrm1-D57N(high)Tg + p53R2Tg bitransgenic 
embryos were observed, and were still underrepresented (Figure 3.6A and 
Table 3.6). The frequency of resorbed embryos increased over the time frame 
analyzed, with few resorptions being observed before e10.5, but 5 or 6 
resorptions at e11.5 and e12.5, respectively. 
Bitransgenic embryos derived from crosses between Rrm1-D57N(high)Tg and 
Rrm2Tg mice displayed great variability in lifespan. At e13.5, the expected 
number of bitransgenic embryos was observed and bitransgenic embryos 
were grossly normal (Figure 3.6B and Table 3.6). However, embryo 
dissections at e15.5 revealed a sharp increase in abnormal or dead 
bitransgenic embryos. Of nine total embryos observed at e15.5, 6 were 
bitransgenic. Of these 6, one was normal while the other 5 appeared to have 
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Figure 3.5. Frequency of cII mutations measured in the lungs of 
Msh6+/+, Msh6+/-, or Msh6-/- mice with or without the D57N transgene. 
Mice harboring the indicated genotypes and the Big Blue transgene were 
analyzed at 3 months of age. Data are represented as mean for each 
genotype. Error bars, standard deviation. Sample sizes: 2, Msh6+/-; 3, 
Msh6-/-; 3, Rrm1-D57NTg Msh6-/-. For all others, n=1. (J.P.) 
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 died by e14.5. Two of the dead bitransgenic embryos displayed neural 
defects (Figure 3.6B). A normal bitransgenic embryo was observed at e16.5, 
while no live or dead bitransgenic embryos were observed at e17.5 or e19.5, 
of approximately 3 expected at each time point. Surprisingly, one live 
bitransgenic neonate was observed at P0, while 2 more were found dead at 
P0.  
The lifespan of Rrm1-D57N(low)Tg + p53R2Tg bitransgenic mice was 
intermediate between that of Rrm1-D57N(high)Tg + Rrm2Tg mice and Rrm1-
D57N(low)Tg + Rrm2Tg mice (Figure 3.8A, B). Rrm1-D57N(low)Tg + p53R2Tg 
bitransgenic mice survived birth. They appeared normal for the first 1-2 days 
of life, after which time runting became apparent (Figure 3.8A). Bitransgenic 
mice developed large, protruding eyes after P3-P4. However, survival of these 
bitransgenics decreased rapidly at P5, with all bitransgenics observed dying at 
either P5 or P6. In order to determine the morphological defects causing 
lethality in these bitransgenics, a broad range of tissues were harvested and 
examined histologically; however, I was unable to detect any defects that 
could account for the postnatal lethality. 
The Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice (Figure 3.8C, D) also 
survived gestation to be born at expected frequencies. From there, the 
majority were able to survive 7 days; following that time there was a rapid 
decline in viability such that few were able to survive 14 days or longer.
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During the second week of life most remaining bitransgenics experienced a 
rapid weight loss and became moribund. They also began to display exterior 
phenotypes, such as runting, thin hair, poor posture, and large protruding eyes 
(Figure 3.8C). Rare surviving mice were obtained that could survive 19, 25, 90, 
or 102 days. These mice will be discussed further. All Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice expired within 3 months of age, in contrast to mice 
harboring a single RNR transgene or Rrm1Tg + Rrm2Tg or Rrm1Tg + p53R2Tg 
bitransgenic mice, all of which appeared healthy and were able to survive 
beyond 12 months. 
 
Pleural effusion characterizes Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
animals 
Despite the finding that rare surviving Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice displayed premature aging phenotypes and severe skeletal 
and cardiac muscle degeneration, these defects are likely not to be the 
primary causes of the synthetic lethality observed. Skeletal and cardiac 
muscle degeneration were only observed in mice that survived at least 19 
days of age or longer; the majority of bitransgenic mice died within the second 
week of life. I therefore sought to determine the defects that arise in the more 
severely affected mice via histological staining of a wide range of tissues at 
earlier time points. Mice were monitored and weighed daily from birth in order 
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to be able to predict when the bitransgenics might expire; at that time the 
entire litter was culled for histological analysis.  
Brain, heart, lungs, liver, kidney, skeletal muscle, spleen, bone marrow, and GI 
tract were all examined by H&E staining for changes in morphology. I first 
noticed upon necropsy that bitransgenic mice, but not control mice, showed 
pleural effusion. Fluid accumulation affected the entire pleural cavity, and in 
mice surviving 8 days or later, also observed within the abdomen. In order to 
determine the type of the pleural effusion, I collected the fluid and analyzed the 
constituents. The data are summarized in Table 3.7. Pleural effusion was 
observed in neonates as early as P4. Later than P5, all bitransgenic neonates 
displayed the fluid accumulation. However, effusion was not observed in the 
mice surviving 19 days or longer. 
Histological analysis of neonates aged at least 9 days old revealed 
small kidneys with a loss of medullary tubules, interstitial fibrosis and edema, 
along with multifocal dilated tubules in the cortex (Figure 3.8A). This was 
observed in two bitransgenics, aged 9 and 11 days. 
Additionally, in neonates aged 6 days or more, the liver showed 
multifocal areas of hepatocellular swelling consistent with increased glycogen 
accumulation (Figure 3.8B). Hepatocellular swelling is caused by excessive 
accumulation of either glycogen or lipid. In order to distinguish between the 
two possibilities, we performed Periodic Acid Schiffʼs (PAS) staining on the 
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liver samples. PAS stains glycogen fuschia while lipid remains colorless. I 
found evidence of accumulation of both glycogen and lipid (Figure 3.8C).  
Kidney pathology was also found in the kidneys of aged mice overexpressing 
either Rrm2 or p53R2 (Figure 3.9). H&E staining reveals extensive protein 
accumulation in the collecting ducts of the medulla. The phenotype was more 
severe in mice harboring the Rrm2Tg than in mice overexpressing p53R2. 
Additional expression of Rrm1Tg did not increase the incidence or severity of 
the proteinuria.  
Severe muscle degeneration in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
mice 
Of approximately 70 Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic adults 
expected, only 5 were observed. Rare surviving Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice were runted compared to littermates. Throughout life, Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice were hunched, inactive, and 
displayed small muscles and alopecia. A rare mouse surviving 19 days 
exhibited general wasting (Figure 3.10A) and inactivity. All Rrm1-D57N(low)Tg 
+ Rrm2Tg bitransgenic mice showed a significant loss of body weight prior to 
death. Upon necropsy, we found that Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice which survived 90 days or longer exhibited severe skeletal 
and cardiac muscle degeneration.
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Hematoxylin and eosin staining of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
and control skeletal muscle samples reveals disorganized fibers, large, open 
nuclei, and decreased stainability in the bitransgenic (Figure 3.10Aiv). To 
further investigate the degree of muscle degeneration, I performed Massonʼs 
trichrome staining of duplicate sections of the same samples. Staining with 
Massonʼs trichrome stain also revealed severe degeneration in the 
bitransgenic, as demonstrated by vacuoles appearing within the skeletal 
muscle fibers and extensive fibrosis developing between muscle fibers (Figure 
3.10Aviii). Histological analysis of cardiac muscle tissue also revealed severe 
degeneration (Figure 3.10B). Analysis of a wider range of tissues did not 
reveal degeneration, suggesting that degeneration was limited to skeletal and 
cardiac muscle tissues. 
By contrast, mice overexpressing Rrm1Tg + Rrm2Tg or Rrm1Tg + 
p53R2Tg displayed only mild degeneration in the skeletal muscle (Figure 3.11) 
and histologically normal cardiac muscle (Figure 3.12). 
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Figure 3.6. Gross morphology of Rrm1-D57N(high)Tg + Rrm2Tg or p53R2Tg 
bitransgenic embryos. A. Rrm1-D57N(high)Tg + p53R2Tg bitransgenic embryos. 
Bitransgenics are grossly normal through 10.5 dpc. At 11.5 dpc, dead bitransgenic 
embryos begin to be observed. B. Rrm1-D57N(high)Tg + Rrm2Tg bitransgenic embryos 
and controls. Bitransgenics are found dead as early as 13.5 dpc. However, some 
normal embryos are observed as late as e15.5. Arrow and arrowhead indicate head and 
spinal abnormalities. (J.P.) 
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Figure 3.7. Reduced survival of bitransgenic mice. A. Gross morphology of Rrm1-
D57N(low)Tg + p53R2Tg bitransgenic mice at P8. B. Reduced survival of bitransgenic 
mice derived from Rrm1-D57N(low)Tg x p53R2Tg cross. Pups were counted on P0 (day 
of birth) and monitored daily. Pups were genotyped by Southern blot analysis of tail 
DNA at 21 days of age or when found dead. Bitransgenic mice (purple line) have a 50% 
survival rate of 5 days. C. Gross morphology of Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice at P15. Bitransgenic mice are runted and show alopecia and 
decreased activity. A bitransgenic mouse (right) is pictured at P15 with a wild type 
littermate (left). D. Survival of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice. Pups 
were genotyped by Southern blot analysis of tail DNA at 21 days of age or when found 
dead. Bitransgenics surviving past 21 days of age were housed with sex-matched 
littermates and monitored frequently, and euthanized when moribund. (J.P) 
 160  
 161  
 Table 3.7. Analysis of fluid collected from Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice. 
Neonate age (days) 
mass of 
pup (g) 
fluid 
recovered
(mL) 
total 
protein 
(g/dL) 
albumin 
(g/dL) 
1 6 ND 80 1.4 1.0 
2 12 ND ND 1.8 ND 
3 12 ND ND 1.8 ND 
4 7 ND ND ND 1.1 
5 8 2.5 135 ND 1.0 
mean ± st 
dev N/A N/A N/A 1.67 ± 0.23 1.03 ± 0.05 
aNeonates were monitored and weighed daily until visibly ill and/or failed to 
thrive (failed to gain weight or lost weight). Mice were euthanized and pleural 
fluid collected. Total protein content or albumin content was measured by the 
Clinical Pathology Lab, College of Veterinary Medicine, Cornell University. ND, 
not determined. (J.P and T.S.) 
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Mitochondrial genome instability does not cause synthetic lethality in 
the bitransgenics 
We previously reported that mice simultaneously overexpressing Rrm1Tg and 
either Rrm2Tg or p53R2Tg displayed age-dependent mitochondrial DNA 
depletion in the skeletal muscle as a result of dNTP pool imbalance(32). Our 
finding of severe skeletal muscle degeneration in surviving Rrm1-D57N(low)Tg 
+ Rrm2Tg bitransgenic mice led us to hypothesize that the degeneration was 
caused by an instability of the mitochondrial genome, leading to dysfunctional 
mitochondria. The degeneration was also observed in the cardiac muscle, and 
if due to mtDNA depletion, this could link the RNR regulation to a concrete 
phenotype causing lethality. In order to test this hypothesis, we measured 
mtDNA copy number in MEFs overexpressing both Rrm1-D57N(low)Tg and 
p53R2Tg or Rrm1-D57N(high)Tg and Rrm2Tg(Figure 3.13A). To mimic the 
quiescent state of skeletal muscle, we serum-starved the MEFs, trapping the 
majority of cells in G1. We found no depletion of mitochondrial DNA in either 
the Rrm1-D57N(low)Tg + p53R2Tg or the Rrm1-D57N(high)Tg + Rrm2Tg 
bitransgenic cell lines or any of the controls. Because the mtDNA depletion in 
the other mouse model was age-dependent, we asked if Rrm1-D57NTg + 
Rrm2Tg or p53R2Tg bitransgenic mice would display mtDNA depletion as they 
aged. The early lethality of the Rrm1- D57N(low)Tg + p53R2Tg bitransgenic 
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Figure 3.8. Spectrum of phenotypes in Rrm1-D57NTg + Rrm2Tg bitransgenic 
neonates. A. H&E analysis of P11 kidney in wild type (left panel) and Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic animals (right panel). The bitransgenic shows 
degeneration of cortical tubules (arrows), dilated tubules in the medulla (arrowheads), 
and fibrosis (thick arrows). Scale bars, 100mm. B. H&E analysis of liver from wild type 
(left) and bitransgenic littermate (right). Arrow indicates focus of hepatocytes with 
abnormal accumulations of lipid or glycogen, leading to swollen appearance. Scale 
bars, 20mm. C. Periodic acid Schiffʼs stain of neonate livers at P6. Yellow arrows 
indicate hepatocytes with glycogen accumulation (fuschia), while blue arrowheads 
indicate hepatocytes with lipid accumulation. Glycogen is abundant in the wild type liver 
but does not accumulate within hepatocytes. Scale bars, 25mm. (J.P., R.P., and T.S.) 
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Figure 3.9. Proteinuria in kidneys of mice overexpressing either small RNR 
subunit. Tissues were stained with H&E following overnight fixation. Collecting 
ducts of kidneys with excessive protein accumulation stain bright pink with eosin. 
Images are representative of their genotype. Numbers indicate total number of 
mice resembling image over total number of mice of that genotype. (T.S. and 
J.P.) 
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neonates and the embryonic demise of bitransgenics harboring Rrm1-
D57N(high)Tg necessitated mtDNA measurements in Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenics. We were able to measure mtDNA copy number in 
bitransgenic mice at P4, P8, P19, P25, and P90 or P102 mice (Figure 3.13B). 
We found the mtDNA copy number in skeletal muscle of control mice 
increased with age, while mtDNA copy number in the skeletal muscle of 
bitransgenic mice failed to expand to the same level throughout development. 
In juvenile mice, mtDNA copy number was equal to controls, but by P19 was 
only ~50% of the wild type level. 
 It is a possibility that skeletal muscle degeneration in the Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice was giving the appearance of depleted mtDNA 
when the mitochondria are actually unaffected. To attempt to control for this, 
we also measured mtDNA content in the heart, kidney, and liver of juvenile 
and young adult mice (Figure 3.13B). In a previous study (Chapter 2), we were 
unable to detect mtDNA depletion in these tissues in aged Rrm1Tg + Rrm2Tg or 
Rrm1Tg + p53R2Tg adult bitransgenic mice. However, these tissues also show 
degenerative phenotypes in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice. 
Therefore, if the observed mtDNA depletion is solely due to tissue 
degeneration and not to defects in mtDNA maintenance, then we would see 
depletion in the heart, kidney, and liver as well as in the skeletal muscle.
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Figure 3.10 Muscle degeneration in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
adult mice. Degeneration of skeletal (A) and cardiac (B) muscle in Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic adults. Tissues from 90-day old mice were fixed overnight in 
formalin at room temperature prior to embedding and sectioning. Tissues were stained 
with H&E (i-iv) or Massonʼs trichrome (v-viii). Both skeletal and cardiac muscle from 
bitransgenic mice (A: iv, viii, B: iv, viii) display irregular fiber size, decreased stainability, 
loss of striation (black arrows), large internal nuclei (white arrows), interstitial 
replacement fibrosis (white arrowheads), and vacuoles within muscle fibers (black 
arrowheads). (J.P. and R.P.) 
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Figure 3.11.  Analysis of skeletal muscle from wild type, 
Rrm1Tg + Rrm2Tg, and Rrm1Tg + p53R2Tg adult mice. A. Skeletal 
muscle from young (3 months; top) or aged (12 months; bottom) 
mice was stained with H&E. Bitransgenics show more variable fiber 
size, increased number of nuclei, and internal nuclei. B. Massonʼs 
trichrome stain was performed on aged wild type and bitransgenic 
mice. Scale bars represent 25mm. Scale bars represent 
50mm.(J.P. and T.S.) 
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Figure 3.12. Analysis of cardiac muscle from wild type, Rrm1Tg + 
Rrm2Tg, and Rrm1Tg + p53R2Tg adult mice. A. Cardiac muscle from 
young (3 months; top) or aged (12 months; bottom) mice was stained 
with H&E. Bitransgenics are normal relative to control mice. B. 
Massonʼs trichrome stain was performed on aged wild type and 
bitransgenic mice. Scale bars repesent 50mm. (J.P. and T.S.) 
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If, however, degeneration is not causing the observed depletion, then 
mtDNA content in these tissues would remain at wild type levels in the Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice. 
The results were largely inconclusive. Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic mice did not show mtDNA depletion in the cardiac muscle as they 
aged (p=0.104, Studentʼs t-test), suggesting either no defect in maintaining 
mtDNA in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, or that an mtDNA 
maintenance defect is restricted to the skeletal muscle, as previously observed 
(Chapter 2). However, to a small extent kidney and liver both showed mtDNA 
depletion with age, but neither of these is statistically significant (kidney, 
p=0.18, Studentʼs t-test; too few samples to analyze liver).  
 Mitochondrial genome instability can also manifest as increased point 
mutations(47) within critical OX-PHOS genes, or large deletions within the 
genome. We sequenced mtDNA in several regions but found no increase in 
mtDNA point mutations (data not shown). It has been further reported that 
dNTP pool imbalances can stimulate long deletions within mitochondrial 
DNA(13). We therefore performed long PCR to assess the total size of the 
mtDNA in bitransgenic mice (Figure 3.13C). In both wild type and Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice, we were able to detect only full-
length mtDNA (16kb).  
 To connect mtDNA depletion to the skeletal muscle degeneration, it 
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was necessary to determine if mitochondrially-encoded complexes were 
functional. In order to test this, we performed COX activity stain on frozen 
skeletal muscle from the P25 bitransgenic, which displayed ~50% mtDNA,  
and a wild type littermate. As a control for mitochondrial presence, we also 
stained for the activity of the nuclear-encoded SDH complex (Figure 3.13D). 
We found normal COX activity in the muscle of the bitransgenic mouse, and 
no increase in SDH signal.  
 We hypothesized that the lack of mitochondrial dysfunction at P25 
could be due to the young age of the bitransgenic. We were able to detect 
mtDNA depletion in mice as young as 19 days; however, it may take more 
time for dysfunctional mitochondria to appear and cause phenotypic effects. 
We therefore tested the expression of SDH from the skeletal muscle of a 
bitransgenic at P90. We hypothesized that if the mitochondrial DNA was 
causing dysfunction throughout life, then at P90 we would be able to see SDH 
upregulation as a compensatory strategy for mitochondrial dysfunction. The 
results are presented in Figure 3.13E. We found increased staining for SDH in 
the skeletal muscle of the bitransgenic relative to the control. We also found 
subsarcolemmal accumulations of mitochondria (arrows), which is a second 
compensation mechanism for sub-functional mitochondria. These data 
suggest that simultaneous overexpression of Rrm1-D57N and either small 
RNR subunit does not cause mitochondrial genome instability early in life, but 
only as bitransgenic mice age, and therefore does not cause the observed 
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synthetic lethality. 
Rrm1-D57NTg + Rrm2Tg or p53R2Tg bitransgenic MEFs proliferate 
normally 
To investigate possible causes for embryonic lethality, I wanted to determine if 
simultaneous disruption of multiple regulatory modes of RNR could affect cell 
cycle progression. A model of rnr1-D57N overexpression in yeast had 
previously reported that increases in dNTP pools caused a delay in origin firing 
in S-phase(36). The similarities between their model and ours prompted us to 
assess the ability of cells overexpressing either Rrm1-D57NTg in combination 
with either small RNR subunit to proliferate (Figure 3.6). I isolated mouse 
embryonic fibroblasts (MEFs) from embryos derived from each of the four 
combinations. The cells were assessed for proliferative ability by culturing on a 
3T3 protocol with counting at every passage; population doublings were 
calculated and compared to wild type or single transgenic controls. I found no 
proliferation defects in any combination of bitransgenics (Figure 3.14). 
Bitransgenic cell lines from each combination doubled their populations at the 
same rate as control cell lines and did not senesce prematurely. I therefore 
conclude that simultaneous overexpression of Rrm1-D57N and either small 
RNR subunit does not cause proliferation defects in MEFs. 
 
DISCUSSION 
The mechanisms governing regulation of ribonucleotide reductase are 
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well known. RNR activity is known to be controlled in eukaryotes through small 
inhibitory proteins such as SML1(48) (in yeast), differential subcellular 
localization (in yeast), limitation of protein levels of a single subunit (the small 
subunits in mammals and the large subunit in yeast)(30, 49), and allosteric 
feedback control(50). We previously reported that overexpression of either 
small RNR subunit in mice causes lung cancer via a mutagenic mechanism(1). 
Noting that one mechanism of RNR regulation had been disabled, leading to 
the phenotype, we sought to deregulate RNR by an independent mechanism. 
Our initial hypothesis was that overexpression of either small subunit would 
disable a single regulatory mechanism of RNR, limitation of small subunit 
protein levels, and therefore increase active RNR complex and elevate dNTP 
pools. Increased dNTP pools have been reported to be mutagenic in multiple 
studies(5, 7, 9, 35, 36, 51). I hypothesized that mutating the allosteric activity 
site would disrupt the other main regulatory mechanism in mammals but also 
cause an increase in dNTPs; therefore the activity site mutant would also be 
tumorigenic. To test this prediction, we generated transgenic mice that 
overexpressed the mutant form of the large subunit. We obtained two 
independent transgenic lines that both show significant overexpression in a 
multitude of tissues. Despite the very high-level overexpression of Rrm1 in the 
Rrm1-D57N transgenic lines, the mice were born at expected frequencies and 
were grossly normal. 
Overexpression of either small RNR subunit, Rrm2 or p53R2, caused 
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lung tumorigenesis at a high frequency. Overexpression of the small subunits 
removes one regulatory mechanism of RNR, and I hypothesized that removing 
the other RNR regulatory mechanism would have a similar effect. I first 
analyzed the lung tumor phenotype in Rrm1-D57N(low)Tg and Rrm1-
D57N(high)Tg mice. I found that the incidence of lung tumors was moderately 
increased in Rrm1-D57NTg mice, but neither the average tumor size, 
malignancy, nor tumor latency was affected. This was in contrast to the lung 
tumors observed in Rrm2Tg and p53R2Tg mice(1).  
This supports our previous hypothesis that overexpression of the radical-
producing subunits of RNR increases reactive oxygen species, thus increasing 
the mutation rate, and is therefore tumorigenic in the lungs of transgenic mice. 
In contrast, overexpression of Rrm1-D57N does not drive lung tumorigenesis, 
and if anything, facilitates lung tumor formation in strains that are predisposed 
to carcinogenesis. Because deregulating RNR by disabling allosteric feedback 
control had limited phenotypes, I sought to further deregulate the enzyme by 
simultaneously disrupting both main regulatory modes. In yeast, simultaneous 
disruption of the two main regulatory mechanisms caused constitutively 
elevated dNTP pools, which resulted in proliferation defects(36). In order to 
determine if mice would have a similar phenotype, I crossed mice 
overexpressing either Rrm1- 
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Figure 3.13. mtDNA integrity in bitransgenic mice. A. mtDNA copy 
number in bitransgenic MEFs from the Rrm1-D57N(low)Tg x p53R2Tg cross. 
MEFs at passage 2 were cultured in 2% serum for 8 days prior to extraction of 
total DNA. mtDNA was quantified by qPCR and normalized to the nuclear 18S 
rRNA. B. mtDNA copy number in tissues from bitransgenic mice from the 
Rrm1-D57N(low)Tg x Rrm2Tg cross. Total DNA was extracted from skeletal 
muscle, heart, kidney, or liver of bitransgenic and control mice at different 
stages of development: juvenile=P4, P8; young adult= P19, P25; aged 
adult=P90, P102. mtDNA was quantified as in part A. C. Long PCR on mtDNA 
from skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic and wild 
type littermate at P25. Only the full 16 kb mtDNA is detected. D. Activity of 
respiratory chain complexes in skeletal muscle of Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic and wild type littermate at P25. Tissues are stained for 
activity of the mtDNA-encoded complex IV (COX, brown), the nDNA-encoded 
complex II (SDH, blue), or both, E. Abundance of total SDH protein (brown) in 
skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic and wild type 
littermate at P102. Arrows indicate subsarcolemmal accumulations of 
mitochondria. Nuclei are counterstained blue with hematoxylin. (E.Y.) 
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D57N transgene to mice overexpressing either small RNR subunit. In mice, 
cell proliferation defects would be expected to lead to embryonic lethality, as 
cell division is required for embryogenesis. Our first observation was that the 
combination of Rrm1-D57N and either small RNR subunit caused synthetic 
lethality in mice, which would be predicted by the previous model. I next found 
that the timing of the lethality was determined by which specific transgenic 
combination was expressed. Combination of Rrm1-D57N(high)Tg with either 
small subunit caused embryonic lethality, with p53R2Tg being more severe 
than Rrm2Tg. Having less mutant Rrm1 allows the Rrm1-D57N(low)Tg strain to 
survive longer, through gestation, when paired with Rrm2Tg or p53R2Tg, but 
the lifespan is still significantly shortened and lasts a matter of days. Again, 
having p53R2Tg made the phenotype more severe than having Rrm2Tg. This 
may be due to the differential patterns of expression of Rrm2 and p53R2. 
p53R2 is expressed at very low levels throughout the cell cycle, while during 
S-phase, Rrm2 is expressed very highly. High-level overexpression of p53R2 
would then be expected to cause a more significant deregulation of RNR than 
overexpression of Rrm2.  
That some bitransgenic mice are able to survive through gestation was 
surprising, given that the effects of similar RNR deregulation in yeast caused 
proliferation defects and would be expected to cause only embryonic lethality 
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Figure 3.14. Proliferation of cells overexpressing either Rrm1-D57N transgene 
and either small RNR subunit. Cells were maintained in media with 10% serum and 
passed every 3 days with counting. Cumulative population doublings were calculated 
and plotted vs. time. (J.P.) 
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 in mice. Also inconsistent with the yeast model was the finding that MEFs 
expressing all four combinations of Rrm1-D57N and either small subunit 
proliferated normally relative to controls. These findings indicate that while 
RNR is deregulated to a lethal extent in these mice, it is not sufficiently altered 
to cause cellular defects. 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, the least severe 
combination, were severely underrepresented in adulthood, most having 
succumbed to illness within the first 2 weeks of life. Rare surviving 
bitransgenic adults displayed severe skeletal and cardiac muscle 
degeneration. In addition to muscle degeneration, they also displayed a 
general wasting phenotype, kyphosis, and alopecia. Taken together, these 
phenotypes are consistent with premature aging. Mice harboring a 
proofreading-deficient DNA Pol γ also display these phenotypes(47), 
suggesting that destabilization of the mitochondrial genome may play a role in 
this synthetic lethality. We also noted that mice that overexpress Rrm1Tg and 
Rrm2Tg or p53R2Tg displayed severe age-dependent mtDNA depletion 
(Chapter 2). This strengthens the link between RNR deregulation and 
mitochondrial genome instability. All together, these results suggested that 
synthetic lethality in Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice may be 
mediated through mitochondrial genome instability. However, analysis of 
mtDNA content at various ages as well as assays for the function of mtDNA-
encoded complexes did not support this notion. Young Rrm1-D57N(low)Tg + 
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Rrm2Tg bitransgenic mice did not show mtDNA depletion. The rare Rrm1-
D57N(low)Tg + Rrm2Tg bitransgenic mice that survived to adulthood did show a 
reduction in mtDNA content, but we must conclude that mtDNA depletion does 
not cause lethality in these bitransgenic mice, as most Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice die during the second week of life, when no mtDNA 
depletion was observed, and only rarely survive long enough to display such 
phenotypes. Nevertheless, given the mtDNA depletion observed in the Rrm1Tg 
+ Rrm2Tg and Rrm1Tg + p53R2Tg bitransgenic mice and that in our model RNR 
is expected to be further deregulated, we do expect that if given enough time, 
the combination of Rrm1-D57N(low)Tg + Rrm2Tg would cause mtDNA 
depletion. We hypothesize that we were unable to observe such depletion 
because of the short lifespan of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic 
mice. Therefore, the mtDNA depletion is secondary to the lethal defect in 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice, and the actual cause of the 
lethality is yet to be determined. 
A third hypothesis to explain the particular phenotypes observed in the 
Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic mice links cellular control of 
nucleotide levels and hypertension. Elevated and/or unbalanced nucleotide 
pools are known to be mutagenic, and can have such severe consequences 
as mtDNA depletion (Chapter 2) and genomic instability(2, 13). A defense 
against unbalanced nucleotide pools is through nucleotide degradation, in 
which dNTPs are cleaved by deaminases and nucleoside phosphorylases and 
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either returned to the substrate cycles or excreted(52). For purines especially, 
elevated degradation products in the bloodstream of mice or humans can have 
adverse effects. The products of purine nucleotide degradation, xanthine, 
hypoxanthine, and uric acid, are elevated in the blood of hypertensive 
patients(53) and elevating uric acid causes hypertension in rats(54). Among 
other phenotypes, hypertension causes pleural effusion(55) and 
glaucoma(56), which are either observed in our mice or are similar to 
phenotypes observed in our mice. Therefore, I hypothesize that simultaneous 
disruption of both main RNR regulatory pathways in Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice elevates nucleotide pools, which are quickly 
degraded in an attempt to keep levels balanced. The increase in xanthine, 
hypoxanthine, and especially uric acid in the blood triggers hypertension, 
which results in pleural effusion and eventually suffocates the bitransgenic 
mice at a young age. 
A second, but not exclusive, pathway to arrive at hypertension is 
through kidney disease. Defects in protein uptake within the proximal renal 
tubules can cause hypertension, leading to pleural effusion and ultimately, 
death(57). Kidney degeneration, characterized by loss of both cortical and 
medullary renal tubules, fibrosis, and dilation of medullary tubules, was found 
in juvenile bitransgenics (P9 and P11). Similar phenotypes were observed in 
mice lacking Myosin-VI(57), which functions in endocytosis. Interestingly, 
mutation of Myo6 in mice led to elevated blood pressure and decreased body 
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weight in adults. Pleural effusion was also observed in Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice, and subsequent analysis of the fluid revealed it to 
be transudative in nature, as opposed to exudative. Transudative pleural 
effusions are caused by defects such as hypertension, kidney failure, and 
heart failure and are characterized by low protein and albumin content(55). 
Exudative pleural effusions are characterized by high protein and albumin 
content, and are caused by local lesions such as lung tumors(55).  
Another link between RNR and kidney defects was found in the kidneys 
of aged Rrm2Tg and p53R2Tg mice, as well as bitransgenics harboring Rrm1Tg 
and either small subunit. I observed proteinuria upon histological staining of 
kidneys from mice overexpressing either small RNR subunit. The Myo6 mutant 
mice also showed significant albuminuria, suggested to begin during kidney 
development and affect phenotypes throughout the life of the animal(57). This 
possibly supports a link between impaired protein uptake by the kidneys 
during development and hypertension, which could later lead to pleural 
effusion in our bitransgenic neonates. 
This hypothesis may help explain the lethality in the Rrm1-D57N(low)Tg 
+ Rrm2Tg bitransgenic mice, but they survive significantly longer than 
bitransgenics from the other crosses, most notably the crosses involving 
Rrm1-D57N(high)Tg. Bitransgenic embryos harboring the Rrm1-D57N(high) 
transgene and either small subunit showed defects in the vasculature. Rrm1-
D57N(high)Tg + p53R2Tg and Rrm1-D57N(high)Tg + Rrm2Tg embryos showed 
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vascular defects in the yolk sac and hemorrhages in the near the dorsal aorta. 
While links between this and nucleotide metabolism are unclear, the 
development of pleural effusion in neonates and hemorrhages in embryos may 
suggest a more general vascular defect as the cause of all of the observed 
synthetic lethality. 
Nucleotides also play significant roles in many other processes and as 
signaling molecules. While ATP stimulates muscle contraction, dATP 
stimulates even stronger contractions. An increase in dATP could possibly 
induce stronger contractions within the cardiac muscle, leading to increased 
blood pressure and the downstream phenotypes associated with it. Other 
possible effects of elevated RNR activity include depletion of nucleotide 
precursors, which could limit the nucleotides available for RNA synthesis and 
signaling. Further work is needed in order to determine the full extent of 
perturbations to nucleotide pools caused by RNR deregulation.  
 Deregulation of RNR in mice by small subunit overexpression causes 
lung tumorigenesis and moderately elevated dNTP pools, while 
overexpression of the feedback-resistant mutant Rrm1-D57N had limited 
phenotypes. Only when these two regulatory modes were simultaneously 
disabled were phenotypes observed, suggesting that these two mechanisms 
are partially redundant. The timing of the lethality is dependent on the degree 
of RNR deregulation, with higher-level overexpression of Rrm1-D57NTg or 
either small subunit resulting in more severe defects and earlier lethality. In 
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yeast, simultaneous loss of both regulatory modes caused proliferation 
defects, while the cells were able to survive. All together, I conclude that 
severe deregulation if RNR in multicellular organisms has hazardous 
consequences, and further work will allow us to explore the ability of cells to 
maintain their genomes in the presence of deregulated RNR. 
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Chapter 4: Allosteric feedback regulation of Ribonucleotide Reductase 
is crucial for survival in mice1 
Abstract 
Ribonucletotide reductase (RNR) catalyzes the rate-limiting step in de 
novo dNTP biosynthesis and so is a key regulator of nucleotide pools, 
controlling the availability of dNTPs for DNA replication and DNA repair. In 
order to tightly regulate nucleotide availability, the activity of RNR must be 
carefully controlled. The mechanisms involved in regulating the activity of RNR 
have been well established in recent years. In mammals, the two main 
regulatory mechanisms include transcriptional control of RNR genes and 
allosteric feedback control. Consequences of deregulating RNR by way of 
disabling the activity site are well characterized in yeast. Importantly, Chabes 
and Stillman found that yeast that overexpressed rnr1-D57N exhibited reduced 
replication origin firing and slow growth. However, transgenic animal models 
featuring overexpression of the Rrm1D57N mutant are grossly normal, indicating 
that the presence of the wild type allele at the endogenous locus allows for 
adequate feedback control. We hypothesized that targeting the Rrm1D57N 
mutation directly to the endogenous Rrm1 locus would remove all allosteric 
feedback inhibition and RNR would be constitutively active. We therefore 
generated mice with Rrm1D57N targeted to the endogenous locus and obtained 
germline transmission in two independent mouse strains. We found that 
homozygosity of Rrm1D57N causes embryonic lethality in mice, slow growth of 
cultured MEFs, and p21 upregulation. Heterozygous mice are born at 
expected frequencies and are grossly normal, which is inconsistent with 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 Jennifer L. Page, Sarah Lagedrost, Lee Gerwitz, Teresa Southard, and 
Robert S. Weiss. Unpublished results. 
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reports that Rrm1D57N is a dominant mutation. We hypothesize that, as in the 
Chabes-Stillman model, persistent elevated dNTP concentrations may act to 
inhibit firing of replication origins and slow growth, which is lethal in a 
developing embryo. This work underscores the importance of tightly controlled 
RNR activity in mammals. 
Introduction 
Accurate genome replication requires an adequate and balanced supply 
of dNTPs, the precursors for DNA synthesis. Insufficient levels of one or more 
dNTPs leads to replication stress and activation of the S-phase checkpoint(1), 
and depletion of mitochondrial DNA(2). However, increased nucleotide pools 
are mutagenic in yeast(3) and mammalian cells(4). Severely unbalanced 
nucleotide pools have been proposed to be a signal for apoptosis(5). The rate-
limiting step in dNTP biosynthesis, the removal of the 2ʼ-OH from the 
ribonucleoside diphosphate to produce the deoxyribonucleoside diphosphate, 
is catalyzed by the cytosolic enzyme ribonucleotide reductase (RNR)(6). RNR 
is comprised of two subunits. The large subunit is a homodimer encoded by a 
single gene, Rrm1, while the small subunit is either a homodimer of the Rrm2 
gene product or the p53R2 gene product. Regulation of RNR activity is a 
principal mechanism by which cells can ensure an optimal nucleotide pool. 
Mammalian cells are known to utilize two main mechanisms to control RNR 
activity, limitation of small subunit protein levels and allosteric feedback 
inhibition.  
The small subunit Rrm2 is induced as the cell enters S-phase so that it 
can complex with Rrm1 to provide dNTPs for DNA replication. Following S-
phase, Rrm2 is specifically degraded by the APCCdh1 complex in order to limit 
the bulk of RNR activity to S-phase(7). The small subunit p53R2 is expressed 
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at low and constant levels throughout the cell cycle, where it can form a 
complex with Rrm1 to provide dNTPs for basal DNA repair and mitochondrial 
DNA synthesis(8). Following DNA damage, p53R2 is induced by p53 in order 
to rapidly provide dNTPs for repair of the damage(9). We previously reported 
that mice that overexpress either small RNR subunit Rrm2 or p53R2 
developed lung tumors at a high frequency(10), suggesting that tight control of 
the small subunit protein levels is critical. 
Regulation of RNR activity in the yeast Saccharomyces cerevisiae 
follows a different pattern. Yeast RNR1 is tightly linked to the cell cycle and 
during S-phase, mRNA levels show a 10-fold increase compared to resting 
phases(11). In contrast, RNR2 mRNA was abundant throughout the cell cycle 
and levels showed at most a 2-fold increase as cells reached S-phase(12). A 
second mechanism for inhibition of RNR activity in yeast relies on binding of 
small protein inhibitors to the R1 subunit. The small protein SML1 (suppressor 
of mec1 lethality) binds the R1 subunit in G1 phase and prevents activity. Due 
to sequence homology between the C-termini of SML1, RNR2, and RNR4, it 
was hypothesized that binding of SML1 to RNR1 would involve the same 
interaction domain as RNR1-RNR2 binding and inhibition would be 
competitive; however, inhibition appeared noncompetitive(13). No mammalian 
homologs of SML1p have been identified yet. A fourth regulatory mechanism 
controlling RNR activity in yeast is differential subcellular localization. During 
quiescent phases of the cell cycle, Rnr2p and Rnr4p are anchored in the 
nucleus by Wtm2(14). Following DNA damage or during S-phase, Rnr2p and 
Rnr4p are released and translocate into the cytosol and complex with 
Rnr1p(14). 
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Control of RNR activity through allosteric feedback inhibition involves 
two separate effector binding sites. A specificity site binds dNTPs in a 
feedback loop in order to determine substrate choice. Mutation of residues 
within this site lead to unbalanced nucleotide pools(1). In cultured mammalian 
cells, an isolated mutation was able to confer resistance to excessive levels of 
dGTP, although the specific mutation was never reported(15). In yeast, a 
series of mutations within Loop 2, proposed to be the functional part of the 
allosteric specificity site, create unbalanced nucleotide pools(1). Despite 
causing extreme variations in the concentration of each dNTP relative to one 
another, most mutations did not trigger activation of the intra-S-phase 
checkpoint. Only mutations which specifically caused depletion of at least one 
dNTP activated the S-phase checkpoint, suggesting that while mutagenic, 
unbalanced nucleotide pools can be tolerated(1). 
A second binding site, the activity site, monitors the ratio of ATP vs. 
dATP, so that ATP stimulates enzyme activity while dATP inhibits further 
production of dNTPs. Mutation of a critical and conserved residue within the 
activity site, aspartic acid 57 to asparagine, destroys the ability of the activity 
site to respond to dATP binding and allowed mammalian cells to survive in the 
presence of excessive dATP(16). Work by Reichard et al. shows that the 
Rrm1-D57N mutant binds dATP with wild type affinity, but that dATP 
stimulates rather than inhibits enzyme activity(17). In yeast, when expressed 
under the endogenous promoter, the rnr1-D57N mutant elevated dNTP pools 
by approximately 3-fold and conferred a mutator phenotype(3). The Rrm1-
D57N mutant is also mutagenic in mammalian cells(16). As a result of dNTP 
pool expansion, cells showed improved survival following DNA damage. Yeast 
which overexpressed rnr1-D57N under a gal-inducible promoter showed an 
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approximately 35-fold increase in [dNTP], resulting in slow growth(18). 
Activation of the intra-S-phase checkpoint was not observed. The slow growth 
phenotype was characterized by reduced loading of the S-phase initiator 
protein Cdc45p. This data indicated that cells which overexpress rnr1-D57N  
were inhibited in activating origins to enter S-phase. Further reduction of the 
available pre-RCs by disabling function of the origin recognition complex 
(ORC) would then be expected to worsen the phenotype observed in rnr1-
D57N overexpressing cells. Simultaneous expression of orc2-1 or orc5-1 
mutants caused synthetic sickness in the cells with overexpressed rnr1-D57N, 
suggesting that inhibition of origin firing in rnr1-D57N-overexpressing cells is 
the cause of the slow growth. Cells that overexpressed rnr1-D57N 
accumulated in G1 phase of the cell cycle, while cells that overexpressed 
RNR1 in the same manner did not(18). Together these results suggest that 
excessively elevated dNTPs may act as a signal for inhibiting DNA replication 
in cells. 
Inhibition of pre-RC activation is one of the functions accomplished by 
the p53-dependent checkpoint protein p21(19). p21 is a member of the 
CIP/KIP family of CDK inhibitors (CKIs), along with p27 and p57(20). p21 was 
shown to interact with both Cdk2 and Cdk3 by a yeast two-hybrid screen, and 
to negatively regulate the cyclin A-Cdk2 complex in cultured human 
fibroblasts(21). p21 is able to effectively block phosphorylation of Rb by both 
A-type and E-type cyclin/Cdk complexes(21), leading to G1 arrest(22). p21 
can also directly bind PCNA in order to block binding sites for DNA 
polymerase d(19).  
Previous work by us indicates that overexpression of Rrm1-D57N in 
mice is not sufficient to cause overt phenotypes (Chapter 3). Rrm1-D57N-
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overexpression was not tumorigenic and was not mutagenic, either alone or in 
combination with mismatch-repair deficiency. Only when overexpression of 
Rrm1-D57N was combined with overexpression of either small RNR subunit, 
relieving RNR of both main regulatory mechanisms, was a phenotype 
observed, in the form of synthetic lethality. Even then, primary MEFs cultured 
from bitransgenic embryos proliferated normally, suggesting no prolonged G1 
phase as in Chabes and Stillman(18). We hypothesized that the limited 
phenotypes observed may be due to variable expression levels of the Rrm1-
D57N transgene in different tissues, minimizing the observable effects of 
Rrm1-D57N overexpression. We reasoned that in order to observe the full 
effects of loss of dATP inhibition, the Rrm1-D57N mutation must be targeted to 
the endogenous locus, thereby standardizing expression and effects as well 
as removing all activity site function. Here we report that loss of allosteric 
feedback control in mice causes embryonic lethality, and preliminary work 
suggests that cells fail to progress beyond G1 phase normally, indicating that 
in mammals, as in yeast, dNTP pools may be a signal determining whether it 
is appropriate to fire origins. 
 
Materials and Methods 
Generation of Rrm1D57N targeting construct.  
The Rrm1 genomic locus was modified using recombineering(23, 24). A BAC 
clone (411e05) derived from 129/svev mice  was electroporated into SW106 
cells(25). Oligos used to generate various constructs are listed in Table 4.1. 
The D57N point mutation was introduced using the GalK replacement system, 
in which the wild-type guanidine base was replaced by homologous 
recombination with the bacterial GalK gene (generating the JePa1 plasmid). 
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Recombined clones were screened on MacConkeyʼs agar plates, in which 
cells able to use galactose are red. The GalK gene was then replaced with the 
mutant adenine by homolgous recombination, and cells were analyzed for loss 
of the ability to utilize galactose by growth on 2ʼ-deoxygalactose plates. 
Positive clones were then confirmed by sequencing of the mutated exon (the 
JePa2 plasmid). A 12-kb region containing approximately half of the Rrm1 
locus was subcloned into the PL253 plasmid, introducing a bacterial TK 
element outside the region of homology (JePa3). A floxed Neo cassette was 
introduced into the second intron approximately 500bp from the mutated base 
pair by homologous recombination (JePa4), generating the Rrm1D57N-Neo 
(hereafter referred to as Rrm1Neo) allele. The final construct was confirmed by 
sequencing of cloning junctions and restriction digests. 
 
Table 4.1. Primers used to generate Rrm1D57N-Neo mice. 
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Embryonic stem cell culture and selection.  
TC-1 embryonic stem cells(26) were cultured on feeders in DMEM 
supplemented with 15% fetal bovine serum, and in the presence of leukemia 
inhibitory factor (LIF). 2 x 107 cells were electroporated with 40mg of the SalI-
linearized JePa4 DNA and seeded approximately 5 x 106 cells/plate. Cells 
were grown for 7 days in the presence of G418 and FIAU. Surviving clones 
were isolated and expanded prior to screening by Southern blot.  
 
Southern blot analysis.  
Total genomic DNA isolated from ESC clones was digested overnight with BclI 
and separated on 0.8% agarose gel. DNA fragments were immobilized on a 
nylon membrane (GeneScreen Plus, Perkin Elmer) and detected by 
hybridization with a DNA probe homologous to a region immediately 3ʼ to the 
targeted sequence (Probe C, Figure 4.1A). Probe C was generated using 
primers JLP 19 and JLP20. The Neo element introduces a novel BclI site that 
cuts the approximately 15 kb wild type band to 12 kb. To confirm the presence 
of a single targeting construct, total DNA was digested with EcoRV and 
detected with a Neo element-specific probe (Probe B, Figure 4.1A). 
To simultaneously detect all three alleles at the Rrm1 locus, DNA was 
digested overnight with BamHI. DNA fragments were separated on 0.8% gel 
as previously described and subjected to a unique probe that hybridized 5ʼ of 
the Neo insertion (Probe A, Figure 4.1A). Probe A was generated using 
primers JLP5 and JLP6. HR insertion of the floxed Neo cassette left a residual 
BamHI site 3ʼ of the Neo element which is maintained following Cre excision, 
allowing the wild type Rrm1 allele to be detected as a long 12kb band (with no 
	   207	  
novel BamHI), the Rrm1Neo allele as a 10-kb band (Figure 4.1D), and the 
Rrm1D57N (Cre excised) allele as a short 400bp band. 
 
PCR genotyping of Rrm1D57N knock-in mice 
Primers were designed to the targeted locus to uniquely recognize specific 
elements within each allele. “D57N KI For3” (Primer 1 in Figure 4.1) (5ʼ-
TGGTAGTGGGAGATGCCTCC-3ʼ) detected the unmodified wild type allele at 
the location that would be disrupted by Neo insertion. “Neo 3ʼ-YAZ” (5ʼ-
GGTATCGCCGCTCCCGATTCGCAG-3ʼ) hybridizes within the inserted Neo 
cassette (Primer 4 in Figure 4.1). “D57N KI For2” (5ʼ-
GAATTCCTGCAGCCCAATTCC-3ʼ) hybridizes to a region 5ʼ of the distal LoxP 
site that is residual PL453 sequence and is retained in the second intron 
following Cre excision of the Neo element (Primer 3, Figure 4.1). Each 
individual forward primer was paired 1:1 with “D57N KI Rev” (5ʼ-
ACTTTCATGGTGATCTGAGC-3ʼ), which hybridizes to the 5ʼ end of exon 3 
(Primer 2, Figure 4.1). PCR to detect the wild type and the Cre-excised allele 
were hybridized at 65°C. PCR to detect the longer Neo product was hybridized 
at 60°C. All PCRs were run 35 cycles. Product sizes were wild type Rrm1, 
400bp; Rrm1D57N, 450bp; Rrm1Neo, 800bp. 
 
Immunoblotting 
Total protein extracts were prepared from e10.5 embryos by lysis in 40-50 mL 
RIPA buffer supplemented with protease inhibitors and sodium orthovanadate 
as a phosphatase inhibitor as described in Chapter 3. Extracts were separated 
on 10% polyacrylamide gel and transferred to PVDF membrane (Perkin 
Elmer). R1 protein was detected by AD203, mouse monoclonal anti-R1, and 
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loading was assessed by detection of a-tubulin with mouse monoclonal anti-a-
tubulin. 
 
Northern blot analysis.  
Total RNA was extracted from mouse cells with RNAStat-60 (TelTech, Inc) 
and separated on agarose/formaldehyde gel. RNA was transferred to a nylon 
membrane (GeneScreen, Perkin Elmer) and detected with Rrm1-specific 
radiolabeled probe as previously reported(10).  
Culture of mouse embryonic fibroblasts (MEFs) 
MEFs were isolated from e10.5 embryos derived from Rrm1+/D57N 
heterozygous or Rrm1+/Neo heterozygous intercrosses. Following dissection 
from the yolk sac and decidua, whole embryos were placed into one well of a 
96-well plate and incubated for 1 minute in 100mL trypsin.  200mL media was 
added and the embryo was disaggregated by pipetting. The cells were 
cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 1% 
nonessential amino acids, 1% L-glutamine, and 1% penicillin-streptomycin 
(Mediatech) in 12-well plates until confluent. A subset of the cells were later 
cultured on plates coated with 0.1% gelatin in PBS. The same set of cells was 
further cultured in DMEM supplemented with 20% FBS. Cells were seeded in 
106 cells/plate in triplicate plates. Every 3 days, the cells were counted and 
split to fresh 10-cm plates or fed 10 mL fresh media if not confluent. Data for 
the triplicate plates were averaged and population doublings calculated.  
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cDNA synthesis and sequencing 
1µg of total RNR from mouse embryonic fibroblasts was reversed-transcribed 
using the Superscript II system (Invitrogen). cDNAs were synthesized using 
random hexamers according to the manufacturerʼs instructions. The Rrm1 
cDNA was amplified using primers “D57N 5ʼ-UTR” (5ʼ-
CCCTCCACATCTGACAGTCGTCTC-3ʼ) and “mRNR1-Rev” (5ʼ-
GCTGTGGTCTTTCAGCCACTTTAC-3ʼ). The reaction was carried out 
according to manufacturerʼs directions. Purified cDNAs were sequenced from 
both directions using “mRNR1-For” (5ʼ-
AGTCATGTGATCAAGCGAGATGGC=3ʼ) AND “mRNR1-Rev”. All sequencing 
was carried out by the Core Sequencing Facility of the Biotechnology 
Resource Center, Cornell University, Ithaca, NY. 
 
Results 
Generation of Rrm1D57N knock-in mice.  
We previously reported (Chapter 3) that mice that overexpress the Rrm1-
D57N mutant are grossly normal. We hypothesized that due to variable 
expression patterns and levels in these transgenic mice, that we were only 
able to observe limited phenotypes. We therefore sought to disbable allosteric 
feedback control by targeting the point mutation to the endogenous locus, to 
deregulate RNR without the need for overexpression.  The Rrm1D57N point 
mutation was introduced into the endogenous Rrm1 locus in mouse by 
homologous recombination in mouse embryonic stem (ES) cells (Figure 4.1A). 
A guanine-to-adenine transition was introduced into the third exon of mouse 
Rrm1, converting a conserved aspartic acid to asparagine within the activity 
site. The construct was electroporated into TC-1 ES cells from the 129/svev 
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strain, and of 80 G418- and FIAU-resistant clones screened by Southern blot 
analysis, 2 were found to have integrated the construct into the correct locus 
(Figure 4.1B). The clones were further confirmed to have received only one 
copy of the construct by Southern blot analysis using a probe specific to the 
introduced Neo cassette (Figure 4.1C). Further Southern blot analysis using 
multiple probes directed to unique regions of the construct confirmed that the 
integrity of the construct was maintained during targeting and selection (Figure 
4.1D). Sequencing of the targeted exon from genomic DNA isolated from both 
positive clones confirmed the presence of the point mutation (Figure 4.1E). 
Both clones were independently microinjected into C57Bl/6 blastocysts. One 
clone, designated ESC 15, gave rise to 3 chimeric mice, 2 males and one 
female. Both males transmitted the mutant allele to the next generation, while 
the female did not, resulting in the “D57N knock-in-15” (DKI-15) mouse strain. 
The other clone, designated ESC 55, gave rise to 5 chimeras, 3 males and 2 
females. One male transmitted the mutated allele to offspring, while the rest 
did not, resulting in the DKI-55 mouse strain. 
Heterozygous Rrm1+/D57N-Neo offspring mice were crossed to Meox2-Cre 
knock-in mice to excise the “floxed” Neo allele. Meox2-Cre mice express Cre 
under the control of the endogenous Meox2 promoter. Cre activity is detected 
as early as e5 and is throughout the embryo proper and extra-embryonic 
mesoderm(27).  Cre expression resulted in the mutated locus harboring the 
point mutation in exon 3 and a residual LoxP site. Cre excision was confirmed 
by PCR detection of the generated Rrm1D57N allele and excision efficiency was 
assessed by simultaneous detection by Southern blot of the Rrm1, Rrm1Neo, 
and Rrm1D57N alleles. Rrm1+/D57N-Neo and Rrm1+/D57N heterozygous mice 
derived from each independently targeted clone were maintained and 
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characterized separately on a pure 129/svev background, but were found to be 
grossly normal and the two strains indistinguishable from one another. 
Because Neo elements have been shown in other mouse models to result in 
hypomorphic alleles of targeted genes, we maintained mice from both strains 
with the Neo cassette preserved (Rrm1Neo). Both Rrm1+/D57N and Rrm1+/Neo 
heterozygous mice were able to survive 18 months of age. These results 
indicate that mice harboring the Rrm1D57N allele are viable. 
 
Rrm1+/Neo and Rrm1+/D57N heterozygous mice display increased 
lung tumorigenesis compared to wild type. 
To determine the in vivo effects of heterozygosity of the Rrm1D57N mutation, 
we maintained a cohort of wild type and heterozygous mice to the age of 18 
months and monitored the mice for signs of disease. The majority of mice of 
all genotypes, wild type, Rrm1+/D57N, and Rrm1+/Neo, survived the full 18 
months. The inbred 129 strains have multiple reported phenotypes, ranging 
from megaesophagus (33% in females and 27% in males), testicular 
degeneration, ovarian atrophy, nephropathy, cardiomyopathy, and lung 
cancer. Reported lung cancer incidences vary widely, from 4%-46%, although 
whether the reported incidences depend on specific substrains was not 
indicated. 4/62 (6%) Rrm1+/+ developed lung adenomas within 18 months of 
age, compared to 9/61 (14%) of Rrm1+/Neo mice and 10/55 (18%) of Rrm1+/D57N 
mice (p=0.02 and 0.002, respectively, chi-square). Overall, lung tumors in 
Rrm1D57N mice were not more malignant than those in wild type mice, as only 
	   212	  
one Rrm1+/D57N mouse developed an adenocarcinoma, compared to 0 from the 
other genotypes. The incidence of megaesophagus was increased in 
Rrm1+/Neo mice relative to Rrm1+/+ and Rrm1+/D57N, with 9/61 (15%) Rrm1+/Neo 
mice displaying megaesophagus compared to 2/62 (3%) of wild type and 2/55 
(3%) Rrm1+/D57N mice. 5 wild type females developed uterine hemorrhages or 
tumors, as did 5 Rrm1+/D57N females; however, 0 Rrm1+/Neo females developed 
any uterine pathology. 
The Rrm1D57N and Rrm1Neo alleles are expressed and translated.  
To assess expression of the modified alleles, we performed Northern 
blot analysis on total RNA extracted from e10.5 embryos. We found that 
overall levels of Rrm1 mRNA were unchanged in heterozygous mice for both 
Rrm1+/Neo and Rrm1+/D57N (Figure 4.2A). The Rrm1Neo/Neo lane showed wild 
type levels of expression, while the Rrm1D57N/D57N lane appeared lighter in 
intensity. However, a single band was observed for each genotype at the 
expected molecular weight, indicating that no aberrant transcripts were 
formed. This was further confirmed through amplification of the Rrm1 cDNAs.  
Immunoblot analysis on lysates isolated from embryos at the same stage 
revealed modest decreases in protein level, but could also be due to a 
technical issue with band smearing (Figure 4.2B). The heterozygotes 
expressed averaged 77% of the wild type level of Rrm1, while the 
homozygous mutants averaged 73%. Neither of these was statistically 
significant by Studentʼs t-test (p=0.1 and p=0.2, respectively). Most 
importantly, only a single 90-kD band was detected in both the heterozygous 
and homozygous samples, indicating that the mutant protein was stable and 
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not truncated (Figure 4.2B). These results indicate that the mutant allele is 
expressed and generates a stable protein, of which only residue 57 is altered. 
Homozygosity of Rrm1D57N results in midgestational embryonic 
lethality in mice. 
We interbred heterozygous mice both with and without the Neo cassette to 
obtain homozygous mutant mice (Table 4.1). Of 154 offspring genotyped from 
the Rrm1+/D57N-Neo x Rrm1+/Neo intercross, no Rrm1Neo/Neo homozygotes were 
observed. Similarly, of 140 offspring genotyped from the Rrm1+/D57N x 
Rrm1+/D57N intercross, no homozygotes were observed. Offspring were 
obtained in an approximately 1 wt: 2 heterozygote: 0 homozygote ratio, further 
suggesting that the Rrm1Neo/Neo and Rrm1D57N/D57N genotypes are incompatible 
with survival, while heterozygotes are viable. We initiated timed mating 
experiments in order to characterize the apparent embryonic lethality in 
Rrm1D57N homozygous embryos.  
Preliminary work revealed that homozygous embryos were generally 
normal at e8.5. Homozygous embryos at e9.5 were smaller than littermates 
(Figure 4.2). We found abnormal homozygous embryos through 10.5 days 
post coitus (dpc), and 0 live homozygous embryos at 11.5dpc or later (Figure 
4.2). Additionally, mouse embryonic fibroblasts (MEFs) cultured from embryos 
at 13.5 dpc failed to proliferate. Likewise, Rrm1Neo/Neo homozygous MEFs from 
13.5 dpc embryos could not be cultured. 
Cell proliferation defects in Rrm1D57N homozygous MEFs. 
To partially elucidate the cause of death in Rrm1D57N homozygous 
embryos, we sought to assess their ability to proliferate under standard cell 
culture conditions. Because homozygous embryos are dead by e13.5, MEFs 
were cultured from e10.5 day embryos. Wild-type MEFs showed a 
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characteristic proliferation curve, with regular population doublings at low 
passages and entrance into a senescent state around passage 7 (Figure 4.3). 
However, both Rrm1+/D57N and Rrm1D57N/D57N MEFs showed defects in 
proliferation. Both genotypes of MEFs required additional time to reach 
confluency, necessitating more time between passages. Both genotypes also 
reached senescence prematurely, and were already senescing when the 
assay began, so that the cells were unable to be passed for two weeks. 
Morphologically, homozygous cells displayed a flattened phenotype and 
resembled cells undergoing serum starvation (data not shown), suggesting 
that Rrm1D57N/D57N homozygous MEFs may be trapped in a quiescent stage of 
the cell cycle. 
p21 activation in Rrm1D57N MEFs 
To investigate the causes of the slow growth in the Rrm1D57N MEFs, we 
tested for cell cycle checkpoint activity that may be retarding the growth of 
these cells in culture. To determine if there was indeed accumulation of cells in 
G1 phase, which was causing slow growth of Rrm1D57N/D57N MEFs, we 
assessed p21 induction via Northern blot analysis. While Rrm1+/+ MEFs 
showed limited expression of p21, both Rrm1+/D57N and Rrm1D57N/D57N MEFs 
showed increased p21 expression (n=1). Rrm1+/D57N MEFs showed 1.77-fold 
expression relative to wild type, and Rrm1D57N/D57N MEFs showed a 2.54-fold 
increase (Figure 4.4). 
This result was confirmed by qRT-PCR analysis. These data suggest 
that p21 might be functioning to prevent homozygous and heterozygous MEFs 
from entering S-phase of the cell cycle. 
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Figure 4.1 Generation of Rrm1D57N knock-in mice. A. Targeting construct. 
The construct contains the modified exon harboring the point mutation, a floxed 
Neo cassette for positive selection in ES cells, and a TK element outside the 
region of homology for negative selection in ES cells. B-D. Southern blot 
analysis of correctly targeted clones. B. Insertion of Neo element introduces a 
novel BclI site, which cuts a 15kb band to approximately 12 kb when detected 
with probe C. C. Confirmation of a single construct element within the targeted 
locus, detected by probe B. D. Various digestions confirming retained integrity 
of the construct upon homologous recombination, each detected using probe A. 
E. Genomic sequence following homologous recombination. In each mutant 
clone, two peaks are observed within codon 57; the wild type G and the mutant 
A. 
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Discussion 
Several studies have underscored the necessity of RNR feedback control in 
maintaining genome stability(1, 3, 5, 16, 18, 28). In this study we presented 
evidence that allosteric feedback regulation is crucial to the survival of mice. 
We generated mice harboring a targeted mutation of Rrm1-D57N via 
homologous recombination in TC-1 mES cells (Figure 1). We obtained two 
independent correctly-targeted clones, referred to as ESC#15 and ESC#55. 
From microinjection of these cells in C57Bl/6-derived blastocycts, we obtained 
a total of 9 chimeric animals, 5 males and 4 females. Three of the 5 males 
transmitted, two from ESC 15 and one from ESC 55. Expression analyses on 
embryos obtained from Rrm1+/Neo or Rrm1+/D57N heterozygote intercrosses 
revealed that the Rrm1 mRNA was produced at wild type levels and was 
stable (Figure 4.2). This result indicates that the targeted allele is as expected, 
with no other changes or mutations introduced other than the intended D57N 
mutation. The result obtained from the Rrm1Neo allele further indicates that we 
did not generate a hypomorphic allele of Rrm1, as in previous models from our 
lab(29) . Mice harboring a single targeted Rrm1D57N allele were viable and 
obtained at expected frequencies. Despite reports that the Rrm1D57N mutation 
is dominant and causes a mutator phenotype, our Rrm1+/Neo and Rrm1+/D57N 
heterozygous mice showed no major tumor pathology or displayed a shorter 
lifespan, indicating that heterozygosity of RrmD57N is compatible with survival. 
lWe were surprised to observe that homozygosity of Rrm1D57N was lethal in 
mice (Table 4.1). Presence or absence of the Neo cassette within the targeted 
allele did not affect expression of the targeted allele (Figure 4.2).  
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Figure 4.2 Expression analysis of Rrm1+/+, Rrm1+/D57N, 
and Rrm1D57N/D57N embryos. A. Northern blot. Total RNA 
from embryos at e10.5 was detected by an Rrm1-specific 
radiolabeled probe. GAPDH is used as a loading control. 
B. Total protein was extracted from embryos at e10.5 and 
separated on a 10% SDS-PAGE gel. Rrm1 was detected 
by probing with AD203, mouse monoclonal anti-Rrm1 
antibody. a-tubulin serves as a control for loading. 
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aFemale mice heterozygous for Rrm1D57N or Rrm1Neo were crossed to males of 
the same genotype. Offspring were genotyped at weaning by PCR. The total 
numbers of mice of each genotype observed are listed to the right of the total 
number expected. bp<0.01, c2. 
Genotype # expected # observed 
Rrm1+/+ 38.5 59 
Rrm1+/Neo 77 95 
Rrm1Neo/Neo 38.5 0 
total  154 
 p<<0.01  
   
Genotype # expected # observed 
Rrm1+/+ 35 44 
Rrm1+/D57N 70 96 
Rrm1D57N/D57N 35 0 
total  140 
 p<<0.01  
Table 4.2. Offspring obtained from Rrm1+/D57N-Neo 
and Rrm1+/D57N heterozygote intercrossesa.  
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Figure 4.3 Lifespan of Rrm1D57N/D57N homozygous embryos. A. Embryos obtained from crosses between 
Rrm1+/D57N x Rrm1+/D57N mice. Timed mating experiments were initiated and embryos analyzed at the indicated 
timepoints.  The total number of embryos of each genotype observed were listed with number of abnormal embryos 
indicated. Expected numbers of embryos are listed in parentheses. babnormal embryo. B. Representative images of 
homozygous embryos with control littermates. Homozygous embryos appear grossly normal at e8.5, but are small 
as soon as e9.5. All homozygous embryos observed at e10.5 or later were dead. 
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Similar to the Rrm1-D57N transgenic mice, Rrm1+/Neo and 
Rrm1+/D57N heterozygous mice showed an increase in the incidence of lung 
tumors, but did not develop larger or more malignant tumors. We hypothesize 
that heterozygosity of Rrm1D57N or overexpression of Rrm1-D57N moderately 
elevates dNTP pools, which facilitates lung tumorigenesis in strains 
predisposed to lung cancer. Elevated dNTPs would be expected to benefit 
proliferative cells, but not necessarily transform them.  
The lethality caused by homozygosity of the Rrm1D57N allele initially led 
us to hypothesize that hyperactive RNR in this model was elevating dNTP 
pools and disrupting mitochondrial DNA maintenance as in our previous 
studies (Chapters 2 and 3). However, inconsistent with this hypothesis was the 
observation that MEFs cultured from homozygous embryos showed dramatic 
proliferation defects (Figure 4.3). Previous work on MEFs with defects in 
oxidative phosphorylation often show wild type proliferation in standard media 
containing glucose, due to an ability to produce energy via glycolysis. Culturing 
these cells in media containing galactose as the only carbon source leads to 
inviability(30, 31) . Consistent with these reports, we previously showed that 
Rrm1-D57N(low)Tg + p53R2Tg bitransgenic MEFs showed mtDNA depletion 
but no proliferation defect in standard media (Chapter 3). These data suggest 
that lethality in Rrm1D57N homozygotes is caused by an event that is 
independent from mitochondrial genome instability, as mtDNA depletion does 
not affect fibroblast proliferation in our models. 
The second main finding contradictory to mitochondrial genome 
instability as the cause of the lethality was that p21 is upregulated in 
homozygous MEFs. p21 functions at multiple steps throughout the cell cycle, 
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the most relevant being inhibition of origin firing to initiate S-phase. 
When DNA damage is present, p21 inhibits the cyclin D2/Cdk2 complex to 
prevent replication origin firing in order to avoid replication of damaged DNA. 
Figure 4.4. Proliferation of MEFs isolated from 
Rrm1D57N/D57N homozygous embryos. Fibroblasts were 
cultured from knock-in embryos at e10.5. Cells were seeded 
106 per plate every 3 days, Data is represented as 
cumulative population doublings vs. time. 
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Figure 4.5. p21 expression is induced in 
Rrm1D57N/D57N homozygous MEFs. Total RNA was 
isolated from wild type, heterozygous, or homozygous 
MEFs and separated on a 0.8% agarose gel. Following 
immobilization on a nylon membrane, gene expression 
was detected by hybridization to specific radiolabeled 
probes. GAPDH serves as a loading control. 
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The model proposed by Chabes and Stillman is largely consistent with 
what we observed in the Rrm1D57N knock-in mice. When yeast cells are 
induced to overexpress the rnr1-D57N mutant, they proliferate poorly due to a 
failure to fire replication origins. Similarly, when mouse embryonic fibroblasts 
are homozygous for the Rrm1D57N mutant, they also proliferate poorly and 
show an upregulation of p21, which inhibits the G1- to S-phase transition. 
Chabes and Stillman suggest that in yeast, persistent elevated dNTP levels 
mimic a DNA damage-response state, in which dNTPs are rapidly elevated 
following DNA damage in order to allow for repair. In the absence of DNA 
damage, constitutively elevated dNTP levels may “trick” the cell into behaving 
as though DNA damage is present and that attempting replication would be 
hazardous, leading to inhibition of replication origin firing. We propose that a 
similar mechanism exists in mammalian cells, where in the absence of DNA 
damage but in the presence of elevated dNTPs, p21 may be signaled to inhibit 
the Cyclin D/Cdk2 complex to prevent S-phase entry(19). 
While our preliminary results somewhat agree with the findings of 
Chabes and Stillman and seem to support their proposed model, the 
differences between the two systems cannot be overlooked. Notably, by 
overexpressing the rnr1-D57N mutant, they were able to simultaneously 
disrupt what are thought of as the two main regulatory mechanisms controlling 
RNR activity: limitation of protein levels of one of the two subunits (in this case 
the large subunit), and allosteric feedback control. Our bitransgenic mouse 
model would be expected to be more similar to their yeast model than our 
Rrm1D57N knock-in mouse model. Most importantly, while it is clear that proper 
allosteric feedback regulation is necessary for survival of mice, only one 
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regulatory mechanism is disabled in the knock-in mouse model. Although 
proteins levels of the small subunits were not tested in Rrm1D57N embryos or 
MEFs, it is expected that the small subunits are expressed normally, still 
limiting the availability of nucleotides outside S-phase.  
To account for the observed cell proliferation defects, we might 
speculate that the low levels of p53R2 protein that are continuously present 
during quiescent phases are able to complex with Rrm1D57N and generate 
enough dNTPs to block entry into S-phase. In this way, RNR is truly 
constitutively active through all cell cycle phases. Further work will be 
necessary to establish whether p53R2 interacts with Rrm1D57N to elevate 
dNTP pools, and whether cells are blocked in G1 phase as a result. 
Alternatively, the lethality may be caused by nuclear genome instability 
(GIN). The Rrm1-D57N mutation has been shown to be mutagenic (3, 16). 
More serious GIN might be observed in the form of chromosome breaks or 
loss, and can easily activate checkpoints and cause slow cell proliferation or 
apoptosis, both of which are fatal to a developing embryo. We could detect 
these by analyzing metaphases of heterozygous and homozygous MEFs. 
When metaphase chromosomes are spread out on slides and stained with 
Giemsa, breaks are readily apparent. Sections of homozygous embryos from 
e9.5 and e10.5 may show increased instability when stained for g-H2AX, 
confirming nuclear GIN. 
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Chapter 5: Summary and Future Directions 
5.1 Models for RNR regulation and consequences of deregulation 
Our lab has developed several mouse models in which RNR is 
deregulated, in order to understand why the enzyme is so tightly controlled 
and the consequences of deregulating the enzyme. 
5.1A Deregulation by small subunit overexpression 
We first disabled the enzyme by overexpressing the small subunits. We 
hypothesized that this would have the effect of making the enzyme 
constitutively active, as normally the small subunit is limiting. Rrm2, one small 
subunit gene, is only expressed during S-phase in order to provide dNTPs for 
DNA synthesis, while p53R2, the other small subunit gene, is expressed 
constantly but at low levels. Therefore, increasing the amounts of either of 
these two genes would allow the cells to have functional RNR throughout the 
entire cell cycle, thus increasing the enzyme activity. When these genes were 
individually overexpressed in mice, they primarily caused lung tumor 
formation. We hypothesize that this is due to increased oxidative stress as the 
result of overproducing radical-generating proteins. Supporting this is the 
tissue specificity. The lungs are already a high-oxygen environment and the 
DNA is under constant attack of reactive oxygen species (ROS). We 
hypothesize that increasing the levels of a protein that produces a radical 
further increases ROS, and overwhelms DNA repair machinery that was 
already saturated, therefore becoming mutagenic and causing lung tumors. It 
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was found that a precipitating event in lung tumor formation was mutation of K-
ras, and oncogene that is mutated in many cases of human lung cancer and 
causes lung cancer in mice when mutated. 
While the mechanism of lung tumor induction is likely unlinked to RNR activity, 
we do have indications that RNR activity is elevated in the tissues of mice 
overexpressing either small subunit. In a later study (Chapter 2), we found in 
skeletal muscle, a tissue that overexpresses all of the RNR transgenes highly, 
that dNTP pools are elevated. Both Rrm2Tg and p53R2Tg were able to 
generate altered nucleotide pools. The nucleotide pools alterations may also 
play a role in the lung tumorigenesis, by enhancing the mutation rate or by 
providing additional dNTPs that cancer cells need in order to proliferate. 
A third phenotype observed in Rrm2Tg and p53R2Tg mice was the 
development of proteinuria within the kidneys as the mice aged. This 
phenotype could have a number of possible causes. This phenotype was not 
observed in Rrm1Tg mice, and like the lung cancer phenotype, may be linked 
to the small subunitsʼ ability to generate a radical. The kidney contains many 
ROS-generating oxidases, and like the lungs, kidney DNA and cells are under 
constant attack by ROS(1). Increased damage in the kidney by ROS can lead 
to proteinuria, renal damage, and hypertension(1). Alternatively, the reason for 
the lack of the kidney phenotype in the Rrm1Tg mice could be due to limited 
overexpression of this transgene in most tissues. Current data in our lab 
supports the ROS mechanism for inducing proteinuria, as in cultured cells 
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Rrm2 and p53R2 overexpression are known to elevate ROS. A model 
summarizing the findings is shown in Figure 5.1. 
Figure 5.1. Possible mechanism explaining formation 
of phenotypes in Rrm2Tg and p53R2Tg mice. 
Overexpression of radical-producing subunits elevates 
ROS, which leads to lung cancer and kidney defects, 
especially proteinuria. Increased small subunit 
expression may also increase dNTP pools, facilitating 
lung tumorigenesis. 
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5.1B Overexpression of multiple wild type RNR subunits 
Since these mouse models deregulated RNR by only a single 
mechanism, further deregulation of RNR was sought. In order to do this, we 
crossed mice overexpressing Rrm1 with mice overexpressing either Rrm2 or 
p53R2. We found that simultaneous overexpression of Rrm1Tg and Rrm2Tg or 
p53R2Tg led to severely unbalanced nucleotide pools in the skeletal muscle. 
Simultaneous overexpression of Rrm1Tg with Rrm2Tg showed a synergistic 
increase in dNTP pools over that of Rrm1Tg or Rrm2Tg alone, suggesting that 
the two overexpressed subunits were combining to form more active complex 
than is formed when either is expressed alone, and this was elevating RNR 
activity. The same synergistic effect was seen in the muscle of mice 
overexpressing Rrm1Tg and p53R2Tg (Chapter 2). Of the tissues 
overexpressing these transgenes, the muscle shows the highest level of 
expression. In skeletal muscle, but not in other muscle, we found that the 
mitochondrial DNA was depleted, and that this progressed with age. We 
hypothesize that the tissue specificity is due to the very high levels of 
overexpression of each subunit. That RNR deregulation causes mtDNA 
depletion was not entirely unexpected, however, all previous models of RNR 
deregulation and mtDNA depletion focused on non-functional RNR. In many 
mouse models and in human cases, dysfunction of RNR genes, most notably 
p53R2, resulted in mtDNA depletion(2-4). In yeast, overexpression of RNR 
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genes results in increases in mtDNA(5); therefore we hypothesized that 
overexpression of RNR would result in mtDNA expansion. However, these 
models from which we based our predictions did not show unbalanced 
nucleotide pools; instead, nucleotide pools were uniformly increased while 
remaining balanced. In our models, nucleotide pools were significantly 
unbalanced. It is well known that unbalanced nucleotide pools cause mtDNA 
depletion(6-8), providing a clear mechanism by which RNR overexpression in 
mice causes mtDNA depletion.  
In these bitransgenic mice, we also observed lung cancer phenotypes 
similar to those observed in mice overexpressing Rrm2Tg or p53R2Tg alone. 
This further supports a role for ROS in lung tumorigenesis, as overexpressing 
Rrm1Tg on top of either small subunit should no further increase ROS, while it 
would be expected to elevate RNR activity, as we observed in the skeletal 
muscle. Therefore, increased RNR activity plays only a limited role in lung 
tumor formation. Similarly, we also found proteinuria in the bitransgenics at the 
same rate as in the small subunit overexpressors, also supporting a role for 
increased ROS but not increased activity, for the same reasons outlined 
above. A model summarizing the possible mechanisms giving rise to these 
phenotypes is shown in Figure 5.2. 
5.1C Deregulation of RNR by loss of allosteric feedback control 
We also wanted to understand the effect of deregulating RNR by an 
independent mechanism. Both models described previously feature loss of the 
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Figure 5.2. Model for development of phenotypes in Rrm1Tg + Rrm2Tg 
and Rrm1Tg + p53R2Tg bitransgenic mice. As before, small subunit 
overexpression generates ROS, which causes lung cancer and proteinuria. 
Interaction of Rrm1 and either small subunit increases RNR activity, elevating 
and unbalancing dNTP pools and causing mtDNA depletion in the muscle. 
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 same regulatory mechanism, which is limitation of small subunit availability. 
The second main regulatory mechanism in mammals of allosteric feedback 
control. To disable this, we generated transgenic mice that broadly 
overexpress the Rrm1-D57N point mutation in most tissues. Of two 
independent transgenic lines obtained, both were grossly normal throughout 
adulthood. Both lines displayed a moderate increase in lung tumor incidence 
compared to control mice, but did not display other features of a tumorigenic 
phenotype. While dNTP pools were not measured in the lungs of D57N 
transgenic mice, we hypothesize that deregulation of this regulatory 
mechanism moderately elevates dNTP pools which, in strains predisposed to 
lung cancer, facilitates tumorigenesis by allowing for increased cell 
proliferation. The fact that Rrm1-D57N mice do not show other characteristics 
consistent with a tumorigenic phenotype, such as increased malignancy, size 
or decreased latency, also lends support to the ROS model for small subunit 
overexpression-induced carcinogenesis. We also failed to observe proteinuria 
in the kidneys of adult D57N transgenic mice despite significant 
overexpression of the transgene within this tissue, also suggesting increased 
ROS as the mechanism for proteinuria.  
5.1D Simultaneous disruption of multiple RNR regulatory modes 
 Because each model featuring loss of one regulatory mechanism 
showed somewhat limited phenotypes with regards to RNR activity, we sought 
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to simultaneously disable both regulatory mechanisms. In yeast, similar RNR 
perturbations had the effect of causing cell proliferation defects and sick 
cells(9). We therefore crossed mice from each Rrm1-D57N transgenic line to 
mice overexpressing either small subunit. We found that all four possible 
combinations caused synthetic lethality. The crosses that utilized Rrm1-
D57N(high)Tg showed embryonic lethality while the crosses with Rrm1-
D57N(low)Tg allowed mice to survive gestation.  
 When Rrm1-D57N(high)Tg was combined with either small subunit, 
bitransgenic embryos showed embryonic lethality beginning as early as e11.5-
e12.5. While overall numbers are small, bitransgenic embryos from both 
showed vascular defects, in the form of aortal hemorrhages and yolk sac 
vascular defects. These particular phenotypes were unexpected, as RNR 
perturbation has not previously been linked to vascular defects. However, the 
signaling networks governing development of the vasculature utilize cAMP, 
potentially linking nucleotide metabolism with vasculature defects. In Rrm1-
D57N(high)Tg + Rrm2Tg bitransgenic embryos, neural defects were also 
observed, which may be secondary to the yolk sac defects. Potentially, failure 
to remove toxic metabolites from the amnion may perturb neural development, 
leading to the head and spine defects we observed. 
 The Rrm1-D57N(low)Tg x Rrm2Tg cross yielded a small number of 
bitransgenic mice that were able to survive to adulthood. In these mice, we 
found characteristics of premature aging. These mice phenocopied Polγ 
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mutator mice, leading us to hypothesize that the synthetic lethality was 
mediated through mtDNA instability. Given that we previously observed 
mtDNA depletion in Rrm1Tg + Rrm2Tg and Rrm1Tg + p53R2Tg bitransgenic 
mice, we naturally assessed mitochondrial genome stability in these mice. We 
were surprised to find that only mice that survive 3 months displayed any 
mtDNA instability. Some mtDNA depletion was observed in bitransgenic mice 
at P19 and 25, but this is 1) possibly an artifact due to the skeletal muscle 
degeneration, and 2) not the cause of the lethality as most bitransgenics died 
before this time.  
We were then left to find a new hypothesis to explain the synthetic 
lethality in these bitransgenic mice. Histological analysis of neonates turned up 
new phenotypes that were previously not seen in Rrm1Tg + Rrm2Tg 
bitransgenic mice. These phenotypes include kidney degeneration, 
hepatocellular swelling in the liver, glaucoma, and pleural effusion. The 
common thread connecting these phenotypes may be hypertension, which 
also has links to nucleotide metabolism. We therefore hypothesize that 
simultaneous overexpression of Rrm1-D57N(low)Tg and Rrm2Tg leads to 
significantly elevated RNR activity. Preliminary data suggests that dNTP pools 
are severely perturbed in tissues from these mice, supporting our hypothesis. 
Increased dNTPs are subject to degradation in order to keep pools 
balanced(10), and the degradation products are deposited in  the bloodstream. 
Degradation products such as uric acid have been shown to cause 
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hypertension in rats(11). Hypertension causes pleural effusion, which could 
ultimately be fatal to mice. Unfortunately, it is impossible to directly test 
bitransgenic neonates for hypertension, so we must take indirect approaches 
and look for changes upstream of hypertension, such as uric acid levels, and 
changes downstream, such as pleural effusion and glaucoma. 
There are some caveats to this model. Firstly, it does not explain the 
kidney degeneration or the hepatocellular swelling in the bitransgenic mice. A 
second, related hypothesis can be made from this, in which kidney 
degeneration(12), possibly mediated through increased uric acid, causes 
hypertension, which leads to pleural effusion and death. The first model is 
favored because through analysis of the neonates, it was found that pleural 
effusion precedes kidney degeneration. We found pleural effusion in neonates 
as young as P4, while no kidney phenotypes were found until P9, when most 
bitransgenics are already dead. However, this does not necessarily indicate 
that this model is false. Kidneys and hypertension are linked through defective 
protein uptake in the kidney during development, which can cause 
hypertension but may not cause visible morphological changes. The finding of 
proteinuria in the kidneys of aged Rrm2Tg mice also potentially supports 
decreased protein uptake by kidneys overexpressing Rrm2Tg, and further 
deregulation of RNR may enhance this phenotype. Kidney degeneration may 
not be mediated through increased uric acid. As stated before, kidneys are 
susceptible to defects in mtDNA maintenance, and may therefore be affected 
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in bitransgenic mice. We found mild age-related mtDNA depletion in the 
kidneys of bitransgenic mice, indicating a possible interaction. 
A second issue with the preferred hypothesis is that preliminary studies 
in serum uric acid levels in bitransgenic neonates failed to reveal increases. 
This does not necessarily indicate that increased nucleotide degradation is not 
occuring, or that uric acid levels are not increased enough to cause 
hypertension. It is still possible that hypertension mechanisms are highly 
sensitive to uric acid increases, while our assay is not; therefore we may not 
be able to detect potentially pathological changes. Most likely, the mechanism 
causing lethality in Rrm1-D57NTg + Rrm2Tg bitransgenic mice is due to a 
combination of factors, possibly the ones listed above. Further work is needed 
to dissect out the causes and the phenotypes and determine what is 
pathologically relevant. A model summarizing the potential contributions of 
each of these pathways is shown in Figure 5.3. 
5.1E Rrm1D57N knock-in mice 
In order to observe the effects of the Rrm1D57N mutation without 
possible artifacts of overexpression, we generated mice with the Rrm1D57N 
mutation targeted to the germline. We obtained 2 independent strains of mice 
that were phenotypically identical. Heterozygous mice were viable and  
expressed the mutant protein at close to normal levels. They were grossly 
normal, having a moderate increase in lung tumor incidence relative to wild 
type. Similar to the Rrm1-D57NTg mice, the tumor malignancy, size, or 
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Figure 5.3. Development of phenotypes in Rrm1-D57N(low)Tg + 
Rrm2Tg bitransgenic mice. Deregulation of RNR results in elevated or 
unbalanced dNTP pools, which are degraded to uric acid or negatively 
affect mtDNA stability. Uric acid causes hypertension, which leads to 
pleural effusion and glaucoma (protruding eyes). Conversely, kidney 
dysfunction leads to hypertension and so on. 
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 latency was unaltered, suggesting that the Rrm1D57N mutation does not drive 
lung tumorigenesis. Instead, we hypothesize that moderately elevated dNTP 
pools facilitate lung tumor formation by transformed cells.  
Homozygosity of Rrm1D57N resulted in embryonic lethality. The embryos 
became small around e9.5, and were mostly dead by e10.5. This was 
surprising, as only one regulatory mechanism of RNR was perturbed. We were 
also surprised to find that homozygous and heterozygous MEFs showed 
proliferation defects. We must be cautious in interpreting that data, as the 
experiment was only conducted once. However, this finding did not fit with our 
previous results from bitransgenic MEFs, which all proliferated normally. Even 
the Rrm1-D57N(high)Tg + p53R2Tg bitransgenic MEFs, which were isolated at 
the same time point as Rrm1D57N knock-in MEFs, showed no defects in cell 
proliferation. Therefore this lethality is mediated by a distinct mechanism than 
that which causes the synthetic lethality. Again, in yeast a slow growth 
phenotype was induced by overexpressing the rnr1-D57N mutant(9), in a 
model that shares some similarities with ours. We therefore looked for 
evidence of cell cycle delays in the homozygous MEFs, and found that p21 
was upregulated. This could possibly function to prevent entry into S-phase, 
as was found in the yeast system.  
This is very different from the Rrm1-D57NTg and synthetic lethal 
phenotypes. The Rrm1-D57NTg mice were viable and showed normal cell 
proliferation. While the bitransgenic mice are not viable, cells isolated from 
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bitransgenic embryos showed normal proliferation. We therefore conclude that 
the defects causing lethality in Rrm1D57N homozygous mice are more severe 
than the synthetic lethal defects. We hypothesize that elevated dNTP pools in 
the homozygous cells are mimicking a state of DNA damage, in which dNTPs 
are elevated, and this prevents entry into S-phase, similar to as was seen in 
yeast. Further experiments, outlined below, are necessary to further 
characterize this lethality.  
Overall, we believe our RNR mouse models provide useful tools by 
which to understand the regulation of dNTP pools and the effects of dNTP 
perturbation. A final model relating RNR manipulation, dNTP pool alterations, 
and phenotypes is shown in Figure 5.4. 
5.2 Future Directions 
5.2A. Identify and characterize a dNTP threshold effect. 
Evidence from our various studies suggests that different phenotypes 
will be observed in the presence of altered dNTPs, depending on the severity 
of the dNTP alteration. In Rrm1Tg + Rrm2Tg and Rrm1Tg + p53R2Tg 
bitransgenic mice, we found unbalanced nucleotide pools that led to age-
dependent mtDNA depletion. Preliminary work in Rrm1-D57N(low)Tg + Rrm2Tg 
bitransgenic neonates has suggested more dramatic dNTP pool alterations 
which may cause the observed synthetic lethality. We hypothesize that more 
moderate dNTP pool increases allowed for increased tumor formation in 
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Figure 5.4. Relationship between RNR manipulation, dNTP pool alterations, 
and phenotype. dNTP pool effects include both elevated pools, represented by 
height of the total bar, and pool imbalances, represented by the pie chart at the 
top of the bar. Blue, dATP; red, dGTP; green, dTTP; purple, dCTP. 
Overexpression of Rrm2Tg or p53R2Tg generates elevated and unbalanced dNTP 
pools, while simultaneous overexpression of both Rrm1Tg and either small 
subunit generates further unbalanced pools and a greater increase in totoal 
dNTPs. Overexpression of Rrm1-D57N is hypothesized to result in moderately 
increased dNTP pools due to loss of a single RNR regulatory mechanism, and 
pools are balanced due to continued function of the specificity site. 
Overexpression of Rrm1-D57N and either small RNR subunit is hypothesized to 
generate significantly elevated nucleotide pools, which are also unbalanced. An 
Rrm1D57N knock-in homozygote is expected to display increased but balanced 
dNTP pool alterations, leading to the observed cell proliferation defects. 
Phenotypes observed in mice of the indicated RNR manipulations are listed. 
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Rrm1-D57N transgenic and knock-in heterozygous mice. Overexpression of 
Rrm1-D57NTg or heterozygosity of Rrm1D57N elevated lung tumorigenesis to 
statistically significant levels. This observation assumes that dNTPs are 
elevated in the lungs of these mice, however we have not measured 
nucleotide pools. These observations together allow us to hypothesize that a 
dNTP threshold exists and that our various mouse models represent different 
dNTP levels across the continuum. This would suggest that dNTP 
measurements in the lungs of Rrm1-D57NTg and Rrm1+/D57N or Rrm1+/Neo mice 
would reveal moderate changes to dNTP pools; dNTP measurements in the 
skeletal muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic neonates would 
reveal more dramatic dNTP pool alterations; in Rrm1-D57N(high)Tg + p53R2Tg 
embryos, the dNTP pool changes would be more dramatic still; and dNTP 
pools in Rrm1D57N/D57N or Rrm1Neo/Neo embryos would be most perturbed. In 
other words, dNTP pool changes would correlate closely with the phenotypes 
observed in the mice. In order to support this model, we would measure dNTP 
pools in the lungs of Rrm1-D57NTg and Rrm1+/D57N mice; in the skeletal 
muscle of Rrm1-D57N(low)Tg + Rrm2Tg bitransgenic neonates and Rrm1-
D57N(high)Tg + p53R2Tg bitransgenic embryos; and in Rrm1D57N/D57N and 
Rrm1Neo/Neo embryos. 
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5.2B. Does expression of Rrm1-D57NTg or Rrm1+/D57N facilitate 
tumorigenesis in cancer-prone models? 
Both mouse models of Rrm1-D57N revealed an increased incidence of 
lung tumorigenesis compared to wild type littermates. Based on our work 
investigating the Rrm2Tg and p53R2Tg lung tumor models(13), we expected 
that an increase in lung tumor incidence would be accompanied by an 
increase in tumor severity and a decrease in latency, but this was not the case 
for either model. We were surprised to find that only lung tumor incidence was 
increased, and this change was statistically significant in both models. We 
hypothesized that the D57N mutation acts to make RNR hyperactive, which 
elevates dNTP pools. Elevated dNTP pools are beneficial to dividing cells, so 
that they then facilitate tumor formation in cells that already contain the 
mutations necessary for transformation. Lungs are for the most part a 
quiescent tissue and cells are not constantly dividing. Therefore, additional 
replication help in the form of elevated dNTPs may be the final circumstance 
required to turn a mutant cell into a tumor cell. We can test this model by 
crossing mice overexpressing Rrm1-D57NTg or mice that are heterozygous for 
Rrm1D57N or Rrm1Neo to mice that harbor known tumorigenic mutations. This 
was already done with mice null for the mismatch repair factor Msh6. The 
Rrm1-D57NTg Msh6-/- mice had a mean lifespan that was nearly 100 days 
shorter than control Msh6-/- mice; however this was not statistically significant 
by log-rank test. When Msh6+/- mice were considered, the addition of Rrm1-
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D57NTg again decreased the average lifespan. One factor in this lack of 
significance can be relatively small sample size. Perhaps addition of a greater 
number of mice to the analysis would provide a more definite understanding of 
the relationship between overexpression of Rrm1-D57NTg and loss of Msh6. 
Additionally, Rrm1-D57N could be overexpressed in the presence of mutated 
K-ras to further promote lung tumors, MMTV-Neu to promote mammary 
tumors, or in the Mcm4Chaos3 breast cancer model. Rrm1-D57N overexpression 
or heterozygosity of Rrm1D57N may also be able to promote skin cancers in the 
two-step DMBA/TPA carcinogenesis model. 
 
5.2C Characterize cell cycle defects in Rrm1D57N/D57N MEFs 
Preliminary work on homozygous Rrm1Neo/Neo and Rrm1D57N/D57N MEFs 
has suggested a defect in cell proliferation. Homozygous MEFs had poor 
population doublings and senesced prematurely. We were also able to detect 
upregulation of p21 in homozygous MEFs, suggesting a cell cycle delay. 
Chabes et al. showed that yeast that overexpressed rnr1-D57N were inhibited 
in entering into S-phase by the excessively high dNTP concentrations(9). 
These data together suggest that Rrm1D57N/D57N and Rrm1Neo/Neo MEFs also 
have defects in initiating S-phase. In order to assess whether Rrm1D57N/D57N 
MEFs are stuck in G1 phase, we propose to perform flow cytometry to 
characterize the cell cycle profiles of homozygous MEFs and controls. We 
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predict that homozygous mutant cells will display a G1 delay and a reduced 
proportion of cells in S- or G2 phases.  
 
5.2D Genotoxin resistance in Rrm1+/D57N mice 
Chabes et al. reported that yeast cells harboring the rnr1-D57N 
mutation were more resistant to genotoxic stress than wild type yeast(14). 
Mutant yeast showed increased survival compared to wild type cells in the 
presence of 4-NQO, a UV mimetic. In this instance, rnr1-D57N mutant yeast 
were able to elevate dNTP levels to roughly 3-fold greater than wild type, 
allowing for DNA repair to occur more efficiently. Elevated dNTP pools can 
also promote lesion bypass(15) and suppress potentially deleterious repair 
methods such as sister chromatid exchange(16). We hypothesize that mice 
which harbor the Rrm1D57N or Rrm1Neo alleles would similarly be able to 
elevate dNTP pools and survive following genotoxic stress longer than wild 
type control mice. Experiments such as these are typically performed initially 
using cell culture models in order to assess such effects without distress to 
animals. However, in our system both homozygous and heterozygous cells 
proliferated poorly even in the absence of stress; it is therefore necessary to 
use surviving heterozygous mice, which are grossly normal.  The poor cell 
proliferation could be an artifact of culturing conditions. Perhaps after the 
experiment is repeated under ideal conditions we may see normal proliferation 
in the heterozygotes which would justify  the use of cells. We would assess the 
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survival of Rrm1+/D57N mice following treatment with several known genotoxins, 
in order to assess the ability to resist different types of DNA damage. 
Proposed treatments include ionizing radiation, which induces DNA double-
strand breaks; mitomycin C (MMC), which affixes bulky adducts to DNA 
blocking accurate replication and transcription; and 4-NQO, the 
aforementioned UV mimetic. We predict that heterozygous mice will show a 
greater resistance to DNA-damaging agents than wild type mice. 
In summary, perturbation of RNR activity and expression in mammals 
can have disastrous consequences. Much of our understanding of RNR 
regulation and the consequences of disrupting that regulation come from 
yeast. While yeast is a good cellular model for basic effects of RNR 
deregulation, it cannot provide the whole story. The effects of deregulating 
RNR in mammals are of particular interest to us as humans, for understanding 
our own biology of how dNTPs are produced and maintained, and providing 
insights into mechanisms of mutagenesis and cancer. We have established 
multiple models of RNR deregulation in mice, and using these models we have 
discovered the consequences of RNR deregulation in mammals. These and 
future experiments will allow us to better understand the importance of RNR 
regulation in mammals. 
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Abstract
Ribonucleotide reductase (RNR) catalyzes the rate-limiting
step in nucleotide biosynthesis and plays a central role in
genome maintenance. Although a number of regulatory
mechanisms govern RNR activity, the physiologic effect of
RNR deregulation had not previously been examined in an
animal model. We show here that overexpression of the small
RNR subunit potently and selectively induces lung neoplasms
in transgenic mice and is mutagenic in cultured cells.
Combining RNR deregulation with defects in DNA mismatch
repair, the cellular mutation correction system, synergistically
increased RNR-inducedmutagenesis and carcinogenesis. More-
over, the proto-oncogene K-ras was identified as a frequent
mutational target in RNR-induced lung neoplasms. Together,
these results show that RNR deregulation promotes lung
carcinogenesis through a mutagenic mechanism and establish
a new oncogenic activity for a key regulator of nucleotide
metabolism. Importantly, RNR-induced lung neoplasms his-
topathologically resemble human papillary adenocarcinomas
and arise stochastically via a mutagenic mechanism, making
RNR transgenic mice a valuable model for lung cancer.
[Cancer Res 2008;68(8):2652–60]
Introduction
An adequate and balanced supply of deoxyribonucleotide
triphosphates (dNTP) is essential for accurate DNA replication
and repair. The rate limiting step in de novo dNTP biosynthesis is
catalyzed by the enzyme ribonucleotide reductase (RNR). RNR
reduces ribonucleoside diphosphate (NDP) to deoxyribonucleoside
diphosphate, phosphorylation of which yields dNTP. RNR is
composed of two nonidentical homodimeric subunits (1). The
large R1 subunit harbors the catalytic site and is encoded by
the Rrm1 gene in mammals. The small R2 subunit contains an
oxygen-bridged dinuclear iron center that generates a tyrosyl-free
radical that is transferred to the R1 subunit for enzyme activity.
Mammalian genomes contain two independent genes, Rrm2 and
Rrm2b (p53R2) , that encode closely related R2 proteins. A
complex of Rrm2 and Rrm1 accounts for most RNR activity
during S phase. p53R2 was originally identified as a target gene for
the p53 tumor suppressor protein and is transcriptionally induced
after DNA damage (2, 3). In addition to its role in stress responses,
p53R2 is expressed at low levels throughout the cell cycle and
complexes with Rrm1 to produce dNTPs for mitochondrial DNA
replication (4).
Because intracellular nucleotide concentrations have a major
effect on DNA replication fidelity (5), RNR enzyme activity is tightly
controlled by several regulatory mechanisms. During an unper-
turbed cell cycle, the transcription of Rrm1 and Rrm2 is
undetectable in G0-G1 phase and reaches maximal levels in
S-phase cells (6–8). However, owing to its long half-life, Rrm1
protein levels are nearly constant throughout the cell cycle and in
excess relative to the R2 subunit. RNR enzyme activity is therefore
determined in part by R2 protein levels. Rrm2 protein is absent
during G0-G1 phase, peaks in S phase, and then falls in mitosis after
ubiquitination by the anaphase promoting complex (8–10).
Consistent with a need for nucleotides during DNA repair, DNA
damage and replication stress induce RNR expression in both yeast
and mammalian cells in a manner dependent on DNA damage
checkpoint pathways (11, 12). Whereas mammalian Rrm1 and
Rrm2 proteins are cytoplasmic (13), p53R2 localizes to the nucleus
in genotoxin-treated cells (2, 3), which may facilitate the localized
production of nucleotides at DNA damage sites.
RNR enzyme activity is also controlled by two allosteric sites in
the R1 subunit. A specificity site regulates the relative cellular
concentration of each of the four dNTPs by influencing substrate
choice, whereas an activity site regulates the total dNTP pool size
by monitoring the ATP/dATP ratio. Analysis of the mutant Rrm1-
D57N, which is insensitive to feedback inhibition by dATP due to a
mutation in the activity site, indicates that loss of RNR allosteric
control results in a mutator phenotype in both yeast and
mammalian cells (14–16).
Although RNR is a major determinant of genomic integrity, the
consequences of RNR deregulation in animals are unknown. We
generated transgenic mice that overexpress Rrm1, Rrm2, or p53R2
and found that overexpression of either small RNR subunit induced
spontaneous lung neoplasms and was mutagenic in cultured cells.
Defects in DNA mismatch repair (MMR) synergistically increased
RNR-induced mutagenesis and carcinogenesis, and activating
mutations in the proto-oncogene K-ras were identified in lung
neoplasms from Rrm2 and p53R2 transgenic mice. These results
identify mutagenic and carcinogenic effects of RNR deregulation
in vivo .
Materials and Methods
Plasmids. Expression plasmids encoding mouse Rrm1, Rrm2 , or p53R2
were constructed in the pCaggs expression vector as described in
Supplementary Materials and Methods.
Transgenic mice. Transgenic mice were generated in the FVB/N strain
background, as described in Supplementary Materials and Methods. For
analysis of tumor development, cohorts of mice were aged until moribund
Note: Supplementary data for this article are available at Cancer Research Online
(http://cancerres.aacrjournals.org/).
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for 15 to 21 mo. Msh6-null mice (17) were obtained from the Mouse Models
of Human Cancers Consortium, bred with Rrm2Tg or p53R2Tg mice, and
aged until moribund for 6 or 17 mo. All mice were maintained identically,
following guidelines approved by the Cornell University Institutional
Laboratory Animal Use and Care Committee. Pathologic assessments were
performed as described in Supplementary Materials and Methods.
Northern blot analysis. Total RNA was isolated from mouse cells and
tissues using RNA STAT-60 (Tel-Test, Inc.), resolved on an agarose/
formaldehyde gel, and hybridized with probes specific to mouse Rrm1,
Rrm2, p53R2 , or Gapdh .
Western blot analysis. Cell or tissue protein extracts were prepared
as described in Supplementary Materials and Methods. The antibodies
used were mouse anti-R1 (Bio Med Tek), goat anti-R2 (Santa Cruz Bio-
technology), rabbit anti-p53R2 (ProSci-inc), and h-actin (Sigma).
Immunohistochemistry. Immunohistochemical detection of pro-SP-C
and CC10 was performed on 5 Am paraffin sections using the Vectastain
ABC kit (Vector Laboratories) as described in Supplementary Materials and
Methods.
Generation of RNR overexpressing 3T3 cell pools. Pools of mouse
NIH/3T3 fibroblasts that overexpress individual RNR genes were generated
as described in Supplementary Materials and Methods.
Determination of mutation rates in mammalian and yeast cells.
Mutation frequencies were determined in 3T3 cell pools and yeast strains by
Hprt mutation and canavanine resistance assays, respectively, as described
in Supplementary Materials and Methods.
Big Blue mutation rate assay. Big Blue C57Bl/6 mice, hemizygous for
the E shuttle vector, were obtained from Stratagene and bred with Rrm1Tg,
Rrm2Tg, p53R2Tg , or Msh6/RNRTg mice. Mutation frequency in the
resulting animals was determined as described in Supplementary Materials
and Methods.
Sequencing of K-ras exons 1 and 2. DNA was prepared from tumor
specimens isolated by laser microdissection, and K-ras exons 1 and 2 were
PCR amplified and sequenced as described in Supplementary Materials and
Methods.
Results
Generation of RNR transgenic mice and analysis of trans-
gene expression. Deregulation of RNR is mutagenic in yeast and
cultured mammalian cells (14, 16). To test the consequences of
RNR deregulation in an animal model, we set out to generate
transgenic mice featuring broad, high-level expression of the
individual mouse RNR genes Rrm1, Rrm2 , and p53R2 , using pCaggs
expression constructs that place the RNR genes under the control
of chicken h-actin promoter and cytomegalovirus enhancer
regulatory sequences. Six Rrm1 , two Rrm2 , and four p53R2
transgene-positive founders were generated and subsequently
maintained on a pure FVB/N strain background. RNR transgenic
mice seemed grossly normal and were fertile. When bred with wild-
type (WT) mice, p53R2 hemizygotes produced fewer than the
expected number of transgene positive offspring (205 p53R2
transgene-positive and 349 transgene-negative mice were identified
among 554 mice genotyped at weaning).
Endogenous and transgenic Rrm1, Rrm2 , and p53R2 mRNA
expression was tested in a variety of organs by Northern blot
analysis. The endogenous Rrm1 and Rrm2 genes were coordinately
expressed, with highest expression in proliferative tissues, such as
testis and thymus (Fig. 1A, left). Expression of the endogenous
p53R2 gene was undetectable in all tested WT FVB tissues.
Importantly, Rrm2Tg and p53R2Tg mice showed high-level transgene
expression in all tissues, with overexpression being highest in
muscle (Fig. 1A, right). Rrm1 overexpression was only observed in
muscle and testis of Rrm1Tg mice. For technical reasons, the Rrm1
transgene included additional noncoding cDNA sequences and was
microinjected as a linearized construct without removal of plasmid
backbone sequences, which may contribute to the relatively poor
transgene expression.
Consistent with results from the Northern blot analyses,
immunoblotting revealed that the Rrm2 and p53R2 proteins were
highly overexpressed in all tested tissues from Rrm2Tg and p53R2Tg
mice (Fig. 1B). Although Northern blotting failed to identify p53R2
expression in WT tissues (Fig. 1A), low levels of p53R2 protein were
apparent in most WT FVB tissues. Rrm1 protein overexpression
was limited to muscle and to a lesser extent lung in Rrm1Tg mice
compared with WT littermates. Together, these results establish the
restricted overexpression of the large RNR subunit Rrm1 and the
widespread, high-level overexpression of the small RNR subunits
Rrm2 and p53R2 in transgenic mice.
Overexpression of the small RNR subunit promotes lung
carcinogenesis. To identify spontaneous neoplasms and other
abnormalities in RNR transgenic mice, we established a cohort
consisting of 52 Rrm1Tg , 75 Rrm2Tg , and 81 p53R2Tg mice, as well as
49 transgene-negative control mice and aged them until they
exhibited clinical illness. Notably, a significantly increased fre-
quency of lung neoplasms was observed in Rrm2Tg and p53R2Tg
mice (Table 1). Seventy-two percent of Rrm2Tg and 74% of p53R2Tg
animals developed spontaneous lung neoplasms. By contrast, 31%
of transgene-negative controls developed lung neoplasms, a
frequency consistent with the reported incidence for aged WT
FVB mice (18). The lung neoplasm incidence in Rrm1Tg mice was
31%, identical to that of the control animals and significantly less
than that of Rrm2Tg or p53R2Tg mice (m2 analysis, P < 0.05). Lung
neoplasms were observed in multiple independent Rrm2Tg and
p53R2Tg lines, indicating that transgene integration site effects did
not account for the neoplastic phenotype. Signs of clinical illness
arose after a latency of 16 to 18 months for all genotypes. No
differences in lung neoplasm incidence between sexes were noted
for any of the transgenic lines. The frequency of epithelial
hyperplasia of alveoli also was increased in p53R2Tg and especially
Rrm2Tg mice. Other neoplasms, including papilloma, histiocytic
sarcoma, mammary carcinoma, and lymphoblastic lymphoma,
were observed in 13% of Rrm1Tg , 12% of Rrm2Tg , and 12% of
p53R2Tg mice, but only 2% of transgene-negative mice.
The lung neoplasms in Rrm2Tg and p53R2Tg mice displayed
several features consistent with a substantial lung cancer
predisposition. A significantly greater lung neoplasm multiplicity
was observed for Rrm2Tg and p53R2Tg mice, and the lung
neoplasms in Rrm2Tg mice were also considerably larger than
those from control animals (Table 1). The lung neoplasms
from Rrm2Tg and p53R2Tg mice ranged from adenoma to advanced
adenocarcinoma (Fig. 2A, I–VI) and resembled human glan-
dular pulmonary neoplasms, particularly adenocarcinomas. RNR-
induced lung adenocarcinomas were primarily of the papillary
subtype and exhibited pleural invasion, heterogeneous growth
pattern, nuclear atypia, high mitotic index, and blood vessel
invasion (Fig. 2A, III–VI). A greater frequency of adenocarcinoma
was observed in Rrm2Tg and p53R2Tg mice compared with Rrm1Tg
or transgene-negative mice (Table 1), with Rrm2 overexpression,
in particular, eliciting pathologically advanced neoplasms. Togeth-
er, these data indicate that overexpression of either small RNR
subunit in mice promotes lung neoplasm formation, with Rrm2
being more potent than p53R2 with respect to tumor size,
multiplicity, and malignancy.
To investigate the possible cell type of origin for RNR-induced
lung neoplasms, we performed immunohistochemistry using
RNR-Induced Lung Carcinogenesis
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antibodies against Clara cell antigen (CC10) and surfactant
apoprotein-C (SP-C), markers that distinguish Clara and alveolar
type II cells, respectively. Eight of eight lung neoplasms from
Rrm2Tg and p53R2Tg mice were positive for SP-C (Fig. 2A, VII),
whereas none was positive for CC10 (Fig. 2A, VIII). Adjacent
bronchioles, on the other hand, were positive for CC10 and
negative for SP-C, as expected. These results suggest that RNR-
induced lung neoplasms arose from alveolar type II cells or their
progenitors.
To confirm a causative role for RNR overexpression in lung
carcinogenesis, we analyzed the expression of Rrm1, Rrm2 , and
p53R2 in lung neoplasms by Northern (Fig. 2B) and Western
(Fig. 1B) blotting. Lung neoplasms from Rrm2Tg and p53R2Tg
animals showed prominent RNR overexpression, consistent with a
Figure 1. Widespread overexpression of RNR genes in transgenic mice. A, Northern blot analysis of RNR expression in WT and RNR transgenic mice. Total
RNA was extracted from the indicated tissues from WT FVB mice (left) or RNR transgenic mice (right ) and subjected to Northern blot hybridization with the indicated
probes specific for Rrm1, Rrm2, or p53R2. Positions of endogenous and transgene-derived RNR transcripts are indicated. B, Western blot analysis of RNR
protein expression in the indicated tissues from WT and RNR transgenic (Tg ) mice, as well as lung neoplasms from the corresponding transgenic strains (Tumor 1,
Tumor 2). Total protein from the indicated tissues was subjected to immunoblotting with antibodies specific to Rrm1, Rrm2, or p53R2. Duplicate membranes were
immunoblotted for h-actin as a loading control.
Table 1. Lung neoplasm characteristics in RNR overexpressing mice
Mouse
genotype
No.
animals
Percentage of
mice with lung
neoplasms
Percentage of
mice with
hyperplasia*
Average lung
neoplasm
size F SD (mm)
Percentage of
mice with multiple
lung neoplasms
Percentage of
mice with lung
adenocarcinoma
WT FVB
c
49 31% 12% 4.04 F 3.98 8% 6%
Rrm1Tg 52 31% 15% 3.96 F 3.59 8% 10%
Rrm2Tg 75 72%
b
44%
b
6.68 F 4.22 53%b 40%b
p53R2Tg 81 74%
b
20% 4.26 F 3.44 47%b 21%
NOTE: Mice were aged until moribund for up to 21 mo, euthanized by asphyxiation using carbon dioxide, and subjected to pathologic examination as
described in Supplementary Materials and Methods.
*Includes mice that had both epithelial hyperplasia of alveoli and lung neoplasms.
cWT FVB refers to transgene-negative control mice.
bStatistically significant difference (P < 0.05) relative to WT FVB mice. Incidences were compared by m2 analysis. Neoplasm sizes were compared by
t test analysis.
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causative role for RNR in the genesis of these lung lesions. By
contrast, lung neoplasms from Rrm1Tg mice did not display high-
level transgene expression, providing further evidence that
carcinogenesis in Rrm2Tg and p53R2Tg mice is highly specific.
Overall, these data identify a novel oncogenic activity for the small
RNR subunit.
Increased mutation frequency after RNR overexpression in
cultured 3T3 cells. We hypothesized that RNR overexpression
induced lung neoplasms through a mutagenic mechanism,
because defects in RNR allosteric control result in increased
mutation frequencies in yeast and mammalian cells (14, 16). To
determine if RNR overexpression was similarly mutagenic, we
generated Rrm1, Rrm2 , or p53R2 overexpressing NIH/3T3 cell
pools using the same expression constructs as used to generate
the transgenic mice. Overexpression of individual RNR genes in
these cell pools was confirmed by Northern and Western blotting
(Fig. 3A and B).
We then measured mutation frequency using the Hprt mutation
detection assay, which identifies cells harboring Hprt mutations by
virtue of their resistance to 6-thioguanine (19). In a representative
experiment (Fig. 3C), a significantly increased mutation frequency
was observed in a Rrm2 overexpressing cell pool (9.0  106)
compared with Rrm1 overexpressing or empty plasmid vector cell
pools (<0.7  106 and <0.8  106, respectively). Three
independent Rrm2 overexpressing cell pools showed a consistently
increased mutation frequency that was 9.9-fold to 16.0-fold greater
than that observed for vector control cells. A p53R2 overexpressing
cell pool showed a more modestly, but nevertheless, significantly
increased mutation frequency of 3.0  106 (Fig. 3C). However,
mutation frequency in p53R2 overexpressing cells varied, with three
Figure 2. Histopathologic and molecular analysis of lung neoplasms from RNR transgenic mice. A, I, lungs from a Rrm2Tg mouse with multiple independent
neoplasms affecting several lobes. II-VI, H&E-stained sections of lung neoplasms. II, solid adenoma from a p53R2Tg mouse. III-VI, papillary adenocarcinomas from
Rrm2Tg or p53R2Tg mice showing pleural invasion (arrow ; III ), regional variation in growth pattern (IV ), multiple mitotic figures (arrows ; V), and blood vessel
invasion (arrow ; VI ). VII and VIII, immunohistochemical staining of RNR-induced lung neoplasms for Pro-SP-C (VII ) or CC10 (VIII ) by the avidin-biotin complex method
with methyl green counterstain. Inserts show higher magnification views of the boxed regions. Calibration bar, II, IV, 50 Am; III, 241 Am; V, 10 Am; VI, 25 Am; VII, VIII,
100 Am. B, Northern blot analysis of lung neoplasms from RNR transgenic mice. Total RNA was prepared from lung neoplasms (Tumor 1, Tumor 2, Tumor 3) or
normal lung tissue (Lung ) from RNR transgenic mice, as well as from WT FVB lung tissue. Northern blotting was performed with the indicated radiolabeled probes.
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p53R2 overexpressing cell pools showing an elevated mutation
frequency that was 4.2-fold to 11.2-fold greater than that for vector
control cells, whereas two other p53R2 overexpressing cell pools
displayed no increase in mutation frequency. Whether this
variability is due to differences in expression levels between
individual cell pools, or to the fact that the mutation frequencies
measured were near the lower end of sensitivity for this assay, has
not been determined. However, three independent Rrm1 over-
expressing cell pools and another five empty plasmid vector cell
pools showed no detectable increase in mutation frequency.
To determine the nature of the mutations conferring 6-
thioguanine resistance, we sequenced the Hprt gene from
individual colonies (20). Interestingly, four of seven Hprt mutations
from the Rrm2 overexpressing cell pool shown in Fig. 3C were
G!T substitutions (Supplementary Table S1), which are relatively
rare among reported spontaneous Hprt mutations (21). Similar
results were obtained in a separate experiment with an indepen-
dent Rrm2 overexpressing cell pool (Supplementary Table S1). One
of six mutations from the p53R2 overexpressing cell pool shown in
Fig. 3C also was a G!T mutation, but no G!T mutations were
observed among six 6-thioguanine resistant clones from a second
independent experiment (Supplementary Table S1). Collectively,
the results indicate that overexpression of the small RNR subunit
causes a mutator phenotype.
Combined defects in RNR regulation and MMR result in
synergistic increases in mutagenesis and carcinogenesis. To
further evaluate a role for mutagenesis in RNR-induced lung
carcinogenesis, we investigated whether combining RNR deregu-
lation with a defect in MMR, the repair system that suppresses
mutation accumulation, would cause a synergistic increase in
mutagenesis and carcinogenesis. In eukaryotic cells, a complex of
Msh2-Msh6 is responsible for recognizing base-base mispairs and
single-base insertion/deletions, whereas a Msh2-Msh3 complex
detects larger insertion/deletion loops (22). We first tested this
hypothesis in Saccharomyces cerevisiae by measuring the mutation
rate by canavanine resistance assay in strains with deregulated
RNR activity and mutations in MMR genes. To deregulate budding
yeast RNR, we used the rnr1-D57N mutant, in which a single–
amino acid change in the R1 activity site makes the enzyme
insensitive to feedback inhibition by dATP (16). Consistent with
published reports (14), rnr1-D57N yeast exhibited a 3.4-fold
increase in mutation rate relative to the WT strain, which had a
mutation rate of 1.5  107 (Fig. 4A). MMR-defective strains also
displayed elevated mutation rates (msh2D : 28.4-fold; msh3D :
2.9-fold; msh6D : 9.8-fold), similar to previous reports (23). Notably,
rnr1-D57N msh2D and rnr1-D57N msh6D double mutants displayed
approximately multiplicative increases in mutation rate relative to
the single mutants (61.4-fold and 23.8-fold, respectively). Multipli-
cative increases in mutagenesis are seen for mutations that affect
factors acting in series in a common pathway (24), suggesting
that the Msh2-Msh6 complex corrects DNA mismatches induced
by RNR deregulation. By contrast, combining rnr1-D57N with
msh3D resulted in only an additive increase in mutation rate (rnr1-
D57N msh3D: 3.9-fold). The spectrum of mutations arising in WT
Figure 3. Increased mutation frequency in RNR
overexpressing NIH/3T3 cell pools. A, Northern blot
analysis of RNR expression in stable 3T3 cell pools
transfected with either pCaggs empty vector or
pCaggs RNR genes. Total RNA was extracted from
the indicated cell lines and subjected to Northern blot
hybridization with probes specific for Rrm1, Rrm2,
p53R2, or Gapdh. B, Western blot analysis of RNR
protein expression in RNR overexpressing 3T3 cells.
Total protein was extracted from the indicated cell
lines and subjected to immunoblotting with antibodies
specific to Rrm1, Rrm2, or p53R2. Duplicate
membranes were immunoblotted for h-actin as a
loading control. Samples in A and B were run on
single blots, which were then cropped to remove
extraneous lanes. C, mutation frequency at the Hprt
locus in Rrm1, Rrm2 , and p53R2 overexpressing
3T3 cells. Mutation frequency was determined by
Hprt assay.
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nr1-D57N, msh2D , and msh6D strains was consistent with previous
publications (14, 23, 25) and included primarily base substitutions,
as well as frameshift mutations for msh2D (Supplementary
Table S2). The frequency of frameshift mutations involving single
nucleotide insertions or deletions was substantially increased in
rnr1-D57N msh2D and rnr1-D57N msh6D strains relative to the
single mutants.
The synergistic effects of RNR deregulation and MMR deficiency
on mutation rates in yeast prompted us to further test genetic
interactions between RNR and MMR in mice by crossing RNR
transgenic mice with Msh6-null mice (17). If RNR overexpression
induces lung carcinogenesis through a mutagenic mechanism,
Msh6 deficiency would be predicted to accelerate lung carcino-
genesis in RNR transgenic mice. A cohort of Msh6/, Msh6+/ , or
Msh6+/+ mice that also carried either the Rrm2 or p53R2 transgene
was established and examined for survival and cancer susceptibil-
ity. Interestingly, the median life span for Msh6/p53R2Tg mice
(136 days) was significantly reduced compared with that of
transgene-negative Msh6/ mice (258 days; P < 0.05; log-rank
test; Fig. 4B). The reduced survival of Msh6/p53R2Tg mice was
associated with early onset lymphomagenesis (Supplementary
Table S3). Because these Msh6/p53R2Tg mice died at a young
age, we could not evaluate whether Msh6 deficiency cooperated
with p53R2 overexpression in inducing lung neoplasms.
The survival rate for Msh6/Rrm2Tg and transgene negative
Msh6/ mice was not significantly different (P = 0.975; log-rank
test), suggesting that Rrm2 overexpression, unlike p53R2 over-
expression, did not enhance lymphomagenesis (Fig. 4B). However,
that 90% of Msh6/Rrm2Tg mice had developed lung neoplasms
despite their shortened life span off10 months was suggestive of
a synergistic genetic interaction (Supplementary Table S3). To
directly test whether lung carcinogenesis was accelerated in
Msh6/Rrm2Tg mice, we sacrificed a cohort of Msh6/Rrm2Tg
mice and littermate controls at 6 months of age. Three of 18
Msh6+/+Rrm2Tg mice and 3 of 17 Msh6+/Rrm2Tg mice had
developed lung neoplasms by 6 months, whereas no lung
neoplasms were observed in transgene-negative Msh6+/+ or
Msh6+/ littermates (Table 2). Lung neoplasms were also observed
in 2 of 13 Msh6/ mice. Msh6 deficiency strongly accelerated
Rrm2-induced lung carcinogenesis, as 13 of 13 Msh6/Rrm2Tg
mice developed lung neoplasms by 6 months of age, with nine of
these mice carrying multiple lung neoplasms.
To determine whether combining RNR overexpression with
MMR deficiency would increase mutation frequency in vivo , we
analyzed the mutation frequency at the E phage cII locus in
lung tissue from 3-month-old RNRTg mice, with or without Msh6
deficiency, using the Big Blue transgene system (26). There was
no difference in mutation frequency in RNR transgenic
Figure 4. Genetic interactions between RNR and MMR. A, canavanine mutation rate assay for RNR1(WT) and rnr1-D57N strains on MMR-deficient backgrounds
(msh3D, msh2D, msh6D, or WT ) of S. cerevisiae. The forward mutation rate (per generation) to canavanine resistance was measured for the indicated single and
double mutant combinations. Error bars show the 95% confidence interval. B, survival curves for Msh6/RNRTg (Rrm2Tg or p53R2Tg ) mice. Mice were aged
until moribund for up to 17 mo. Survival curves were generated using SPSS software. The following number of animals was analyzed for each genotype: Msh+/+ (11),
Msh6+/ (23), Msh6+/Rrm2Tg (22), Msh6+/p53R2Tg (11), Msh6/ (34), Msh6/Rrm2Tg (20), Msh6/ p53R2Tg (17). C and D, mutation frequency at the E cII locus
in lung (C ) or spleen (D ) tissues from RNR overexpressing and control mice. Genomic DNA was isolated from 3-mo-old mice of the indicated genotypes and packaged
into infectious phage. Mutation frequency was determined based on the ratio of the number of mutant phage obtained to the total number of phage analyzed.
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mice compared with WT mice (Fig. 4C and Supplementary
Table S4), possibly because the Big Blue system is relatively
insensitive due to a high background mutation frequency.
However, the mutation frequency in Msh6/Rrm2Tg (55.2 F
20.9  105) and Msh6/p53R2Tg (54.0 F 15.4  105) lung
tissues was consistently higher than that in Msh6/ lung tissue
(31.1 F 10.4  105), although these differences were not
statistically significant. By contrast, the mutation frequency was
similar in spleen tissue from Msh6/Rrm2Tg (52.0 F 20.1  105)
and Msh6/ (50.5 F 16.3  105) mice, but slightly elevated
in Msh6/p53R2Tg (63.7 F 10.7  105) animals (Fig. 4D
and Supplementary Table S5). Together, these results indicate
that MMR deficiency synergizes with RNR overexpression in
a tissue-specific manner to increase mutagenesis and carcino-
genesis.
RNR-induced lung neoplasms display a unique signature of
K-ras activating mutations. A mutagenic mechanism implies that
RNR overexpression triggers additional genetic alterations while
promoting tumor development. Because mutations in codons 12
and 61 of the K-ras proto-oncogene are often observed in human
and mouse lung cancers (27, 28), we examined the frequency of
K-ras mutations in microdissected lung neoplasms from the
RNR cohort. 100% of Rrm2-induced lung neoplasms and 79% of
p53R2-induced lung neoplasms carried K-ras activating muta-
tions (Supplementary Table S6), indicating that RNR-induced lung
carcinogenesis frequently involves K-ras activating mutations.
56% and 100% of the rare lung neoplasms from transgene-
negative control and Rrm1Tg mice, respectively, also had K-ras
mutations.
Sequence analysis revealed that the lung neoplasms from
Rrm2Tg and p53R2Tg mice exhibited distinct mutation spectra
relative to those from transgene-negative and Rrm1Tg mice
(Supplementary Table S7). In particular, 50% of the K-ras codon
12 mutations from Rrm2-induced lung neoplasms were G!T
transversions (GGT!GTT, G12V), as were 30% of those from
p53R2-induced lung neoplasms. By contrast, lung neoplasms from
transgene-negative and Rrm1Tg mice showed exclusively G!A
transitions (GGT!GAT, G12D) in K-ras codon 12. We conclude
that K-ras activating mutations, common events in lung
carcinogenesis, are central to Rrm2-induced and p53R2-induced
lung carcinogenesis and arise through a mechanism that seems
distinct from that underlying spontaneous lung tumor develop-
ment in WT animals.
Discussion
RNR enzyme activity has long been positively correlated with
cancer cell division (29), and RNR inhibition is an effective strategy
for suppressing tumor proliferation and survival (30). Yet,
investigation of the effects of RNR deregulation in animal models
has been incomplete. We report that overexpression of Rrm2 or
p53R2 specifically induces lung but not other neoplasms at high
frequency in transgenic mice. Previous studies indicated that
human RRM2 has transforming activity in cultured cells (31),
whereas p53R2 has been suggested to have tumor suppressor
activity based on its regulation by p53 and its role in the DNA
damage response (2). RNR may be an example of a growth
regulator that has dual roles both as a tumor suppressor and
oncogene. Whereas impaired RNR function can trigger genomic
instability by limiting nucleotide availability for DNA replication
and repair purposes, RNR hyperactivity may be equally detrimental
due to its mutagenic effects. Interestingly, the genomic regions
containing human RRM2 (2p25-2p24) and p53R2 (8q23.1) are
commonly amplified in human lung cancers (32–35), raising the
possibility that RNR deregulation might have a causative role in
human lung carcinogenesis. Because RNR is a DNA damage-
inducible enzyme, our results also suggest that increased RNR
levels due to chronic DNA damage in the lungs of smokers may
contribute to tumor development.
In contrast to Rrm2Tg and p53R2Tg mice, Rrm1Tg mice did not
show increased lung carcinogenesis. This might be due to the
relatively limited overexpression of the Rrm1 transgene or the
fact that the R2 subunit is the limiting component of the enzyme
(7, 36). However, Rrm1 shows tumor suppressor activity both in
cultured cells and human lung cancer patients (37–39).
Consistent with our findings, Rrm1 overexpression in another
mouse model also did not result in any overt spontaneous
phenotypes and instead was reported to suppress chemical
carcinogenesis in the lung (40). Thus, lung tumor induction
Table 2. Combining RNR overexpression with MMR deficiency results in a synergistic increase in lung carcinogenesis
Mouse
genotype
No.
animals
Percentage of
mice with lung
neoplasms
Percentage of
mice with multiple
lung neoplasms
No. lung
neoplasms per
mouse* F SD
Average lung
neoplasm
size F SD (mm)
Percentage of
mice with
lymphoma
Msh6/Rrm2Tg 13 100%c 69%c 2.9 F 1.99 1.30 F 0.54 31%
Msh6/ 13 15% 0% 1.0 F 0 1.25 F 1.06 8%
Msh6+/Rrm2Tg 17 18% 0% 1.0 F 0 0.73 F 0.68 12%
Msh6+/ 10 0% 0% N/A N/A 0%
Msh6+/+Rrm2Tg 18 17% 6% 1.33 F 0.58 1.23 F 0.25 0%
Msh6+/+ 14 0% 0% N/A N/A 0%
NOTE: Mice were aged for 6 mo, euthanized by asphyxiation using carbon dioxide, and subjected to pathologic examination as described in
Supplementary Materials and Methods. Only mice that lived to 6 mo were included. Four Msh6/Rrm2Tg mice died before 6 mo due to lymphoma, one
of which also had a lung neoplasm. Four Msh6/ mice died before 6 mo due to lymphoma.
*Values refer to the average number of lung neoplasms per mouse among tumor-bearing animals only.
cStatistically significant difference (P < 0.01) relative to Msh6/, Msh6+/Rrm2Tg , or Msh6+/+Rrm2Tg mice as determined by Fisher’s exact test.
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might be specific to the small RNR subunit and independent of
RNR enzyme activity.
We determined that RNR-induced lung tumorigenesis pro-
ceeded through a mutagenic mechanism. Overexpression of Rrm2
or p53R2 , but not Rrm1 , in 3T3 cells resulted in a significant
increase in mutation frequency. Additional experiments in
budding yeast indicated that MMR normally corrects base
mispairs that arise due to RNR deregulation, as multiplicative
increases in mutation rate were observed when the allosteric site
mutant rnr1-D57N was combined with MMR gene mutations. A
similar genetic interaction between RNR and MMR was observed
in mice. Msh6-null mice develop primarily lymphoma (17), and
p53R2 overexpression cooperated with Msh6-deficiency to cause
an earlier onset of lymphomagenesis and shortened life span in
Msh6/p53R2Tg mice compared with Msh6/ controls. We also
observed that Msh6 deficiency strongly accelerated Rrm2-induced
lung carcinogenesis, with 100% of Msh6/Rrm2Tg mice develop-
ing lung neoplasms by 6 months of age. The accelerated lung
carcinogenesis in Msh6/Rrm2Tg mice was associated with
increased mutation frequency in lung tissue, whereas the
accelerated lymphomagenesis in Msh6/p53R2Tg mice correlated
with a modestly elevated mutation frequency in spleen tissue. The
synergy observed between these pathways raises the possibility
that aberrant RNR expression may be selected for in MMR-
deficient cancers.
A key question arising from this study is the molecular basis for
mutagenesis and lung tumor induction by Rrm2 and p53R2
overexpression. One possibility is that increased RNR expression
leads to dNTP level alterations that impair replication fidelity and
trigger mutations in growth regulatory genes. Abnormal nucleotide
levels result in increased base misinsertion during DNA replication,
as well as decreased proof-reading due to enhanced polymerization
rates (5). Consistent with the notion that regulators of nucleotide
biosynthesis can influence cell transformation, overexpression of
another enzyme involved in dNTP biosynthesis, thymidylate
synthase, transforms cultured cells (41) and promotes tumor
formation in transgenic mice (42).
Alternatively, carcinogenesis due to R2 subunit overexpression
could be independent of nucleotide metabolism. One possibility
is that free radical production by Rrm2 and p53R2 contributes to
cell transformation. During each catalytic cycle the small RNR
subunit generates a tyrosyl radical that normally is transferred to
the active site in Rrm1 for use in NDP reduction (1). R2 protein
overexpression might lead to increased radical generation and
the formation of reactive oxygen species (ROS), which cause
oxidative DNA damage and are mutagenic. ROS also have
mitogenic effects and can play a direct role in neoplastic
transformation (43). Notably, human RRM2 protein generates
ROS in vitro , although recombinant p53R2 was reported in the
same study to have antioxidant activity, despite the fact that both
RRM2 and p53R2 generate tyrosyl-free radicals (44). G!T
transversions, a signature of oxidative DNA damage, were
detected at K-Ras codon 12 in lung neoplasms from Rrm2Tg
and p53R2Tg mice, and also at the Hprt locus in Rrm2 and p53R2
overexpressing 3T3 cells. Because MMR corrects mismatches
arising from both replication errors (22) and oxidative DNA
damage (45), the multiplicative increases in mutagenesis and
carcinogenesis observed when combining RNR overexpression
with MMR deficiency are compatible with both dNTP level
alterations and increased ROS production as possible mecha-
nisms of action.
The possibility that R2 subunit overexpression induces muta-
genesis and tumorigenesis through excessive free radical produc-
tion may account for the observation that RNR transgenic mice,
despite broad RNR overexpression, develop lung but not other
neoplasms at high frequency. The lung is an oxygen-rich
environment with a high basal level of ROS (46) and thus may be
more susceptible to increased free radical production. Alternatively,
it could be that the mutational targets of RNR dictate the tissue
specificity. Indeed, activated K-ras preferentially induces lung
neoplasms in mice (47). Other more trivial explanations for the
lung-specific carcinogenesis, such as subtle transgene expression
level differences or varying DNA repair efficiencies among tissues,
also cannot be ruled out.
Although Rrm2 and p53R2 encode related R2 proteins, they did
not give identical results in our experiments. Whereas over-
expression of either was capable of inducing lung neoplasms,
Rrm2 overexpression elicited larger and more malignant tumors.
p53R2 overexpression, on the other hand, significantly accelerated
lymphomagenesis in Msh6-null mice, suggesting a broad effect of
p53R2 overexpression. Rrm2 also was more mutagenic than
p53R2 in cultured cells and induced a greater proportion of G!T
transversions in both the Hprt and K-ras genes. One possible
explanation for the partially distinct phenotypes associated with
Rrm2 and p53R2 is that both dNTP alterations and ROS
production can contribute to neoplastic transformation and that
these activities differ between Rrm2 and p53R2. The distinct
subcellular localizations of Rrm2 and p53R2 (2, 3, 13) could
contribute to such differing effects on dNTP biosynthesis or ROS
production.
Mouse models hold great promise for facilitating the develop-
ment of diagnostic tools, prognostic markers, and therapeutics for
lung cancer, the leading cause of cancer death world-wide. Like
human lung adenocarcinomas (48), the RNR-induced lung neo-
plasms expressed SP-C, a marker of type II alveolar cells.
Furthermore, RNR-induced lung neoplasms arose with moderate
latency in a stochastic process associated with an elevated
mutation rate, suggesting that this may be a particularly authentic
model for lung cancer. A mutagenic mechanism for RNR-induced
lung carcinogenesis implies that several genetic alterations are
required for lung carcinogenesis. Consistent with this model, we
observed activating K-ras mutations at very high frequency in
RNR-induced lung neoplasms. K-ras has been reported to be
mutated in 90% of mouse lung neoplasms and as many as 25% of
human lung adenocarcinomas (27, 28). That G!T transversions in
K-ras codon 12 were detected in RNR-induced lung neoplasms
further validates this lung cancer model, as G!T transversions are
the most common mutations at K-ras codon 12 in human lung
cancers and correlate with a poorer prognosis (49, 50). Continued
use of the RNR lung cancer model has great potential for revealing
additional genetic alterations that contribute to lung tumor
initiation and progression.
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